<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Corticosteroids for treating sepsis in children and adults - Annane, D - 2019 | Cochrane Library</title> <meta content="Corticosteroids for treating sepsis in children and adults - Annane, D - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002243.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Corticosteroids for treating sepsis in children and adults - Annane, D - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002243.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002243.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Corticosteroids for treating sepsis in children and adults" name="citation_title"/> <meta content="Djillali Annane" name="citation_author"/> <meta content="Center for Neuromuscular Diseases" name="citation_author_institution"/> <meta content="djillali.annane@aphp.fr" name="citation_author_email"/> <meta content="Eric Bellissant" name="citation_author"/> <meta content=" Raymond Poincaré Hospital (AP‐HP)" name="citation_author_institution"/> <meta content="Pierre Edouard Bollaert" name="citation_author"/> <meta content="Hôpital Pontchaillou" name="citation_author_institution"/> <meta content="Josef Briegel" name="citation_author"/> <meta content="Hôpital Central" name="citation_author_institution"/> <meta content="Didier Keh" name="citation_author"/> <meta content="Klinikum der Universität" name="citation_author_institution"/> <meta content="Yizhak Kupfer" name="citation_author"/> <meta content="Charité‐Campus Virchow Clinic, Charité Universitätsmedizin Berlin" name="citation_author_institution"/> <meta content="Romain Pirracchio" name="citation_author"/> <meta content="Maimonides Medical Center" name="citation_author_institution"/> <meta content="Bram Rochwerg" name="citation_author"/> <meta content="Zuckerberg San Francisco General Hospital and Trauma Center, University of California" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD002243.pub4" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/12/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002243.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002243.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002243.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [adverse effects, *therapeutic use]; Hospital Mortality; Length of Stay; Randomized Controlled Trials as Topic; Risk Factors; Sepsis [*drug therapy, *mortality]; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002243.pub4&amp;doi=10.1002/14651858.CD002243.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="IYhCEbRn";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002243\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002243\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ja","fa","fr","de","zh_HANT","ru","ko","th","pt","ms","hr","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002243.pub4",title:"Corticosteroids for treating sepsis in children and adults",firstPublishedDate:"Dec 6, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Emergency and Critical Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002243.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002243.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002243.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002243.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002243.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002243.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002243.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002243.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002243.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002243.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>17223 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002243.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-sec-0175"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-sec-0050"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-sec-0051"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-sec-0056"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-sec-0057"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-sec-0087"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-sec-0166"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/appendices#CD002243-sec-0180"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/table_n/CD002243StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/table_n/CD002243StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Corticosteroids for treating sepsis in children and adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information#CD002243-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Djillali Annane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information#CD002243-cr-0003">Eric Bellissant</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information#CD002243-cr-0004">Pierre Edouard Bollaert</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information#CD002243-cr-0005">Josef Briegel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information#CD002243-cr-0006">Didier Keh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information#CD002243-cr-0007">Yizhak Kupfer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information#CD002243-cr-0008">Romain Pirracchio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information#CD002243-cr-0009">Bram Rochwerg</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information/en#CD002243-sec-0199">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 December 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002243.pub4">https://doi.org/10.1002/14651858.CD002243.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002243-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002243-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002243-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002243-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002243-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002243-abs-0013">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002243-abs-0017">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD002243-abs-0015">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002243-abs-0001" lang="en"> <section id="CD002243-sec-0001"> <h3 class="title" id="CD002243-sec-0001">Background</h3> <p>Sepsis occurs when an infection is complicated by organ failure. Sepsis may be complicated by impaired corticosteroid metabolism. Thus, providing corticosteroids may benefit patients. The original review was published in 2004 and was updated in 2010 and 2015 prior to this update. </p> </section> <section id="CD002243-sec-0002"> <h3 class="title" id="CD002243-sec-0002">Objectives</h3> <p>To examine the effects of corticosteroids on death in children and adults with sepsis.</p> </section> <section id="CD002243-sec-0003"> <h3 class="title" id="CD002243-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, LILACS, ClinicalTrials.gov, ISRCTN, and the WHO Clinical Trials Search Portal, on 25 July 2019. In addition, we conducted reference checking and citation searching, and contacted study authors, to identify additional studies as needed. </p> </section> <section id="CD002243-sec-0004"> <h3 class="title" id="CD002243-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) of corticosteroids versus placebo or usual care (antimicrobials, fluid replacement, and vasopressor therapy as needed) in children and adults with sepsis. We also included RCTs of continuous infusion versus intermittent bolus of corticosteroids. </p> </section> <section id="CD002243-sec-0005"> <h3 class="title" id="CD002243-sec-0005">Data collection and analysis</h3> <p>All review authors screened and selected studies for inclusion. One review author extracted data, which was checked by the others, and by the lead author of the primary study when possible. We obtained unpublished data from the authors of some trials. We assessed the methodological quality of trials and applied GRADE to assess the certainty of evidence. Review authors did not contribute to assessment of eligibility and risk of bias, nor to data extraction, for trials they had participated in. </p> </section> <section id="CD002243-sec-0006"> <h3 class="title" id="CD002243-sec-0006">Main results</h3> <p>We included 61 trials (12,192 participants), of which six included only children, two included children and adults, and the remaining trials included only adults. Nine studies are ongoing and will be considered in future versions of this review. We judged 19 trials as being at low risk of bias. </p> <p><b><i>Corticosteroids versus placebo or usual care</i> </b> </p> <p>Compared to placebo or usual care, corticosteroids probably slightly reduce 28‐day mortality (risk ratio (RR) 0.91, 95% confidence interval (CI) 0.84 to 0.99; 11,233 participants; 50 studies; moderate‐certainty evidence). Corticosteroids may result in little to no difference in long‐term mortality (RR 0.97, 95% CI 0.91 to 1.03; 6236 participants; 7 studies; low‐certainty evidence) and probably slightly reduce hospital mortality (RR 0.90, 95% CI 0.82 to 0.99; 8183 participants; 26 trials; moderate‐certainty evidence). Corticosteroids reduced length of intensive care unit (ICU) stay for all participants (mean difference (MD) ‐1.07 days, 95% CI ‐1.95 to ‐0.19; 7612 participants; 21 studies; high‐certainty evidence) and resulted in a large reduction in length of hospital stay for all participants (MD ‐1.63 days, 95% CI ‐2.93 to ‐0.33; 8795 participants; 22 studies; high‐certainty evidence). Corticosteroids increase the risk of muscle weakness (RR 1.21, 95% CI 1.01 to 1.44; 6145 participants; 6 studies; high‐certainty evidence). Corticosteroids probably do not increase the risk of superinfection (RR 1.06, 95% CI 0.95 to 1.19; 5356 participants; 25 studies; moderate‐certainty evidence). Corticosteroids increase the risk of hypernatraemia (high‐certainty evidence) and probably increase the risk of hyperglycaemia (moderate‐certainty evidence). Moderate‐certainty evidence shows that there is probably little or no difference in gastroduodenal bleeding, stroke, or cardiac events, and low‐certainty evidence suggests that corticosteroids may result in little to no difference in neuropsychiatric events. </p> <p><b><i>Continuous infusion of corticosteroids versus intermittent bolus</i> </b> </p> <p>We are uncertain about the effects of continuous infusion of corticosteroids compared with intermittent bolus administration. Three studies reported data for this comparison, and the certainty of evidence for all outcomes was very low. </p> </section> <section id="CD002243-sec-0007"> <h3 class="title" id="CD002243-sec-0007">Authors' conclusions</h3> <p>Moderate‐certainty evidence indicates that corticosteroids probably reduce 28‐day and hospital mortality among patients with sepsis. Corticosteroids result in large reductions in ICU and hospital length of stay (high‐certainty evidence). There may be little or no difference in the risk of major complications; however, corticosteroids increase the risk of muscle weakness and hypernatraemia, and probably increase the risk of hyperglycaemia. The effects of continuous versus intermittent bolus administration of corticosteroids are uncertain. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002243-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002243-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD002243-abs-0010">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD002243-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002243-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002243-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002243-abs-0020">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002243-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002243-abs-0014">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002243-abs-0019">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002243-abs-0018">Português</a> </li> <li class="section-language"> <a class="" href="full/ro#CD002243-abs-0021">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002243-abs-0012">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD002243-abs-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002243-abs-0011">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002243-abs-0005" lang="en"> <h3>Corticosteroids for treating sepsis</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence on the effect on death of using corticosteroids in children and adults with sepsis. </p> <p><b>Background</b> </p> <p>Sepsis is present when an infection is complicated by organ failure. People develop rapid breathing, hypotension (low blood pressure), and mental confusion. Sepsis can interfere with the effectiveness of the body’s corticosteroids, which serve as a key defence against infection. Corticosteroids have been given for decades to people with infection resulting from various causes. </p> <p><b>Search date</b> </p> <p>The evidence provided in this review is current to July 2019.</p> <p><b>Study characteristics</b> </p> <p>This review included 61 trials (12,192 participants). Fifty‐eight trials compared corticosteroids to no corticosteroids (placebo or usual care in 48 and nine trials, respectively); three trials also compared continuous versus bolus administration of corticosteroids. </p> <p><b>Study funding sources</b> </p> <p>Three trials were funded by a drug company, 27 by public organizations or through charitable funding, and six by both a drug company and public organizations or charitable funding; 25 did not declare the source of funding. </p> <p><b>Key results</b> </p> <p>We have analysed the following two comparisons.</p> <p>• Corticosteroids versus placebo/usual care.</p> <p>Corticosteroids probably reduce the risk of death at 28 days by 9% (50 trials; 11,233 participants), with consistent treatment effects between children and adults. They also probably slightly reduce the risk of dying in hospital. There may be little or no effect of corticosteroids on risk of dying over the long term (longer than three months), but these results are less certain. Corticosteroids result in a large reduction in length of stay in the intensive care unit (ICU) and in hospital. Corticosteroids increase the risk of muscle weakness and hypernatraemia. They probably increase the risk of hyperglycaemia. They probably do not increase the risk of superinfection. There may be little or no effect of corticosteroids on risk of gastroduodenal bleeding, neuropsychiatric events, stroke, or cardiac events. </p> <p>• Continuous infusion versus intermittent boluses of corticosteroids.</p> <p>We are uncertain about the effects of continuous infusion of corticosteroids compared with intermittent bolus administration. Three studies reported data for this comparison, and the certainty of evidence for all outcomes was very low. </p> <p><b>Certainty of evidence</b> </p> <p>• Corticosteroids versus placebo/usual care</p> <p>We judged the certainty of evidence for 28‐day mortality as moderate due to some inconsistency related to differences among study populations, types of corticosteroids and how they were given, and use of additional interventions. </p> <p>• Continuous infusion versus intermittent boluses of corticosteroids</p> <p>We judged the certainty of evidence for 28‐day mortality as very low due to inconsistency and imprecision. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002243-sec-0175" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002243-sec-0175">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002243-sec-0257">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002243-sec-0175"></div> <h3 class="title" id="CD002243-sec-0176">Implications for practice</h3> <section id="CD002243-sec-0176"> <p>Moderate‐certainty evidence indicates that corticosteroids probably reduce 28‐day, 90‐day, and hospital mortality among patients with sepsis. Corticosteroids result in a large reduction in ICU and hospital length of stay (high‐certainty evidence). There may be little or no difference in the risk of major complications; however, corticosteroids increase the risk of muscle weakness and hypernatraemia (high‐certainty evidence), and probably increase the risk of hyperglycaemia (moderate‐certainty evidence). The effects of continuous versus intermittent bolus administration of corticosteroids are uncertain. </p> </section> <h3 class="title" id="CD002243-sec-0177">Implications for research</h3> <section id="CD002243-sec-0177"> <p>The criteria for critical illness‐related corticosteroid insufficiency in septic shock remain to be defined. </p> <p>Subgroup analyses suggest that additional studies are needed to address these topics related to the use of corticosteroids in patients with sepsis. </p> <p> <ul id="CD002243-list-0010"> <li> <p>The role of a long course of low‐dose corticosteroids for treatment of septic shock in children. </p> </li> <li> <p>The role of a long course of low‐dose corticosteroids for treatment of patients with sepsis without shock, or with a mild form of septic shock; patients with ARDS; and patients with sepsis related to community‐acquired pneumonia. </p> </li> <li> <p>The role of mineralocorticoid replacement.</p> </li> <li> <p>Optimal timing of initiation of treatment.</p> </li> <li> <p>Optimal dose and duration of hydrocortisone (or equivalent).</p> </li> <li> <p>Optimal modality to administer treatment that is continuous versus intermittent bolus.</p> </li> <li> <p>Optimal modality to stop treatment with or without taper off.</p> </li> <li> <p>The role of a long course of low‐dose corticosteroids for treatment of sepsis caused by different types of infections. </p> </li> <li> <p>Long‐term neuromuscular effects of steroids.</p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002243-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002243-sec-0050"></div> <div class="table" id="CD002243-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Corticosteroids compared to placebo or usual care for treating sepsis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Corticosteroids compared to placebo or usual care for treating sepsis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children and adults with sepsis<br/> <b>Setting:</b> hospitalised patients; trials were performed in numerous countries from the 5 continents<br/> <b>Intervention:</b> corticosteroids<br/> <b>Comparison:</b> placebo or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or usual care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with corticosteroids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28‐Day all‐cause mortality<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.84 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11233<br/> (50 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably slightly reduce 28‐day all‐cause mortality</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>264 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 per 1000<br/> (222 to 261) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Long‐term mortality<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.91 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6236<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids may result in little to no difference in long‐term mortality</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>386 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>374 per 1000<br/> (351 to 397) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hospital mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.82 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8183<br/> (26 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably slightly reduce hospital mortality</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>323 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>291 per 1000<br/> (265 to 320) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of intensive care unit stay for all participants in days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean length of intensive care unit stay for all participants was 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.07 lower<br/> (1.95 lower to 0.19 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7612<br/> (21 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids reduced length of intensive care unit stay for all participants</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay for all participants in days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean length of hospital stay for all participants was 21 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.63 lower<br/> (2.93 lower to 0.33 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8795<br/> (22 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids result in a large reduction in length of hospital stay for all participants</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events ‐ superinfection (up to longest follow‐up)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/> (0.95 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5356<br/> (25 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably do not increase the number of participants with adverse events ‐ superinfection </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000<br/> (161 to 202) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events ‐ muscle weakness (up to longest follow‐up)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.21<br/> (1.01 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6145<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids increase the number of participants with adverse events ‐ muscle weakness</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/> (57 to 81) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio. </p> <p>The unit of measure for length of stay is days.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Sensitivity analysis based on trials judged as being at low risk of bias showed an RR for dying at 28 days of 0.91 (95% CI 0.84 to 0.98; P = 0.01; 7896 participants; 17 studies; I² = 0%). </p> <p><sup>b</sup>Downgraded one level for inconsistency; there was significant statistical heterogeneity. </p> <p><sup>c</sup>Long‐term mortality was recorded up to six months for three trials (<a href="./references#CD002243-bbs2-0004" title="AnnaneD , RenaultA , Brun‐BuissonC , MegarbaneB , QuenotJP , SiamiS , et al. Hydrocortisone plus fludrocortisone for adults with septic shock. New England Journal of Medicine2018;378(9):809‐18. [PUBMED: 29490185] ">Annane 2018</a>; <a href="./references#CD002243-bbs2-0025" title="KehD , TripsE , MarxG , WirtzSP , AbduljawwadE , BerckerS , et al. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA2016;316(17):1775‐85. [PUBMED: 27695824] ">Keh 2016</a>; <a href="./references#CD002243-bbs2-0058" title="VenkateshB , FinferS , CohenJ , RajbhandariD , ArabiY , BellomoR , et al. Adjunctive glucocorticoid therapy in patients with septic shock. New England Journal of Medicine2018;378:797–808. [DOI: 10.1056/NEJMoa1705835; PUBMED: 29347874] VenkateshB , FinferS , MybrughJ , CohenJ , BillotL . Long‐term outcomes of the ADRENAL trial [2018]. New England Journal of Medicine2018;378(18):174‐5. [PUBMED: 29694789] ">Venkatesh 2018</a>), and up to one year for four trials (<a href="./references#CD002243-bbs2-0002" title="AnnaneD , SebilleV , CharpentierC , BollaertPE , FrançoisB , KorachJM , et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA2002;288(7):862‐71. [PUBMED: 12186604] ">Annane 2002</a>; <a href="./references#CD002243-bbs2-0009" title="BriegelJ , ForstH , HallerM , SchellingG , KilgerE , KupratG , et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double‐blind, single‐center study. Critical Care Medicine1999;27(4):723‐32. [PUBMED: 10321661] ">Briegel 1999</a>; <a href="./references#CD002243-bbs2-0033" title="MeduriGU , GoldenE , FreireAX , TaylorE , ZamanM , CarsonSJ , et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest2007;131(4):954‐63. [PUBMED: 17426195] ">Meduri 2007</a>; <a href="./references#CD002243-bbs2-0049" title="SprungC , AnnaneD , KehD , MorenoR , SingerM , FreivogelK , et al. Hydrocortisone therapy for patients with septic shock. New England Journal of Medicine2008;358(2):111‐24. [PUBMED: 18184957] ">Sprung 2008</a>). </p> <p><sup>d</sup>Large 95% confidence interval overlapping the neutrality line. </p> <p><sup>e</sup>Upgraded one level due to large size effects. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002243-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002243-sec-0051">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002243-sec-0212">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD002243-sec-0051"></div> <section id="CD002243-sec-0052"> <h3 class="title" id="CD002243-sec-0052">Description of the condition</h3> <p>Sepsis occurs when the host response to an infection is dysregulated (<a href="./references#CD002243-bbs2-0170" title="SingerM , DeutschmanCS , SeymourCW , Shankar‐HariM , AnnaneD , BauerM , et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis‐3). JAMA2016;315(8):801‐10. [PUBMED: 26903338] ">Singer 2016</a>). The dysregulated host response is usually defined by the presence of a sequential organ failure assessment (SOFA) score of 2 or higher (<a href="./references#CD002243-bbs2-0170" title="SingerM , DeutschmanCS , SeymourCW , Shankar‐HariM , AnnaneD , BauerM , et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis‐3). JAMA2016;315(8):801‐10. [PUBMED: 26903338] ">Singer 2016</a>; <a href="./references#CD002243-bbs2-0177" title="VincentJL , MorenoR , TakalaJ , WillattsS , DeMendonçaA , BruiningH , et al. The SOFA (Sepsis‐related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis‐Related Problems of the European Society of Intensive Care Medicine. Intensive Care Medicine1996;22(7):707‐10. [PUBMED: 8844239] ">Vincent 1996</a>). Septic shock is a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with greater risk of mortality than is sepsis alone. Patients with septic shock can be clinically identified by a vasopressor requirement to maintain mean arterial pressure of 65 mmHg or greater and serum lactate levels greater than 2 mmol/L (&gt; 18 mg/dL) in the absence of hypovolaemia. The dysregulated response may result in systemic inflammation and organ damage, or in immune paresis and secondary infection (<a href="./references#CD002243-bbs2-0175" title="van derPollT , van deVeerdonkFL , SciclunaBP , NeteaMG . The immunopathology of sepsis and potential therapeutic targets. Nature Reviews. Immunology2017;17(7):407‐20. [PUBMED: 28436424] ">van der Poll 2017</a>). In 2017, the World Health Organization estimated that around 31 million people develop sepsis each year, and about 10 million die (<a href="./references#CD002243-bbs2-0179" title="WHO . Improving prevention, diagnosis and clinical management of sepsis. https://www.who.int/servicedeliverysafety/areas/sepsis/en/#.XAAf362Zqkk.mendeley. 2018. Accessed 29 November 2018. ">WHO 2018</a>). According to a recent retrospective cohort study of adult patients admitted to 409 academic, community, and federal hospitals in the USA from 2009 to 2014, sepsis was present in 6% of adult hospitalizations (<a href="./references#CD002243-bbs2-0162" title="RheeC , DantesR , EpsteinL , MurphyDJ , SeymourCW , IwashynaTJ , et al. CDC Prevention Epicenter Program. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009‐2014. JAMA2017;318(13):1241‐9. [PUBMED: 28903154] ">Rhee 2017</a>). Another study of electronic health records from 27 academic hospitals in the USA reported an annual incidence of septic shock of about 19 per 1000 hospitalizations in 2014 (<a href="./references#CD002243-bbs2-0139" title="KadriSS , RheeC , StrichJR , MoralesMK , HohmannS , MenchacaJ , et al. Estimating ten‐year trends in septic shock incidence and mortality in United States academic medical centers using clinical data. Chest2017;151(2):278‐28. [PUBMED: 27452768] ">Kadri 2017</a>). People with sepsis usually die from hypotension or progressive multiple organ failure (<a href="./references#CD002243-bbs2-0101" title="AngusDC , van derPollT . Severe sepsis and septic shock. New England Journal of Medicine2013;369(21):840‐51. [PUBMED: 23984731] ">Angus 2013</a>; <a href="./references#CD002243-bbs2-0103" title="AnnaneD , AegerterP , Jars‐GuincestreMC , GuidetB , CUB‐Rea Network. Current epidemiology of septic shock: the CUB‐Réa Network. American Journal of Respiratory and Critical Care Medicine2003;168(2):165‐72. [PUBMED: 12851245] ">Annane 2003</a>; <a href="./references#CD002243-bbs2-0104" title="AnnaneD , BellissantE , CavaillonJM . Septic shock. Lancet2005;365(9453):63‐78. [PUBMED: 15639681] ">Annane 2005</a>; <a href="./references#CD002243-bbs2-0158" title="ParrilloJE . Pathogenic mechanisms of septic shock. New England Journal of Medicine1993;328(20):1471‐7. [PUBMED: 8479467] ">Parrillo 1993</a>). There is no current diagnostic test for sepsis. Its standard management includes control of the source of infection with antibiotics and surgery whenever needed, as well as control of tissue oxygenation with fluid replacement, oxygen with or without respiratory support, and vasopressors whenever needed (<a href="./references#CD002243-bbs2-0164" title="RhodesA , EvansLE , AlhazzaniW , LevyMM , AntonelliM , FerrerR , et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Medicine2017;43(3):304‐77. [PUBMED: 28101605] ">Rhodes 2017</a>). No specific interventions are yet available to control immune responses to invading pathogens (<a href="./references#CD002243-bbs2-0164" title="RhodesA , EvansLE , AlhazzaniW , LevyMM , AntonelliM , FerrerR , et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Medicine2017;43(3):304‐77. [PUBMED: 28101605] ">Rhodes 2017</a>). The financial burden of sepsis on the healthcare system has been calculated to be &gt; 24 billion USD, representing 6.2% of total hospital costs in 2013 (<a href="./references#CD002243-bbs2-0179" title="WHO . Improving prevention, diagnosis and clinical management of sepsis. https://www.who.int/servicedeliverysafety/areas/sepsis/en/#.XAAf362Zqkk.mendeley. 2018. Accessed 29 November 2018. ">WHO 2018</a>). Studies in Europe and Canada estimated the daily costs of hospital care for a septic patient in 2000 to be between EUR 710 and EUR 1033 (equivalent to about USD 645 and USD 939, respectively) (<a href="./references#CD002243-bbs2-0179" title="WHO . Improving prevention, diagnosis and clinical management of sepsis. https://www.who.int/servicedeliverysafety/areas/sepsis/en/#.XAAf362Zqkk.mendeley. 2018. Accessed 29 November 2018. ">WHO 2018</a>). </p> </section> <section id="CD002243-sec-0053"> <h3 class="title" id="CD002243-sec-0053">Description of the intervention</h3> <p>Corticosteroids include the natural steroid hormones produced by adrenocortical cells and a broad variety of synthetic analogues. These substances have various effects that may be grossly classified into glucocorticoid and mineralocorticoid effects. Glucocorticoid effects include mainly regulation of carbohydrate, lipid, and protein metabolism, as well as regulation of inflammation. Mineralocorticoid effects include mainly regulation of electrolyte and water metabolism. At molecular levels, glucocorticoids have non‐genomic and genomic effects (<a href="./references#CD002243-bbs2-0106" title="AnnaneD , PastoresSM , ArltW , BalkRA , BeishuizenA , BriegelJ , et al. Critical illness‐related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Medicine2017;43(12):1781‐92. [PUBMED: 28940017] ">Annane 2017a</a>; <a href="./references#CD002243-bbs2-0114" title="CainDW , CidlowskiJA . Immune regulation by glucocorticoids. Nature Reviews. Immunology2017;17(4):233‐47. [PUBMED: 28192415] ">Cain 2017</a>). Rapid (within minutes) non‐genomic effects of glucocorticoids include a decrease in platelet aggregation, in cell adhesion, and in intracellular phosphotyrosine kinases, and they include an increase in annexin 1 externalization (<a href="./references#CD002243-bbs2-0147" title="LowenbergM , TuynmanJ , BilderbeekJ , GaberT , ButtgereitF , vanDeventerS , et al. Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. Blood2005;106(5):1703‐10. [PUBMED: 15899916] ">Lowenberg 2005</a>). These effects may result from the interaction of glucocorticoids with specific membrane sites (<a href="./references#CD002243-bbs2-0156" title="NormanAW , MizwickiMT , NormanDP . Steroid‐hormone rapid actions, membrane receptors, and a conformational ensemble model. Nature Reviews. Drug Discovery2004;3(1):27‐41. [PUBMED: 14708019] ">Norman 2004</a>). Glucocorticoids have indirect genomic effects, called trans‐repression (<a href="./references#CD002243-bbs2-0163" title="RhenT , CidlowskiJA . Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. New England Journal of Medicine2005;353(16):1711‐23. [PUBMED: 16236742] ">Rhen 2005</a>). These occur within a few hours following exposure of cells to glucocorticoids. They result from the physical interaction between the monomeric glucocorticoid‐glucocorticoid receptor (G‐GR)α complex and various nuclear transcription factors, such as nuclear factor (NF)‐κB and activator protein (AP)‐1. Subsequently, these nuclear transcription factors are sequestrated in the cytosol and cannot enter the nucleus, preventing the expression of genes encoding for most if not all pro‐inflammatory mediators. Glucocorticoids also have direct genomic effects, called transactivation. They require only a few days of cell exposure to glucocorticoids. Indeed, conformational changes (i.e. dimerization of the G‐GRα complex) are needed before this complex can migrate to the nucleus to interact with glucocorticoid‐responsive elements, that is, parts of genes encoding for regulators of termination of inflammation. Then, key anti‐inflammatory factors are up‐regulated, leading to phagocytosis, chemokinesis, and anti‐oxidative processes. The net effect of glucocorticoids involves reprogramming rather than inhibiting immune cell function (<a href="./references#CD002243-bbs2-0123" title="EhrchenJ , SteinmüllerL , BarczykK , TenbrockK , NackenW , EisenacherM , et al. Glucocorticoids induce differentiation of a specifically activated, anti‐inflammatory subtype of human monocytes. Blood2007;109(3):1265‐74. [PUBMED: 17018861] ">Erschen 2007</a>). Glucocorticoids induce specific activated anti‐inflammatory monocyte subtypes that migrate quickly to inflamed tissues (<a href="./references#CD002243-bbs2-0176" title="VargaG , EhrchenJ , TsianakasA , TenbrockK , RattenhollA , SeeligerS , et al. Glucocorticoids induce an activated, anti‐inflammatory monocyte subset in mice that resembles myeloid‐derived suppressor cells. Journal of Leukocyte Biology2008;84(3):644‐50. [PUBMED: 18611985] ">Varga 2008</a>). They prolong survival of this subtype of monocyte via A3 adenosine receptor‐triggered anti‐apoptotic effects (<a href="./references#CD002243-bbs2-0108" title="BarczykK , EhrchenJ , TenbrockK , AhlmannM , KneidlJ , ViemannD , et al. Glucocorticoids promote survival of anti‐inflammatory macrophages via stimulation of adenosine receptor A3. Blood2010;116(3):446‐55. [PUBMED: 20460503] ">Barczyk 2010</a>). Overall, these molecular mechanisms of action of glucocorticoids are appropriate for counteracting the uncontrolled inflammation that may characterize sepsis. </p> </section> <section id="CD002243-sec-0054"> <h3 class="title" id="CD002243-sec-0054">How the intervention might work</h3> <p>Researchers have explored the biological mechanisms of sepsis to investigate potential interventions. Corticosteroids have been a topic of particular focus because of their influence on the immune response (<a href="./references#CD002243-bbs2-0114" title="CainDW , CidlowskiJA . Immune regulation by glucocorticoids. Nature Reviews. Immunology2017;17(4):233‐47. [PUBMED: 28192415] ">Cain 2017</a>). In sepsis, the hypothalamic‐pituitary gland hormonal pathway to the adrenal glands stimulates corticosteroid production (<a href="./references#CD002243-bbs2-0106" title="AnnaneD , PastoresSM , ArltW , BalkRA , BeishuizenA , BriegelJ , et al. Critical illness‐related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Medicine2017;43(12):1781‐92. [PUBMED: 28940017] ">Annane 2017a</a>; <a href="./references#CD002243-bbs2-0115" title="ChrousosGP . The hypothalamic‐pituitary‐adrenal axis and immune‐mediated inflammation. New England Journal of Medicine1995;322(20):1351‐62. [PUBMED: 7715646] ">Chrousos 1995</a>; <a href="./references#CD002243-bbs2-0116" title="CooperMS , StewartPM . Corticosteroid insufficiency in acutely ill patients. New England Journal of Medicine2003;348(8):727‐34. [PUBMED: 12594318 ] ">Cooper 2003</a>; <a href="./references#CD002243-bbs2-0133" title="HemingN , SivanandamoorthyS , MengP , BounabR , AnnaneD . Immune effects of corticosteroids in sepsis. Frontiers in Immunology2018;9:1736. [DOI: 10.3389/fimmu.2018.01736; PUBMED: 30105022] ">Heming 2018</a>). These hormones affect inflammation through the production of white blood cells, cytokines (proteins that influence the immune response), and nitric oxide. In sepsis, cytokines may suppress adrenocorticotropin hormone synthesis (<a href="./references#CD002243-bbs2-0106" title="AnnaneD , PastoresSM , ArltW , BalkRA , BeishuizenA , BriegelJ , et al. Critical illness‐related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Medicine2017;43(12):1781‐92. [PUBMED: 28940017] ">Annane 2017a</a>; <a href="./references#CD002243-bbs2-0160" title="PolitoA , SonnevilleR , GuidouxC , BarrettL , ViltartO , MattotV , et al. Changes in CRH and ACTH synthesis during experimental and human septic shock. PLoS One2011;6(11):e25905. [PUBMED: 22073145] ">Polito 2011</a>; <a href="./references#CD002243-bbs2-0168" title="SharsharT , GrayF , Lorin de la GrandmaisonG , HopkinsonNS , RossE , DorandeuA , et al. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet2003;362(9398):1799‐805. [PUBMED: 14654318] ">Sharshar 2003</a>), along with the cortisol response to exogenous adrenocorticotropin hormone (<a href="./references#CD002243-bbs2-0106" title="AnnaneD , PastoresSM , ArltW , BalkRA , BeishuizenA , BriegelJ , et al. Critical illness‐related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Medicine2017;43(12):1781‐92. [PUBMED: 28940017] ">Annane 2017a</a>; <a href="./references#CD002243-bbs2-0135" title="HottaM , BairdA . Differential effects of transforming growth factor type beta on the growth and function of adrenocortical cells in vitro. Proceedings of the National Academy of Sciences of the United States of America1986;83(20):7795‐9. [PUBMED: 3020557] ">Hotta 1986</a>; <a href="./references#CD002243-bbs2-0138" title="JaattelaM , IlvesmakiV , VoutilainenR , StenmanUH , SakselaE . Tumor necrosis factor as a potent inhibitor of adrenocorticotropin‐induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology1991;128(1):623‐9. [PUBMED: 1702707] ">Jaattela 1991</a>). Likewise, sepsis may be associated with alterations in scavenger receptor B1‐mediated cholesterol delivery (<a href="./references#CD002243-bbs2-0113" title="CaiL , JiA , deBeerFC , TannockLR , van derWesthuyzenDR . SR‐BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. Journal of Clinical Investigation2008;118(1):364–75. [PUBMED: 18064300] ">Cai 2008</a>). This causes poor adrenal activity in almost half of patients (<a href="./references#CD002243-bbs2-0102" title="AnnaneD , SébilleV , TrochéG , RaphaelJC , GajdosP , BellissantE . A 3‐level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA2000;283(8):1038‐45. [PUBMED: 10697064] ">Annane 2000</a>; <a href="./references#CD002243-bbs2-0146" title="LipinerD , SprungCL , LaterrePF , WeissY , GoodmanSV , VogeserM , et al. Adrenal function in sepsis: the retrospective CORTICUS cohort study. Critical Care Medicine2007;35(4):1012‐8. [PUBMED: 17334243] ">Lipiner 2007</a>; <a href="./references#CD002243-bbs2-0148" title="MarikPE , PastoresSM , AnnaneD , MeduriGU , SprungCL , ArltW , et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Critical Care Medicine2008;36(6):1937–49. [PUBMED: 18496365] ">Marik 2008</a>; <a href="./references#CD002243-bbs2-0166" title="RothwellPM , UdwadiaZF , LawlerPG . Cortisol response to corticotropin and survival in septic shock. Lancet1991;337(8741):582‐3. [PUBMED: 1671944] ">Rothwell 1991</a>), as well as possible resistance of body tissues to corticosteroids due to fewer corticosteroid receptors or receptors with lower affinity (<a href="./references#CD002243-bbs2-0109" title="BarnesPJ , GreeningAP , CromptonGK . Glucocorticoid resistance in asthma. American Journal of Respiratory and Critical Care Medicine1995;152(Suppl 6 Pt 2):125‐40. [PUBMED: 7489120] ">Barnes 1995</a>; <a href="./references#CD002243-bbs2-0136" title="HuangZH , GaoH , XuRB . Study on glucocorticoid receptors during intestinal ischemia shock and septic shock. Circulatory Shock1987;23(1):27‐36. [PUBMED: 3690811] ">Huang 1987</a>; <a href="./references#CD002243-bbs2-0149" title="MeduriGU , ChrousosGP . Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way?. Chest1998;114(2):355‐60. [PUBMED: 9726712] ">Meduri 1998a</a>; <a href="./references#CD002243-bbs2-0152" title="MolijnGJ , KoperJW , vanUffelenCJ , deJongFH , BrinkmannAO , BruiningHA , et al. Temperature‐induced down‐regulation of the glucocorticoid receptor in peripheral blood mononuclear leucocyte in patients with sepsis or septic shock. Clinical Endocrinology1995;43(2):197‐203. [PUBMED: 7554315 ] ">Molijn 1995</a>). Alteration of corticosteroid receptor numbers and in binding capacity may be related at least in part to nitric oxide (<a href="./references#CD002243-bbs2-0121" title="DumaD , Silva‐SantosJE , AssreuyJ . Inhibition of glucocorticoid receptor binding by nitric oxide in endotoxemic rats. Critical Care Medicine2004;32(11):2304–10. [PUBMED: 15640646] ">Duma 2004</a>; <a href="./references#CD002243-bbs2-0126" title="GalignianaMD , Piwien‐PilipukG , AssreuyJ . Inhibition of glucocorticoid receptor binding by nitric oxide. Molecular Pharmacology1999;55(2):317–23. [PUBMED: 9927624] ">Galigniana 1999</a>). Recent work suggests that immune cells ‐ not steroid‐secreting cells ‐ are key regulators of the interaction between the immune system and the adrenals (<a href="./references#CD002243-bbs2-0141" title="KanczkowskiW , AlexakiVI , TranN , GroßklausS , ZacharowskiK , MartinezA , et al. Hypothalamo‐pituitary and immune‐dependent adrenal regulation during systemic inflammation. Proceedings of the National Academy of Science2013;110(36):14801–6. [PUBMED: 23959899] ">Kanczkowski 2013</a>). In addition, acute illness such as sepsis may be associated with decreased cortisol clearance from plasma (<a href="./references#CD002243-bbs2-0110" title="BoonenE , VervenneH , MeerssemanP , AndrewR , MortierL , DeclercqPE , et al. Reduced cortisol metabolism during critical illness. New England Journal of Medicine2013;388(16):1477‐88. [PUBMED: 23506003] ">Boonen 2013</a>; <a href="./references#CD002243-bbs2-0150" title="MelbyJC , SpinkWW . Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. Journal of Clinical Investigation1958;37(12):1791‐8. [PUBMED: 13611047] ">Melby 1958</a>), likely resulting from altered hepatic and renal inactivation of cortisol (<a href="./references#CD002243-bbs2-0110" title="BoonenE , VervenneH , MeerssemanP , AndrewR , MortierL , DeclercqPE , et al. Reduced cortisol metabolism during critical illness. New England Journal of Medicine2013;388(16):1477‐88. [PUBMED: 23506003] ">Boonen 2013</a>). Early studies showed that a pharmacological dose of corticosteroids prolonged survival among animals with sepsis (<a href="./references#CD002243-bbs2-0124" title="FabianTC , PattersonR . Steroid therapy in septic shock. Survival studies in a laboratory model. American Surgeon1982;48(12):614‐7. [PUBMED: 6760756] ">Fabian 1982</a>). More recent studies in rodents have demonstrated that lower doses of corticosteroids, for example, 0.1 mg/kg of dexamethasone, improved haemodynamic and organ function, favourably modulated the inflammatory response, and prolonged survival (<a href="./references#CD002243-bbs2-0120" title="diVilla BiancaRE , LippolisL , AutoreG , PopoloA , MarzoccoS , SorrentinoL , et al. Dexamethasone improves vascular hyporeactivity induced by LPS in vivo by modulating ATP‐sensitive potassium channel activity. British Journal of Pharmacology2003;140(1):91–6. [PUBMED: 12967938] ">di Villa Bianca 2003</a>; <a href="./references#CD002243-bbs2-0132" title="HellerAR , HellerSC , BorkensteinA , StehrSN , KochT . Modulation of host defence by hydrocortisone in stress doses during endotoxaemia. Intensive Care Medicine2003;29(9):1456‐63. [PUBMED: 12879235 ] ">Heller 2003</a>; <a href="./references#CD002243-bbs2-0173" title="TsaoCM , HoST , ChenA , WangJJ , LiCY , TsaiSK , et al. Low‐dose dexamethasone ameliorates circulatory failure and renal dysfunction in conscious rats with endotoxemia. Shock2004;21(5):484‐91. [PUBMED: 15087827] ">Tsao 2004</a>; <a href="./references#CD002243-bbs2-0174" title="VachharajaniV , VitalS , RussellJ , ScottLK , GrangerDN . Glucocorticoids inhibit the cerebral microvascular dysfunction associated with sepsis in obese mice. Microcirculation2006;13(6):477‐87. [PUBMED: 16864414 ] ">Vachharajani 2006</a>). Protective effects of these glucocorticoids against sepsis may be mediated in part by the endothelial glucocorticoid receptor (<a href="./references#CD002243-bbs2-0127" title="GoodwinJE , FengY , VelazquezH , SessaWC . Endothelial glucocorticoid receptor is required for protection against sepsis. Proceedings of the National Academy of Science2013;110(1):306–11. [PUBMED: 23248291] ">Goodwin 2013</a>). In healthy volunteers challenged with endotoxin, a low dose of corticosteroids, for example, 10 mg of prednisolone, blocked the release of pro‐inflammatory cytokines, prevented endothelial cell and neutrophil activation, and inhibited the acute phase response without altering coagulation and fibrinolysis balance (<a href="./references#CD002243-bbs2-0118" title="deKruifMD , LemaireLC , GiebelenIA , vanZoelenMA , PaterJM , van denPangaartPS , et al. Prednisolone dose‐dependently influences inflammation and coagulation during human endotoxemia. Journal of Immunology2007;178(3):1845‐51. [PUBMED: 17237435] ">de Kruif 2007</a>). Studies in patients with septic shock have shown that a short course of corticosteroids may result in a rebound in the systemic inflammatory response (<a href="./references#CD002243-bbs2-0111" title="BriegelJ , KellermannW , ForstH , HallerM , BittlM , HoffmannGE , et al. Low‐dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clinical Investigation1994;72(10):782‐7. [PUBMED: 7865982] ">Briegel 1994</a>; <a href="./references#CD002243-bbs2-0024" title='KehD , BoehnkeT , Weber‐CartensS , SchulzC , AhlersO , BerckerS , et al. Immunologic and hemodynamic effects of "low‐dose" hydrocortisone in septic shock: a double‐blind, randomized, placebo‐controlled, crossover study. American Journal of Respiratory and Critical Care Medicine2003;167(4):512‐20. [PUBMED: 12426230 ] '>Keh 2003</a>). In addition, it is now recognized that increased pro‐inflammatory cytokine release can be sustained for longer than a week in patients with sepsis (<a href="./references#CD002243-bbs2-0143" title="KellumJA , KongL , FinkMP , WeissfeldLA , YealyDM , PinskyMR , et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Archives of Internal Medicine2007;167(15):1655‐63. [PUBMED: 17698689] ">Kellum 2007</a>). Likewise, the timing of initiation of corticosteroids may be an important factor in the response to treatment. Indeed, in observational studies, short‐term mortality increased with delayed initiation of hydrocortisone (<a href="./references#CD002243-bbs2-0142" title="KatsenosCS , AntonopoulouAN , ApostolidouEN , IoakeimidouA , KalpakouGT , PapanikolaouMN , et al. on behalf of the Hellenic Sepsis Study Group. Early administration of hydrocortisone replacement after the advent of septic shock: impact on survival and immune response. Critical Care Medicine2014;42(7):1651‐7. [PUBMED: 24674923] ">Katsenos 2014</a>; <a href="./references#CD002243-bbs2-0157" title="ParkHY , SuhGY , SongJU , YooH , JoIJ , ShinTG , et al. Early initiation of low‐dose corticosteroid therapy in the management of septic shock: a retrospective observational study. Critical Care2012;16(1):R3. [PUBMED: 22226237] ">Park 2012</a>). For these reasons, we would anticipate that corticosteroid treatment is beneficial for patients with sepsis, and that differences in dose, timing, or duration of corticosteroid treatment may differentially affect patient response to treatment. Finally, several authors have argued that in patients with sepsis, hydrocortisone should be given as a continuous infusion rather than as intermittent boluses to reduce the risk of metabolic complications (<a href="./references#CD002243-bbs2-0164" title="RhodesA , EvansLE , AlhazzaniW , LevyMM , AntonelliM , FerrerR , et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Medicine2017;43(3):304‐77. [PUBMED: 28101605] ">Rhodes 2017</a>). In sepsis trials, continuous infusion of hydrocortisone was variably associated with better outcomes or worse outcomes than intermittent intravenous boluses (<a href="./references#CD002243-bbs2-0029" title="LoisaP , ParviainenI , TenhunenJ , HovilehtoS , RuokonenE . Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial. Critical Care2007;11(1):R21. [PUBMED: 17306016] ">Loisa 2007</a>; <a href="./references#CD002243-bbs2-0053" title="TiloucheN , JaouedO , Ben Sik AliH , GharbiR , Fekih HassenM , ElatrousS . Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock2019;52:481‐6. [DOI: 10.1097/SHK.0000000000001316.; PUBMED: 30628950] ">Tilouche 2019</a>). </p> </section> <section id="CD002243-sec-0055"> <h3 class="title" id="CD002243-sec-0055">Why it is important to do this review</h3> <p>Initially, researchers used high doses of corticosteroids, usually given as a single bolus, in an attempt to block potential bursts in pro‐inflammatory cytokines. Two systematic reviews and meta‐analyses of trials of corticosteroids in sepsis or in septic shock included 10 ‐ <a href="./references#CD002243-bbs2-0145" title="LeferingR , NeugebauerEAM . Steroid controversy in sepsis and septic shock: a meta‐analysis. Critical Care Medicine1995;23(7):1294‐303. [PUBMED: 7600840 ] ">Lefering 1995</a> ‐ and nine ‐ <a href="./references#CD002243-bbs2-0117" title="CroninL , CookDJ , CarletJ , HeylandDK , KingD , LansangMAD , et al. Corticosteroid treatment for sepsis: a critical appraisal and meta‐analysis of the literature. Critical Care Medicine1995;23(8):1430‐9. [PUBMED: 7634816 ] ">Cronin 1995</a> ‐ randomized controlled trials (RCTs), respectively. These systematic reviews showed no significant effect on relative risk of death, gastrointestinal bleeding, or superinfection associated with the use of corticosteroids. </p> <p>Subsequently, most clinicians will not recommend the use of high doses of corticosteroids in sepsis (<a href="./references#CD002243-bbs2-0107" title="AnnaneD , PastoresSM , RochwergB , ArltW , BalkRA , BeishuizenA , et al. Guidelines for the diagnosis and management of critical illness‐related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Medicine2017;43(12):1751‐63. [PUBMED: 28940011] ">Annane 2017b</a>; <a href="./references#CD002243-bbs2-0164" title="RhodesA , EvansLE , AlhazzaniW , LevyMM , AntonelliM , FerrerR , et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Medicine2017;43(3):304‐77. [PUBMED: 28101605] ">Rhodes 2017</a>). The potential benefits of a lower dose (≤ 400 mg hydrocortisone or equivalent per day) and a longer duration at full dose (≥ 3 days) of treatment have been investigated in numerous RCTs over the past three decades (<a href="./references#CD002243-bbs2-0107" title="AnnaneD , PastoresSM , RochwergB , ArltW , BalkRA , BeishuizenA , et al. Guidelines for the diagnosis and management of critical illness‐related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Medicine2017;43(12):1751‐63. [PUBMED: 28940011] ">Annane 2017b</a>; <a href="./references#CD002243-bbs2-0144" title="LamontagneF , RochwergB , LytvynL , GuyattGH , MøllerMH , AnnaneD , et al. Corticosteroid therapy for sepsis: a clinical practice guideline. BMJ2018;362:k3284. [PUBMED: 30097460] ">Lamontagne 2018</a>; <a href="./references#CD002243-bbs2-0165" title="RochwergB , OczkowskiSJ , SiemieniukRAC , AgoritsasT , Belley‐CoteE , D'AragonF , et al. Corticosteroids in sepsis: an updated systematic review and meta‐analysis. Critical Care Medicine2018;46(9):1411‐20. [PUBMED: 29979221] ">Rochwerg 2018</a>). In the past two years, clinical practice guidelines about corticosteroid use in sepsis have been released by at least five entities (<a href="./references#CD002243-bbs2-0107" title="AnnaneD , PastoresSM , RochwergB , ArltW , BalkRA , BeishuizenA , et al. Guidelines for the diagnosis and management of critical illness‐related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Medicine2017;43(12):1751‐63. [PUBMED: 28940011] ">Annane 2017b</a>; <a href="./references#CD002243-bbs2-0144" title="LamontagneF , RochwergB , LytvynL , GuyattGH , MøllerMH , AnnaneD , et al. Corticosteroid therapy for sepsis: a clinical practice guideline. BMJ2018;362:k3284. [PUBMED: 30097460] ">Lamontagne 2018</a>; <a href="./references#CD002243-bbs2-0155" title="NishidaO , OguraH , EgiM , FujishimaS , HayashiY , IbaT , et al. The Japanese clinical practice guidelines for management of sepsis and septic shock 2016 (J‐SSCG 2016). Acute Medicine and Surgery2018;5:3‐89. [PUBMED: 29445505] ">Nishida 2018</a>; <a href="./references#CD002243-bbs2-0164" title="RhodesA , EvansLE , AlhazzaniW , LevyMM , AntonelliM , FerrerR , et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Medicine2017;43(3):304‐77. [PUBMED: 28101605] ">Rhodes 2017</a>; <a href="./references#CD002243-bbs2-0172" title="TavaréA , O’FlynnN . Recognition, diagnosis, and early management of sepsis: NICE guideline. British Journal of General Practice2017;67(657):185‐6. [PUBMED: 28360070] ">Tavaré 2017</a>). All but one of the guidelines ‐ <a href="./references#CD002243-bbs2-0144" title="LamontagneF , RochwergB , LytvynL , GuyattGH , MøllerMH , AnnaneD , et al. Corticosteroid therapy for sepsis: a clinical practice guideline. BMJ2018;362:k3284. [PUBMED: 30097460] ">Lamontagne 2018</a> ‐ recommended against the use of corticosteroids in sepsis, except in patients with septic shock and a poor response to fluid replacement and vasopressor therapy. Some guidelines suggested that corticosteroids should be given as a continuous infusion rather than in intermittent boluses (<a href="./references#CD002243-bbs2-0107" title="AnnaneD , PastoresSM , RochwergB , ArltW , BalkRA , BeishuizenA , et al. Guidelines for the diagnosis and management of critical illness‐related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Medicine2017;43(12):1751‐63. [PUBMED: 28940011] ">Annane 2017b</a>; <a href="./references#CD002243-bbs2-0164" title="RhodesA , EvansLE , AlhazzaniW , LevyMM , AntonelliM , FerrerR , et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Medicine2017;43(3):304‐77. [PUBMED: 28101605] ">Rhodes 2017</a>). In the year 2018, five different systematic reviews and meta‐analyses addressed the effects of corticosteroids in sepsis (<a href="./references#CD002243-bbs2-0100" title="AllenJM , FeildC , ShouldersBR , VoilsSA . Recent updates in the pharmacological management of sepsis and septic shock: a systematic review focused on fluid resuscitation, vasopressors, and corticosteroids. Annals of Pharmacotherapy2018;53:385‐95. [DOI: 10.1177/1060028018812940; PUBMED: 30404539 ] ">Allen 2018</a>; <a href="./references#CD002243-bbs2-0125" title="FangF , ZhangY , TangJ , LunsfordLD , LiT , TangR , et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta‐analysis. JAMA Internal Medicine2019;179(2):213‐23. [DOI: 10.1001/jamainternmed.2018.5849; PUBMED: 30575845] ">Fang 2018</a>; <a href="./references#CD002243-bbs2-0154" title="NiYN , LiuYM , WangYW , LiangBM , LiangZA . Can corticosteroids reduce the mortality of patients with severe sepsis? A systematic review and meta‐analysis. American Journal of Emergency Medicine2018;S0735‐6757:30953‐7. [PUBMED: 30522935] ">Ni 2018</a>; <a href="./references#CD002243-bbs2-0165" title="RochwergB , OczkowskiSJ , SiemieniukRAC , AgoritsasT , Belley‐CoteE , D'AragonF , et al. Corticosteroids in sepsis: an updated systematic review and meta‐analysis. Critical Care Medicine2018;46(9):1411‐20. [PUBMED: 29979221] ">Rochwerg 2018</a>; <a href="./references#CD002243-bbs2-0167" title="RygårdSL , ButlerE , GranholmA , MøllerMH , CohenJ , FinferS , et al. Low‐dose corticosteroids for adult patients with septic shock: a systematic review with meta‐analysis and trial sequential analysis. Intensive Care Medicine2018;44(7):1003‐16. [PUBMED: 29761216] ">Rygard 2018</a>). The number of included trials was different in all reviews and ranged from 14 to 42. The risk ratio of death in the short term varied from 0.91 to 0.96, and the upper limit of the 95% confidence interval (CI) varied from 0.98 to 1.03. Another systematic review and meta‐analysis of one randomized trial and 17 observational studies examined the risk of acquired muscle weakness associated with exposure to corticosteroids in patients in the intensive care unit (ICU) (<a href="./references#CD002243-bbs2-0180" title="YangT , LiZ , JiangL , XiX . Corticosteroid use and intensive care unit‐acquired weakness: a systematic review and meta‐analysis. Critical Care2018;22(1):187. [DOI: 10.1186/s13054‐018‐2111‐0; PUBMED: 30075789] ">Yang 2018</a>). This review found an odds ratio for acquired muscle weakness of 1.84 (95% CI 1.26 to 2.67) with corticosteroids compared to control. </p> <p>Therefore, we aim to systematically review the effects of corticosteroids in children and adults with sepsis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002243-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002243-sec-0056">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002243-sec-0217">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002243-sec-0056"></div> <p>To examine the effects of corticosteroids on death in children and adults with sepsis.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002243-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002243-sec-0057">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002243-sec-0218">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002243-sec-0057"></div> <section id="CD002243-sec-0058"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002243-sec-0059"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs) with no methodological restrictions. We excluded quasi‐randomized trials (i.e. trials assigning patients to treatment arms based on systematic methods, such as alternation, assignment based on date of birth, case record number, and date of presentation). </p> </section> <section id="CD002243-sec-0060"> <h4 class="title">Types of participants</h4> <p>We included children and adults with sepsis as defined by the Sepsis 3 criteria ‐ <a href="./references#CD002243-bbs2-0170" title="SingerM , DeutschmanCS , SeymourCW , Shankar‐HariM , AnnaneD , BauerM , et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis‐3). JAMA2016;315(8):801‐10. [PUBMED: 26903338] ">Singer 2016</a> ‐ or by the following criteria (<a href="./references#CD002243-bbs2-0099" title="ACCP/SCCM Consensus ConferencePanel . American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine1992;20(6):864‐74. [PUBMED: 1597042 ] ">ACCP/SCCM 1992</a>; <a href="./references#CD002243-bbs2-0178" title="VincentJL , OpalSM , MarshallJC , TraceyKJ . Sepsis definitions: time for change. Lancet2013;381(9868):774‐5. [PUBMED: 23472921] ">Vincent 2013</a>). </p> <p> <ul id="CD002243-list-0001"> <li> <p>Suspected or documented infection defined as culture or Gram stain of blood, sputum, urine, or normally sterile body fluid that is positive for a pathogenic micro‐organism; or a focus of infection identified by visual inspection (e.g. ruptured bowel with the presence of free air or bowel contents in the abdomen found at the time of surgery; wound with purulent drainage). </p> </li> <li> <p>At least two symptoms of a systemic inflammatory response syndrome, such as fever (body temperature &gt; 38°C) or hypothermia (&lt; 36°C), tachycardia (&gt; 90 beats per minute), tachypnoea (&gt; 20 breaths per minute), or hyperventilation (arterial carbon dioxide tension (PaCO₂) &lt; 32 mmHg), and abnormal white blood cell count (&gt; 12,000 cells/mL or &lt; 4000 cells/mL) or more than 10% immature band of neutrophils. </p> </li> <li> <p>At least one sign of organ dysfunction, that is, metabolic acidosis, arterial hypoxaemia (arterial oxygen tension (PaO₂):fractional inspired oxygen (FiO₂) &lt; 250 mmHg), oliguria (&lt; 30 mL/h for ≥ 3 hours), coagulopathy, or encephalopathy. </p> </li> </ul> </p> <p>Septic shock is defined by the presence of sepsis and of hypotension (persisting systolic arterial pressure &lt; 90 mmHg) that is refractory to fluid resuscitation and requires vasopressor support (i.e. &gt; 5 µg/kg of body weight per minute of dopamine or any dose of epinephrine or norepinephrine). </p> <p>We included data from trials of community‐acquired pneumonia or acute respiratory distress syndrome (ARDS) when separate data were available for participants with sepsis, or when contact with study authors resulted in provision of the data. </p> </section> <section id="CD002243-sec-0061"> <h4 class="title">Types of interventions</h4> <section id="CD002243-sec-0062"> <h5 class="title">Corticosteroids versus placebo/usual care</h5> <section id="CD002243-sec-0063"> <h6 class="title">Intervention</h6> <p>Systemic treatment was provided as any type of corticosteroid preparation (e.g. cortisone, hydrocortisone, methylprednisolone, betamethasone, dexamethasone). </p> <p>Low‐dose corticosteroid treatment was defined by a total dose per day of 400 mg or less of hydrocortisone (or equivalent); otherwise, the dose of corticosteroid would be considered high. A long course for the intervention was defined by a full‐dose treatment duration of three or more days; otherwise, treatment was considered as a short course. </p> </section> <section id="CD002243-sec-0064"> <h6 class="title">Control</h6> <p>Standard therapy was provided, which may have included antibiotics, fluid replacement, inotropic or vasopressor therapy, mechanical ventilation, or renal replacement therapy, or placebo. </p> </section> </section> <section id="CD002243-sec-0065"> <h5 class="title">Continuous infusion versus bolus administration of corticosteroids</h5> <section id="CD002243-sec-0066"> <h6 class="title">Intervention</h6> <p>Continuous infusion was defined by intravenous infusion of corticosteroids with or without an initial loading dose. </p> </section> <section id="CD002243-sec-0067"> <h6 class="title">Control</h6> <p>Bolus administration was defined by intermittent intravenous injections with duration less than 30 minutes. </p> </section> </section> </section> <section id="CD002243-sec-0068"> <h4 class="title">Types of outcome measures</h4> <section id="CD002243-sec-0069"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD002243-list-0002"> <li> <p>28‐Day all‐cause mortality</p> </li> </ul> </p> <p>Indeed, this was the primary outcome measure in most of the RCTs on sepsis conducted since 1992 (<a href="./references#CD002243-bbs2-0105" title="AnnaneD . Improving clinical trials in the critically ill: unique challenge: sepsis. Critical Care Medicine2009;37(1 Suppl):117‐28. [PUBMED: 19104211] ">Annane 2009b</a>). Most studies performed before 1992 looked at 14‐day or hospital mortality rates. We used these data to compute the pooled analysis for 28‐day mortality, unless we could obtain actual 28‐day mortality rates from primary study authors. </p> </section> <section id="CD002243-sec-0070"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD002243-list-0003"> <li> <p>90‐Day all‐cause mortality</p> </li> </ul> </p> <p>This was the primary outcome in the two most recent and largest trials on corticosteroids for sepsis. </p> <p> <ul id="CD002243-list-0004"> <li> <p>Long‐term (longest available follow‐up beyond three months) all‐cause mortality</p> </li> <li> <p>ICU all‐cause mortality</p> </li> <li> <p>Hospital all‐cause mortality</p> </li> </ul> </p> <p>In‐ICU and in‐hospital mortality outcomes provide the location of death, which adds context to the primary outcome. </p> <p> <ul id="CD002243-list-0005"> <li> <p>Number of participants with shock reversal (as defined by stable haemodynamic status ≥ 24 hours after withdrawal of vasopressor therapy) at day seven and at day 28 </p> </li> <li> <p>Number of organs affected and severity of organ dysfunction at day seven, in individual patients, as measured by the SOFA score (<a href="./references#CD002243-bbs2-0177" title="VincentJL , MorenoR , TakalaJ , WillattsS , DeMendonçaA , BruiningH , et al. The SOFA (Sepsis‐related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis‐Related Problems of the European Society of Intensive Care Medicine. Intensive Care Medicine1996;22(7):707‐10. [PUBMED: 8844239] ">Vincent 1996</a>). This score scales from 0 (normal function) to 4 (most severe) the dysfunction of six organ systems (Respiration, Coagulation, Liver, Cardiovascular, Central nervous system, Renal). It ranges from 0 (no organ failure) to 24 (most severe organ dysfunction) </p> </li> <li> <p>Length of stay in the ICU (for all participants and for survivors only). This outcome is expressed in mean (standard deviation (SD)) number of days, and is calculated by the difference between dates of ICU discharge and ICU admission, with first and last days of ICU stays counted as full ICU days regardless of the time of admission and time of discharge </p> </li> <li> <p>Length of hospital stay (for all participants and for survivors only). This outcome is expressed in mean (SD) number of days, and is calculated by the difference between dates of hospital discharge and hospital admission, with first and last days of hospital stays counted as full hospital days regardless of time of admission and time of discharge </p> </li> <li> <p>Adverse events (i.e. gastrointestinal bleeding, superinfection, hyperglycaemia, hypernatraemia, muscle weakness, neuropsychiatric events, stroke, cardiac events, or any other adverse effects or complications of corticosteroid treatment). Each adverse event is expressed as the number (%) of patients with at least one episode of this event, as defined in individual studies, except for hyperglycaemia and hypernatraemia. Whenever possible, hyperglycaemia was defined by values &gt; 180 mg/dL, and hypernatraemia by values &gt; 149 mmol/L. </p> </li> </ul> </p> </section> </section> </section> <section id="CD002243-sec-0071"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant studies regardless of language or publication status (e.g. published, unpublished, in press, in progress). </p> <section id="CD002243-sec-0072"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2019 Issue 7), in the Cochrane Library, using the search terms 'sepsis', 'septic shock', 'steroids', and 'corticosteroids' (for the detailed search strategy, see <a href="./appendices#CD002243-sec-0181">Appendix 1</a>). </p> <p>We also searched (to 25 July 2019) MEDLINE ALL (Ovid SP), Embase (Ovid SP), and Latin American Caribbean Health Sciences Literature (LILACS), using the topic search terms in combination with the search strategy for identifying trials developed by Cochrane (<a href="./references#CD002243-bbs2-0134" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). (For detailed search strategies, see <a href="./appendices#CD002243-sec-0182">Appendix 2</a> (MEDLINE), <a href="./appendices#CD002243-sec-0183">Appendix 3</a> (Embase), and <a href="./appendices#CD002243-sec-0184">Appendix 4</a> (LILACS).) </p> <p>Finally, we searched for ongoing RCTs (to 25 July 2019) at ClinicalTrials.gov, International Standard Randomized Controlled Trials Number (ISRCTN), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), using the search terms 'septic shock', 'sepsis', steroids', 'corticosteroids', 'adrenal cortex hormones', and 'glucocorticoids'. </p> </section> <section id="CD002243-sec-0073"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists and citations of all trials and relevant systematic reviews identified by the electronic searches, and we contacted study authors to request additional published or unpublished data. We also searched the proceedings of annual meetings of major critical care medicine symposia, that is, Society of Critical Care Medicine, American Thoracic Society, International Symposium on Intensive Care and Emergency Medicine, American College of Chest Physicians, and European Society of Intensive Care Medicine (1998 to 2019). </p> </section> </section> <section id="CD002243-sec-0074"> <h3 class="title" id="CD002243-sec-0074">Data collection and analysis</h3> <section id="CD002243-sec-0075"> <h4 class="title">Selection of studies</h4> <p>All review authors checked the titles and abstracts identified during the search. All review authors examined, in full, any trial that potentially met the inclusion criteria. We decided which trials met the inclusion criteria. We resolved disagreements between review authors by discussion until we reached consensus. Review authors did not contribute to the decision for inclusion of trials in which they had participated. </p> <p>One review author (DA) contacted study authors for clarification, when necessary.</p> </section> <section id="CD002243-sec-0076"> <h4 class="title">Data extraction and management</h4> <p>One review author (DA) drew up a standard data extraction form, and four other review authors (PEB, JB, DK, YK) amended and validated the design of the form before data abstraction. Review authors (DA, PEB, JB, DK, RP, BR) independently extracted data, except those from trials in which they had participated. </p> <p>One review author (DA) systematically contacted the authors of trials to request missing data when possible. </p> <p>One review author (DA) and one member of this author’s research staff independently extracted and entered data into the computer. All review authors checked the accuracy of data entered against the original articles. </p> </section> <section id="CD002243-sec-0077"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias within individual trials as recommended by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002243-bbs2-0134" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We considered the following domains: selection bias, performance bias, detection bias, attrition bias, reporting bias, and any other bias. We judged selection bias on the basis of how the random sequence was generated, and how allocation was concealed. We judged performance bias and detection bias on the basis of who was blinded and how, among participants, caregivers, pharmacists, data collectors, outcome assessors, and data analysts (<a href="./references#CD002243-bbs2-0119" title="DevereauxPJ , MannsBJ , GhaliWA , QuanH , LacchettiC , MontoriVM , et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA2001;285(15):2000‐3. [PUBMED: 11308438 ] ">Devereaux 2001</a>). In judging attrition bias, we considered how many participants were lost to follow‐up or were not included in analyses (and the reasons why). When available, we compared outcomes reported in trial protocols versus actual results reported, to identify potential selective reporting bias. We resolved disagreements between review authors by discussion until we reached consensus. </p> <p>One review author (DA) contacted study authors for clarification, when necessary.</p> <p>We assessed, independently and in duplicate (two of DA, BR, or RP), for each outcome of individual studies using a modified Cochrane risk of bias tool (<a href="./references#CD002243-bbs2-0131" title="GuyattGH , BusseJ . Methods commentary: risk of bias in randomized trials 1. Evidence Partners 2013 (accessed 15 December 2018):http://distillercer.com/resources/methodological‐resources/risk‐of‐biascommentary/. ">Guyatt 2013</a>), which classifies risk of bias as "low", "probably low", "probably high", or "high" for each of the following domains: sequence generation, allocation sequence concealment, blinding, selective outcome reporting, and other bias. We rated the overall risk of bias as the highest risk attributed to any criterion. </p> <p>Review authors did not contribute to the assessment of risk of bias of any trial in which they had participated. </p> </section> <section id="CD002243-sec-0078"> <h4 class="title">Measures of treatment effect</h4> <p> <ul id="CD002243-list-0006"> <li> <p>We performed intention‐to‐treat (ITT) analyses. We performed all statistical calculations using <a href="./references#CD002243-bbs2-0161" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> or <a href="./references#CD002243-bbs2-0171" title="StataCorp.2015 . Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015. ">Stata 2015</a>, as appropriate </p> </li> <li> <p>We calculated a weighted treatment effect across trials. We expressed results as risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes, and as mean differences (MDs, 95% CIs) for continuous outcomes </p> </li> </ul> </p> </section> <section id="CD002243-sec-0079"> <h4 class="title">Unit of analysis issues</h4> <p>In this review, we used data from trials in which the unit of randomization was the individual, and in which parallel groups were designed. For events that may occur repeatedly, such as receiving vasopressor therapy or staying in the ICU, we used only the first occurrence of the event. </p> <p>When trials included more than two arms (e.g. comparing vs control two different corticosteroids or two different modes of administration of the same corticosteroid), we pooled data from the experimental arms for comparison of steroids versus control. </p> </section> <section id="CD002243-sec-0080"> <h4 class="title">Dealing with missing data</h4> <p>We systematically tried to contact primary authors of original trials to obtain missing information and unpublished data. We obtained additional data from primary authors of 28 trials, including access to individual patient data for 16 trials (<a href="./appendices#CD002243-sec-0185">Appendix 5</a>). This information is provided for each trial in the notes section of <a href="./references#CD002243-sec-0209" title="">Characteristics of included studies</a>. </p> <p>For the primary outcome of this review (28‐day all‐cause mortality), we systematically contacted trial authors when needed to obtain data for participants who dropped out. When trials did not report 28‐day all‐cause mortality, and contact with trial authors failed to yield actual 28‐day mortality rates, we used available mortality data closest to 28 days. </p> <p>When trials reported length of stay in the ICU or in hospital only as median and interquartile ratio (IQR), and when contact with trial authors failed to elicit means and SDs, we did not include these trials in the analysis. </p> </section> <section id="CD002243-sec-0081"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered that evidence for significant heterogeneity was present when I² &gt; 30%.</p> </section> <section id="CD002243-sec-0082"> <h4 class="title">Assessment of reporting biases</h4> <p>We sought evidence of publication bias by using the funnel plot method. We used <a href="./references#CD002243-bbs2-0171" title="StataCorp.2015 . Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015. ">Stata 2015</a> to prepare a contour‐enhanced funnel plot (<a href="./references#CD002243-bbs2-0159" title="PetersJL , SuttonAJ , JonesDR , AbramsKR , RushtonL . Contour‐enhanced meta‐analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology2008;61(10):991‐6. [PUBMED: 18538991] ">Peters 2008</a>). This graphical analysis used the standard error of the log of the RR. We plotted contours illustrating the statistical significance of study effect estimates by using a two‐tailed test. </p> </section> <section id="CD002243-sec-0083"> <h4 class="title">Data synthesis</h4> <p>We considered methods based on the random‐effects model for all analyses, except when we found no evidence for significant heterogeneity in the results (i.e. I² ≤ 30%). Indeed, we suspected that we would observe heterogeneity across studies, as they were conducted over a wide period of time (almost half a century between first and last trials) and the rationale on which studies were designed varied greatly over time, with marked differences in treatment strategies and in populations between studies conducted before and after the early 1990s. </p> </section> <section id="CD002243-sec-0084"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>To identify potential sources of heterogeneity, we sought, a priori, to conduct a subgroup analysis based on 'dose and duration', that is, a long course (≥ 3 days at full dose) of low‐dose (≤ 400 mg/d) hydrocortisone or equivalent. This subgroup analysis allowed evaluation of a strategy based on developments in our understanding of the role of corticosteroids in host response to sepsis, as tested in trials performed after 1992. Older trials used most often a short course (one to four bolus doses within 24 hours) of high‐dose corticosteroids (&gt; 400 mg of hydrocortisone or equivalent), and trials conducted after 1992 used most often low‐dose corticosteroids at full dose over a longer period (≥ 3 days). </p> <p>We also conducted a subgroup analysis based on the type of corticosteroids, the method of corticosteroid administration, intravenous bolus versus continuous infusion, and termination without versus with tapering off. To further explore the putative interaction between corticosteroid dose and duration and the magnitude of effect, we considered performing a meta‐regression analysis using 28‐day all‐cause mortality as the dependent variable, and dosage and duration of corticosteroids as predictors. We performed meta‐regression analyses using <a href="./references#CD002243-bbs2-0171" title="StataCorp.2015 . Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015. ">Stata 2015</a>. We also tested, a priori, the interaction between baseline severity of illness and magnitude of effect in a meta‐regression analysis using mortality rates in controls as predictors. Finally, we conducted a subgroup analysis based on targeted population, sepsis, only septic shock, sepsis with ARDS, community‐acquired pneumonia, and sepsis with critical illness‐related corticosteroid insufficiency (<a href="./references#CD002243-bbs2-0106" title="AnnaneD , PastoresSM , ArltW , BalkRA , BeishuizenA , BriegelJ , et al. Critical illness‐related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Medicine2017;43(12):1781‐92. [PUBMED: 28940017] ">Annane 2017a</a>). </p> <p> <ul id="CD002243-list-0007"> <li> <p>We assessed the validity of subgroup analyses on the basis of the following criteria.</p> <ul id="CD002243-list-0008"> <li> <p>Subgroup comparisons within rather than between studies.</p> </li> <li> <p>Hypothesis preceding the analysis.</p> </li> <li> <p>One of very few hypotheses.</p> </li> <li> <p>Large and consistent differences across studies.</p> </li> <li> <p>External evidence supporting the results (<a href="./references#CD002243-bbs2-0130" title="GuyattGH , WyerP , IoannidisJ . When to believe a subgroup analysis. In: GuyattG , RennieR , MeadeM , CookD editor(s). User’s Guides to the Medical Literature: A Manual for Evidence‐Based Clinical Practice. New York: McGraw‐Hill, 2008. ">Guyatt 2008b</a>). </p> </li> </ul> </li> </ul> </p> <p>When subgroup analyses met these criteria and were found to be statistically significant, we applied GRADE criteria to evaluate the certainty of evidence (<a href="./references#CD002243-bbs2-0128" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 7 April 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>; <a href="./references#CD002243-bbs2-0129" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924‐6. [PUBMED: 18436948 ] ">Guyatt 2008a</a>). </p> </section> <section id="CD002243-sec-0085"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses based on generation of allocation sequence, concealment of allocation, and blinding, and for trials judged at low risk of bias. </p> <section id="CD002243-sec-0086"> <h5 class="title">'Summary of findings' table and GRADE</h5> <p>For assessment of the overall certainty of evidence for each outcome that included pooled data from RCTs only, we downgraded the evidence from "high certainty" by one level for serious (or by two for very serious) study limitations (according to risk of bias evaluation), indirectness of evidence, serious inconsistency (i.e. when I² &gt; 30%), imprecision of effect estimates (large 95% confidence intervals or small treatment effects), or potential publication bias. </p> <p>We exported data from Review Manager 5 to <a href="./references#CD002243-bbs2-0128" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 7 April 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a> to create 'Summary of findings' tables. We included the following patient‐centred outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD002243-list-0009"> <li> <p>28‐Day all‐cause mortality.</p> </li> <li> <p>In‐hospital all‐cause mortality.</p> </li> <li> <p>Long‐term (longest follow‐up beyond three months) all‐cause mortality.</p> </li> <li> <p>Length of stay in the ICU.</p> </li> <li> <p>Length of hospital stay.</p> </li> <li> <p>Number of participants with superinfection up to longest follow‐up.</p> </li> <li> <p>Number of participants with muscle weakness up to longest follow‐up.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002243-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002243-sec-0087"></div> <section id="CD002243-sec-0088"> <h3 class="title">Description of studies</h3> <section id="CD002243-sec-0089"> <h4 class="title">Results of the search</h4> <p>Our search results are detailed in <a href="#CD002243-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD002243-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD002243-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The search strategy yielded 98 trials that evaluated corticosteroids in sepsis, of which we excluded 28 trials (see <a href="./references#CD002243-sec-0210" title="">Characteristics of excluded studies</a>). Nine trials are still ongoing (see <a href="./references#CD002243-sec-0211" title="">Characteristics of ongoing studies</a>). </p> </section> <section id="CD002243-sec-0090"> <h4 class="title">Included studies</h4> <p>Since the last update in 2015 (see <a href="#CD002243-sec-0205">Published notes</a>), we have included 28 additional trials for a total of 61 trials (n = 12,192 participants); we have described these below (see <a href="./references#CD002243-sec-0209" title="">Characteristics of included studies</a>). </p> <section id="CD002243-sec-0091"> <h5 class="title">Source of information</h5> <p>In addition to data extracted from these publications, we obtained unpublished information from 28 trials by contacting the primary authors (<a href="./appendices#CD002243-sec-0185">Appendix 5</a>). We did not contact the authors of 10 trials, mainly because of the absence of contact details (<a href="./references#CD002243-sec-0209" title="">Characteristics of included studies</a>). For the remaining trials, contact with study authors did not lead to the provision of additional information (<a href="./references#CD002243-sec-0209" title="">Characteristics of included studies</a>). </p> </section> <section id="CD002243-sec-0092"> <h5 class="title">Trial centres</h5> <p>Twenty trials were multi‐centre trials (i.e. &gt; 2 centres) (<a href="./references#CD002243-sec-0209" title="">Characteristics of included studies</a>). Twenty‐four trials were conducted in Europe, 11 in North America, 12 in Asia, five in the Middle East, five in Africa, and one in Latin America, and three multi‐national trials were conducted in North America and Africa (<a href="./references#CD002243-bbs2-0046" title="SlusherT , GbaderoD , HowardC , LewinsonL , GiroirB , ToroL , et al. Randomized, placebo‐controlled, double blinded trial of dexamethasone in African children with sepsis. Pediatric Infectious Diseases Journal1996;15(7):579‐83. [PUBMED: 8823850] ">Slusher 1996</a>), in Europe and the Middle East (<a href="./references#CD002243-bbs2-0049" title="SprungC , AnnaneD , KehD , MorenoR , SingerM , FreivogelK , et al. Hydrocortisone therapy for patients with septic shock. New England Journal of Medicine2008;358(2):111‐24. [PUBMED: 18184957] ">Sprung 2008</a>), and in Australia, New Zealand, Europe, and the Middle East (<a href="./references#CD002243-bbs2-0058" title="VenkateshB , FinferS , CohenJ , RajbhandariD , ArabiY , BellomoR , et al. Adjunctive glucocorticoid therapy in patients with septic shock. New England Journal of Medicine2018;378:797–808. [DOI: 10.1056/NEJMoa1705835; PUBMED: 29347874] VenkateshB , FinferS , MybrughJ , CohenJ , BillotL . Long‐term outcomes of the ADRENAL trial [2018]. New England Journal of Medicine2018;378(18):174‐5. [PUBMED: 29694789] ">Venkatesh 2018</a>) (<a href="./references#CD002243-sec-0209" title="">Characteristics of included studies</a>). </p> </section> <section id="CD002243-sec-0093"> <h5 class="title">Age of participants</h5> <p>Two trials enrolled both children and adults (<a href="./references#CD002243-bbs2-0013" title="Cooperative Study Group. The effectiveness of hydrocortisone in the management of severe infections. JAMA1963;183(6):462‐5. [DOI: 10.1001/jama.1963.63700060029012] ">CSG 1963</a>; <a href="./references#CD002243-bbs2-0032" title="McHardyVU , SchonellME . Ampicillin dosage and use of prednisolone in treatment of pneumonia: co‐operative controlled trial. BMJ1972;4(5840):569‐73. [PUBMED: 4404939] ">McHardy 1972</a>). Six trials included only children (<a href="./references#CD002243-bbs2-0016" title="El‐NawawyA , KhaterD , OmarH , WaliY . Evaluation of early corticosteroid therapy in management of paediatric septic shock in paediatric intensive care patients: a randomized clinical study. Pediatric Infectious Disease Journal2017;36(2):155‐9. [PUBMED: 27798546] ">El‐Nawawy 2017</a>; <a href="./references#CD002243-bbs2-0036" title="MenonK , McNallyD , O'HearnK , AcharyaA , WongHR , LawsonM , et al. A randomized controlled trial of corticosteroids in paediatric septic shock: a pilot feasibility study. Pediatric Critical Care Medicine2017;18(6):505‐12. [PUBMED: 28406862] ">Menon 2017</a>; <a href="./references#CD002243-bbs2-0039" title="NagyB , GasparI , PappA , BeneZ , NagyBJr , VokoZ , et al. Efficacy of methylprednisolone in children with severe community acquired pneumonia. Pediatric Pulmonology2013;48:168‐75. [PUBMED: 22588852] ">Nagy 2013</a>; <a href="./references#CD002243-bbs2-0046" title="SlusherT , GbaderoD , HowardC , LewinsonL , GiroirB , ToroL , et al. Randomized, placebo‐controlled, double blinded trial of dexamethasone in African children with sepsis. Pediatric Infectious Diseases Journal1996;15(7):579‐83. [PUBMED: 8823850] ">Slusher 1996</a>; <a href="./references#CD002243-bbs2-0051" title="TagaroA , OtheoE , Baquero‐ArtigaoF , NavarroML , VelascoR , RuizM , et al. Dexamethasone for parapneumonic pleural effusion: a randomized, double‐blind, clinical trial. Journal of Pediatrics2017;185:117‐23. [PUBMED: 28363363] ">Tagaro 2017</a>; <a href="./references#CD002243-bbs2-0056" title="ValoorHT , SinghiS , JayashreeM . Low‐dose hydrocortisone in paediatric septic shock: an exploratory study in a third world setting. Pediatric Critical Care Medicine2009;10(1):121‐5. [PUBMED: 19057445] ">Valoor 2009</a>). All of the remaining trials included only adults. </p> </section> <section id="CD002243-sec-0094"> <h5 class="title">Description of participants</h5> <p>Eleven trials included both participants with sepsis and individuals with septic shock. Four trials included participants with sepsis without shock (<a href="./references#CD002243-bbs2-0017" title="Fernández‐SerranoS , DorcaJ , Garcia‐VidalC , Fernández‐SabéN , CarratalàJ , Fernández‐AgüeraA , et al. Effect of corticosteroids on the clinical course of community‐acquired pneumonia: a randomized controlled trial. Critical Care2011;15(2):R96. [PUBMED: 21406101] ">Fernández‐Serrano 2011</a>; <a href="./references#CD002243-bbs2-0025" title="KehD , TripsE , MarxG , WirtzSP , AbduljawwadE , BerckerS , et al. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA2016;316(17):1775‐85. [PUBMED: 27695824] ">Keh 2016</a>; <a href="./references#CD002243-bbs2-0043" title="RinaldiS , AdembriC , GrechiS , DeGaudioR . Low‐dose hydrocortisone during severe sepsis: effects on microalbuminemia. Critical Care Medicine2006;34(9):2334‐9. [PUBMED: 16850006] ">Rinaldi 2006</a>; <a href="./references#CD002243-bbs2-0044" title="SabryNA , El‐Din OmarE . Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacology and Pharmacy2011;2:73‐81. ">Sabry 2011</a>). Fifteen trials targeted participants with community‐acquired pneumonia‐related sepsis. Five trials focused on participants with ARDS and sepsis (<a href="./references#CD002243-bbs2-0028" title="LiuL , LiJ , HuangYZ , LiuSQ , YangCS , GuoFM , et al. The effect of stress dose glucocorticoid on patients with acute respiratory distress syndrome combined with critical illness‐related corticosteroid insufficiency. Zhonghua Nei Ke Za Zhi2012;51(8):599‐603. [PUBMED: 23158856] ">Liu 2012</a>; <a href="./references#CD002243-bbs2-0033" title="MeduriGU , GoldenE , FreireAX , TaylorE , ZamanM , CarsonSJ , et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest2007;131(4):954‐63. [PUBMED: 17426195] ">Meduri 2007</a>; <a href="./references#CD002243-bbs2-0042" title="RezkNA , IbrahimAM . Effects of methyl prednisolone in early ARDS. Egyptian Journal of Chest Diseases and Tuberculosis2013;62(1):167–72. [DOI: 10.1016/j.ejcdt.2013.02.013] ">Rezk 2013</a>; <a href="./references#CD002243-bbs2-0054" title="TongyooS , PermpikulC , MongkolpunW , VattanavanitV , UdompanturakS , KocakM , et al. Hydrocortisone treatment in early sepsis associated acute respiratory distress syndrome: results of a randomized controlled trial. Critical Care2016;20(1):329. [PUBMED: 27741949] ">Tongyoo 2016</a>; <a href="./references#CD002243-bbs2-0061" title="ZhouM . Application value of glucocorticoid for comprehensive treatment of acute respiratory distress syndrome induced by serious community acquired pneumonia. Clinical Medicine and Engineering2015;22:57‐8. [DOI: 10.3969/j.issn.1674‐4659.2015.01.0057] ">Zhou 2015</a>). The remaining trials focused on participants with septic shock treated by a vasopressor. Three trials included only participants with septic shock and adrenal insufficiency as defined by a cortisol increment less than 9 µg/dL after a corticotropin bolus (<a href="./references#CD002243-bbs2-0001" title="AboabJ , PolitoA , OrlikowskiD , SharsharT , CastelM , AnnaneD . Hydrocortisone effects on cardiovascular variability in septic shock: a spectral analysis approach. Critical Care Medicine2008;36(5):1481‐6. [PUBMED: 18434902] ">Aboab 2008</a>; <a href="./references#CD002243-bbs2-0022" title="HuhJW , LimCM , KohY , HongSB . Effect of low doses of hydrocortisone in patient with septic shock and relative adrenal insufficiency: 3 days versus 7 days treatment. Critical Care Medicine2006;34(12 suppl):A101. ">Huh 2007</a>; <a href="./references#CD002243-bbs2-0052" title="TandanSM , GuleriaR , GuptaN . Low dose steroids and adrenocortical insufficiency in septic shock: a double‐blind randomised controlled trial from India. Proceedings of the American Thoracic Society Meeting. 2005:A24. ">Tandan 2005</a>). In 18 trials, investigators systematically performed a short corticotropin test at baseline. </p> </section> <section id="CD002243-sec-0095"> <h5 class="title">Control</h5> <section id="CD002243-sec-0096"> <h6 class="title">Comparison of corticosteroids versus placebo or usual care</h6> <p>Nine studies did not use a placebo and compared corticosteroid therapy versus usual care, that is, antibiotics, fluid resuscitation, and vasopressor when needed (<a href="./references#CD002243-bbs2-0015" title="El‐GhamrawayAH , ShokeirMH , EsmatAA . Effects of low dose hydrocortisone in ICU patients with severe community acquired pneumonia. Egyptian Journal of Chest2006;55:91‐9. ">El Ghamrawy 2006</a>; <a href="./references#CD002243-bbs2-0020" title="HuB , LiJG , LiangH , ZhouQ , YuZ , LiL , et al. The effect of low‐dose hydrocortisone on requirement of norepinephrine and lactate clearance in patients with refractory septic shock. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue2009;21(9):529‐31. [PUBMED: 19751560] ">Hu 2009</a>; <a href="./references#CD002243-bbs2-0021" title="HuangR , ZhangZ , XuM , ChangX , QiaoQ , WangL , et al. Effect of Sini decoction on function of hypothalamic‐pituitary‐adrenal axis in patients with sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2014;26(3):184‐7. [PUBMED: 24598293] ">Huang 2014</a>; <a href="./references#CD002243-bbs2-0027" title="LiG , GuC , ZhangS , LianR , ZhangG . Value of glucocorticoid steroids in the treatment of patients with severe community acquired pneumonia complicated with septic shock. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2016;28(9):780‐4. [DOI: 10.3760/cma.j.issn.2095‐4352.2016.09.003] ">Li 2016</a>; <a href="./references#CD002243-bbs2-0032" title="McHardyVU , SchonellME . Ampicillin dosage and use of prednisolone in treatment of pneumonia: co‐operative controlled trial. BMJ1972;4(5840):569‐73. [PUBMED: 4404939] ">McHardy 1972</a>; <a href="./references#CD002243-bbs2-0037" title="MireaL , UngureanuR , PavelescuD , GrintescuIC , DumitracheC , GrintescuI , et al. Continuous administration of corticosteroids in septic shock can reduce risk of hypernatraemia. Critical Care2014;18:S86. ">Mirea 2014</a>; <a href="./references#CD002243-bbs2-0043" title="RinaldiS , AdembriC , GrechiS , DeGaudioR . Low‐dose hydrocortisone during severe sepsis: effects on microalbuminemia. Critical Care Medicine2006;34(9):2334‐9. [PUBMED: 16850006] ">Rinaldi 2006</a>; <a href="./references#CD002243-bbs2-0050" title="SuiDJ , ZhangW , LiWS , ZhaoHX , WangZY . Clinical efficacy in the treatment of severe community acquired pneumonia and its impact on CRP. Chinese Journal of Integrative Medicine2013;18:1171‐3. ">Sui 2013</a>; <a href="./references#CD002243-bbs2-0061" title="ZhouM . Application value of glucocorticoid for comprehensive treatment of acute respiratory distress syndrome induced by serious community acquired pneumonia. Clinical Medicine and Engineering2015;22:57‐8. [DOI: 10.3969/j.issn.1674‐4659.2015.01.0057] ">Zhou 2015</a>). In one study, only one centre used a placebo (<a href="./references#CD002243-bbs2-0048" title="SprungCL , CaralisPV , MarcialEH , PierceM , GelbardMA , LongWM , et al. The effects of high‐dose corticosteroids in patients with septic shock. A prospective, controlled study. New England Journal of Medicine1984;311(18):1137‐43. [PUBMED: 6384785 ] ">Sprung 1984</a>). One trial that compared hydrocortisone versus hydrocortisone plus fludrocortisone did not use a placebo of fludrocortisone for technical reasons (<a href="./references#CD002243-bbs2-0003" title="COIITSS Study Investigators, AnnaneD , CariouA , MaximeV , AzoulayE , D'honneurG , et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA2010;303(4):341‐8. [PUBMED: 20103758] ">Annane 2010</a>). Another trial compared duration of hydrocortisone treatment (i.e. 3 days vs 7 days) and did not use a placebo (<a href="./references#CD002243-bbs2-0022" title="HuhJW , LimCM , KohY , HongSB . Effect of low doses of hydrocortisone in patient with septic shock and relative adrenal insufficiency: 3 days versus 7 days treatment. Critical Care Medicine2006;34(12 suppl):A101. ">Huh 2007</a>). The remaining trials compared corticosteroid therapy to placebo. </p> </section> <section id="CD002243-sec-0097"> <h6 class="title">Comparison of continuous infusion versus intermittent intravenous boluses of corticosteroids</h6> <p>Three trials compared continuous infusion versus bolus administration of hydrocortisone (<a href="./references#CD002243-bbs2-0023" title="HyvernatH , BarelR , GentilhommeA , Césari‐GiordaniJF , FrecheA , KaidomarM , et al. Effects of increasing hydrocortisone to 300 mg per day in the treatment of septic shock: a pilot study. Shock2016;46:498‐505. [PUBMED: 27405061] ">Hyvernat 2016</a>; <a href="./references#CD002243-bbs2-0029" title="LoisaP , ParviainenI , TenhunenJ , HovilehtoS , RuokonenE . Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial. Critical Care2007;11(1):R21. [PUBMED: 17306016] ">Loisa 2007</a>; <a href="./references#CD002243-bbs2-0053" title="TiloucheN , JaouedO , Ben Sik AliH , GharbiR , Fekih HassenM , ElatrousS . Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock2019;52:481‐6. [DOI: 10.1097/SHK.0000000000001316.; PUBMED: 30628950] ">Tilouche 2019</a>). One trial had three parallel arms including continuous infusion of 200 mg hydrocortisone daily for seven days, intravenous bolus of 50 mg hydrocortisone every six hours for seven days, and usual care (<a href="./references#CD002243-bbs2-0037" title="MireaL , UngureanuR , PavelescuD , GrintescuIC , DumitracheC , GrintescuI , et al. Continuous administration of corticosteroids in septic shock can reduce risk of hypernatraemia. Critical Care2014;18:S86. ">Mirea 2014</a>). </p> </section> </section> <section id="CD002243-sec-0098"> <h5 class="title">Corticosteroid dose and treatment course</h5> <p>Thirty‐seven trials tested the effects of a long‐course (three or more days at full dose) of low‐dose hydrocortisone. In one trial (<a href="./references#CD002243-bbs2-0022" title="HuhJW , LimCM , KohY , HongSB . Effect of low doses of hydrocortisone in patient with septic shock and relative adrenal insufficiency: 3 days versus 7 days treatment. Critical Care Medicine2006;34(12 suppl):A101. ">Huh 2007</a>), investigators compared hydrocortisone 50 mg intravenously every six hours when given for three days versus seven days. One trial had three parallel groups including continuous infusion of 200 mg hydrocortisone per day for seven days, intravenous bolus of 50 mg hydrocortisone every six hours for seven days, and usual care (<a href="./references#CD002243-bbs2-0037" title="MireaL , UngureanuR , PavelescuD , GrintescuIC , DumitracheC , GrintescuI , et al. Continuous administration of corticosteroids in septic shock can reduce risk of hypernatraemia. Critical Care2014;18:S86. ">Mirea 2014</a>). In three trials, investigators compared continuous infusion versus intermittent intravenous boluses of hydrocortisone (<a href="./references#CD002243-bbs2-0023" title="HyvernatH , BarelR , GentilhommeA , Césari‐GiordaniJF , FrecheA , KaidomarM , et al. Effects of increasing hydrocortisone to 300 mg per day in the treatment of septic shock: a pilot study. Shock2016;46:498‐505. [PUBMED: 27405061] ">Hyvernat 2016</a>; <a href="./references#CD002243-bbs2-0029" title="LoisaP , ParviainenI , TenhunenJ , HovilehtoS , RuokonenE . Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial. Critical Care2007;11(1):R21. [PUBMED: 17306016] ">Loisa 2007</a>; <a href="./references#CD002243-bbs2-0053" title="TiloucheN , JaouedO , Ben Sik AliH , GharbiR , Fekih HassenM , ElatrousS . Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock2019;52:481‐6. [DOI: 10.1097/SHK.0000000000001316.; PUBMED: 30628950] ">Tilouche 2019</a>). Another trial compared seven‐day treatment with hydrocortisone versus seven‐day treatment with the combination of hydrocortisone plus fludrocortisone (<a href="./references#CD002243-bbs2-0003" title="COIITSS Study Investigators, AnnaneD , CariouA , MaximeV , AzoulayE , D'honneurG , et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA2010;303(4):341‐8. [PUBMED: 20103758] ">Annane 2010</a>). One trial compared a short course (two days at full dose) of low‐dose intravenous hydrocortisone (300 mg on day one and 250 mg on day two) versus placebo (<a href="./references#CD002243-bbs2-0013" title="Cooperative Study Group. The effectiveness of hydrocortisone in the management of severe infections. JAMA1963;183(6):462‐5. [DOI: 10.1001/jama.1963.63700060029012] ">CSG 1963</a>). Another study used a cross‐over design to compare a three‐day course of low‐dose hydrocortisone versus placebo (<a href="./references#CD002243-bbs2-0024" title='KehD , BoehnkeT , Weber‐CartensS , SchulzC , AhlersO , BerckerS , et al. Immunologic and hemodynamic effects of "low‐dose" hydrocortisone in septic shock: a double‐blind, randomized, placebo‐controlled, crossover study. American Journal of Respiratory and Critical Care Medicine2003;167(4):512‐20. [PUBMED: 12426230 ] '>Keh 2003</a>). </p> <p>Five trials tested the effects of a long course of low‐dose prednisone or prednisolone (<a href="./references#CD002243-bbs2-0006" title="BlumCA , NigroN , BrielM , SchuetzP , UllmerE , Suter‐WidmerI , et al. Adjunct prednisone therapy for patients with community‐acquired pneumonia: a multicentre, double‐blind, randomised, placebo‐controlled trial. Lancet2015;385(9977):1511‐8. [PUBMED: 25608756] ">Blum 2015</a>; <a href="./references#CD002243-bbs2-0032" title="McHardyVU , SchonellME . Ampicillin dosage and use of prednisolone in treatment of pneumonia: co‐operative controlled trial. BMJ1972;4(5840):569‐73. [PUBMED: 4404939] ">McHardy 1972</a>; <a href="./references#CD002243-bbs2-0047" title="SnijdersD , DanielsJMA , deGraaffCS , van derWerfTS , BoersmaWG . Efficacy of corticosteroids in community‐acquired pneumonia – a randomized double blinded clinical trial. American Journal of Respiratory and Critical Care Medicine2010;181(9):975‐82. [PUBMED: 20133929] ">Snijders 2010</a>; <a href="./references#CD002243-bbs2-0059" title="YildizO , DoganayM , AygenB , GuvenM , KeleutimurF , TutuuA . Physiological‐dose steroid therapy in sepsis. Critical Care2002;6(3):251‐9. [PUBMED: 12133187] ">Yildiz 2002</a>; <a href="./references#CD002243-bbs2-0060" title="YildizO , TanriverdiF , SimsekS , AygenB , KelestimurF . The effects of moderate‐dose steroid therapy in sepsis: a placebo‐controlled, randomized study. Journal of Research in Medical Sciences2011;16(11):1410‐21. [PUBMED: 22973341] ">Yildiz 2011</a>). </p> <p>Two trials tested the effects of a long course of low‐dose dexamethasone (<a href="./references#CD002243-bbs2-0011" title="CicarelliDD , VieiraJE , BenseñorFE . Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial. Sao Paulo Medical Journal2007;125(4):237‐41. [PUBMED: 17992396 ] ">Cicarelli 2007</a>; <a href="./references#CD002243-bbs2-0035" title="MeijvisSC , HardemanH , RemmeltsHH , HeijligenbergR , RijkersGT , vanVelzen‐BladH , et al. Dexamethasone and length of hospital stay in patients with community‐acquired pneumonia: a randomised, double‐blind, placebo‐controlled trial. Lancet2011;377(9782):2023‐30. [PUBMED: 21636122] ">Meijvis 2011</a>). Two trials tested the effects of a short course (two days at full dose) of low‐dose dexamethasone (<a href="./references#CD002243-bbs2-0046" title="SlusherT , GbaderoD , HowardC , LewinsonL , GiroirB , ToroL , et al. Randomized, placebo‐controlled, double blinded trial of dexamethasone in African children with sepsis. Pediatric Infectious Diseases Journal1996;15(7):579‐83. [PUBMED: 8823850] ">Slusher 1996</a>; <a href="./references#CD002243-bbs2-0051" title="TagaroA , OtheoE , Baquero‐ArtigaoF , NavarroML , VelascoR , RuizM , et al. Dexamethasone for parapneumonic pleural effusion: a randomized, double‐blind, clinical trial. Journal of Pediatrics2017;185:117‐23. [PUBMED: 28363363] ">Tagaro 2017</a>). </p> <p>Eight studies tested the effects of a long course of low‐dose intravenous methylprednisolone (<a href="./references#CD002243-bbs2-0017" title="Fernández‐SerranoS , DorcaJ , Garcia‐VidalC , Fernández‐SabéN , CarratalàJ , Fernández‐AgüeraA , et al. Effect of corticosteroids on the clinical course of community‐acquired pneumonia: a randomized controlled trial. Critical Care2011;15(2):R96. [PUBMED: 21406101] ">Fernández‐Serrano 2011</a>; <a href="./references#CD002243-bbs2-0027" title="LiG , GuC , ZhangS , LianR , ZhangG . Value of glucocorticoid steroids in the treatment of patients with severe community acquired pneumonia complicated with septic shock. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2016;28(9):780‐4. [DOI: 10.3760/cma.j.issn.2095‐4352.2016.09.003] ">Li 2016</a>; <a href="./references#CD002243-bbs2-0033" title="MeduriGU , GoldenE , FreireAX , TaylorE , ZamanM , CarsonSJ , et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest2007;131(4):954‐63. [PUBMED: 17426195] ">Meduri 2007</a>; <a href="./references#CD002243-bbs2-0039" title="NagyB , GasparI , PappA , BeneZ , NagyBJr , VokoZ , et al. Efficacy of methylprednisolone in children with severe community acquired pneumonia. Pediatric Pulmonology2013;48:168‐75. [PUBMED: 22588852] ">Nagy 2013</a>; <a href="./references#CD002243-bbs2-0042" title="RezkNA , IbrahimAM . Effects of methyl prednisolone in early ARDS. Egyptian Journal of Chest Diseases and Tuberculosis2013;62(1):167–72. [DOI: 10.1016/j.ejcdt.2013.02.013] ">Rezk 2013</a>; <a href="./references#CD002243-bbs2-0050" title="SuiDJ , ZhangW , LiWS , ZhaoHX , WangZY . Clinical efficacy in the treatment of severe community acquired pneumonia and its impact on CRP. Chinese Journal of Integrative Medicine2013;18:1171‐3. ">Sui 2013</a>; <a href="./references#CD002243-bbs2-0055" title="TorresA , SibilaO , FerrerM , PolverinoE , MenendezR , MensaJ , et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community‐acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; Vol. 313, issue 7:677‐86. [PUBMED: 25688779] ">Torres 2015</a>; <a href="./references#CD002243-bbs2-0061" title="ZhouM . Application value of glucocorticoid for comprehensive treatment of acute respiratory distress syndrome induced by serious community acquired pneumonia. Clinical Medicine and Engineering2015;22:57‐8. [DOI: 10.3969/j.issn.1674‐4659.2015.01.0057] ">Zhou 2015</a>). </p> <p>Five trials tested the effects of a short course of a large dose of methylprednisolone (<a href="./references#CD002243-bbs2-0008" title="BoneRG , FisherCJ , ClemmerTP , SlotmanGJ , MetzCA , BalkRA . A controlled clinical trial of high‐dose methylprednisolone in the treatment of severe sepsis and septic shock. New England Journal of Medicine1987;317(11):653‐8. [PUBMED: 3306374] ">Bone 1987</a>; <a href="./references#CD002243-bbs2-0030" title="LuceJM , MontgomeryAB , MarksJD , TurnerJ , MetzCA , MurrayJF . Ineffectiveness of high‐dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. American Review of Respiratory Diseases1988;138(1):62‐8. [PUBMED: 3202402 ] ">Luce 1988</a>; <a href="./references#CD002243-bbs2-0045" title="SchumerW . Steroids in the treatment of clinical septic shock. Annals of Surgery1976;184(3):333‐41. [PUBMED: 786190 ] ">Schumer 1976</a>; <a href="./references#CD002243-bbs2-0048" title="SprungCL , CaralisPV , MarcialEH , PierceM , GelbardMA , LongWM , et al. The effects of high‐dose corticosteroids in patients with septic shock. A prospective, controlled study. New England Journal of Medicine1984;311(18):1137‐43. [PUBMED: 6384785 ] ">Sprung 1984</a>; <a href="./references#CD002243-bbs2-0057" title="Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high‐dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. New England Journal of Medicine1987;317(11):659‐65. [PUBMED: 2888017] ">VASSCSG 1987</a>), and two tested the effects of a large dose of dexamethasone (<a href="./references#CD002243-bbs2-0045" title="SchumerW . Steroids in the treatment of clinical septic shock. Annals of Surgery1976;184(3):333‐41. [PUBMED: 786190 ] ">Schumer 1976</a>; <a href="./references#CD002243-bbs2-0048" title="SprungCL , CaralisPV , MarcialEH , PierceM , GelbardMA , LongWM , et al. The effects of high‐dose corticosteroids in patients with septic shock. A prospective, controlled study. New England Journal of Medicine1984;311(18):1137‐43. [PUBMED: 6384785 ] ">Sprung 1984</a>). </p> <p>One trial did not report the type of corticosteroids given (<a href="./references#CD002243-bbs2-0026" title="KurugundlaN , IrugulapatiL , KilariD , AmchentsevA , DevakondaA , GeorgeL , et al. Effect of steroids in septic shock patients without relative adrenal insufficiency. American Thoracic Society2008;116. ">Kurungundla 2008</a>). </p> </section> <section id="CD002243-sec-0099"> <h5 class="title">Outcomes</h5> <p>Overall, data from 52 trials was used to inform 28‐day mortality rates. One trial (<a href="./references#CD002243-bbs2-0037" title="MireaL , UngureanuR , PavelescuD , GrintescuIC , DumitracheC , GrintescuI , et al. Continuous administration of corticosteroids in septic shock can reduce risk of hypernatraemia. Critical Care2014;18:S86. ">Mirea 2014</a>) provided data for both comparison of corticosteroids versus placebo or usual care and comparison of continuous infusion versus bolus administration of corticosteroids. Two trials ( <a href="./references#CD002243-bbs2-0023" title="HyvernatH , BarelR , GentilhommeA , Césari‐GiordaniJF , FrecheA , KaidomarM , et al. Effects of increasing hydrocortisone to 300 mg per day in the treatment of septic shock: a pilot study. Shock2016;46:498‐505. [PUBMED: 27405061] ">Hyvernat 2016</a>;<a href="./references#CD002243-bbs2-0053" title="TiloucheN , JaouedO , Ben Sik AliH , GharbiR , Fekih HassenM , ElatrousS . Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock2019;52:481‐6. [DOI: 10.1097/SHK.0000000000001316.; PUBMED: 30628950] ">Tilouche 2019</a>) provided data for the comparison of continuous infusion versus bolus administration of corticosteroids. Fifty trials were used in the comparison of corticosteroids versus placebo or usual care. Of these trials, 29 explicitly reported on 28‐day mortality and contact with the primary author of three additional trials led to recording of 28‐day mortality rates (<a href="./references#CD002243-bbs2-0033" title="MeduriGU , GoldenE , FreireAX , TaylorE , ZamanM , CarsonSJ , et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest2007;131(4):954‐63. [PUBMED: 17426195] ">Meduri 2007</a>; <a href="./references#CD002243-bbs2-0043" title="RinaldiS , AdembriC , GrechiS , DeGaudioR . Low‐dose hydrocortisone during severe sepsis: effects on microalbuminemia. Critical Care Medicine2006;34(9):2334‐9. [PUBMED: 16850006] ">Rinaldi 2006</a>; <a href="./references#CD002243-bbs2-0048" title="SprungCL , CaralisPV , MarcialEH , PierceM , GelbardMA , LongWM , et al. The effects of high‐dose corticosteroids in patients with septic shock. A prospective, controlled study. New England Journal of Medicine1984;311(18):1137‐43. [PUBMED: 6384785 ] ">Sprung 1984</a>). Thus, actual 28‐day mortality rates were computed for 32 trials. For 18 additional trials, 28‐day mortality rates were extrapolated from hospital mortality rates (<a href="./references#CD002243-bbs2-0001" title="AboabJ , PolitoA , OrlikowskiD , SharsharT , CastelM , AnnaneD . Hydrocortisone effects on cardiovascular variability in septic shock: a spectral analysis approach. Critical Care Medicine2008;36(5):1481‐6. [PUBMED: 18434902] ">Aboab 2008</a>, <a href="./references#CD002243-bbs2-0015" title="El‐GhamrawayAH , ShokeirMH , EsmatAA . Effects of low dose hydrocortisone in ICU patients with severe community acquired pneumonia. Egyptian Journal of Chest2006;55:91‐9. ">El Ghamrawy 2006</a>,<a href="./references#CD002243-bbs2-0017" title="Fernández‐SerranoS , DorcaJ , Garcia‐VidalC , Fernández‐SabéN , CarratalàJ , Fernández‐AgüeraA , et al. Effect of corticosteroids on the clinical course of community‐acquired pneumonia: a randomized controlled trial. Critical Care2011;15(2):R96. [PUBMED: 21406101] ">Fernández‐Serrano 2011</a>, <a href="./references#CD002243-bbs2-0030" title="LuceJM , MontgomeryAB , MarksJD , TurnerJ , MetzCA , MurrayJF . Ineffectiveness of high‐dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. American Review of Respiratory Diseases1988;138(1):62‐8. [PUBMED: 3202402 ] ">Luce 1988</a>, <a href="./references#CD002243-bbs2-0032" title="McHardyVU , SchonellME . Ampicillin dosage and use of prednisolone in treatment of pneumonia: co‐operative controlled trial. BMJ1972;4(5840):569‐73. [PUBMED: 4404939] ">McHardy 1972</a>, <a href="./references#CD002243-bbs2-0036" title="MenonK , McNallyD , O'HearnK , AcharyaA , WongHR , LawsonM , et al. A randomized controlled trial of corticosteroids in paediatric septic shock: a pilot feasibility study. Pediatric Critical Care Medicine2017;18(6):505‐12. [PUBMED: 28406862] ">Menon 2017</a>,<a href="./references#CD002243-bbs2-0038" title="NafaeRM , RagabMI , AmanyFM , RashedSB . Adjuvant role of corticosteroids in the treatment of community acquired pneumonia. Egyptian Journal of Chest Diseases and Tuberculosis2013;62:439‐45. ">Nafae 2013</a>, <a href="./references#CD002243-bbs2-0045" title="SchumerW . Steroids in the treatment of clinical septic shock. Annals of Surgery1976;184(3):333‐41. [PUBMED: 786190 ] ">Schumer 1976</a>, <a href="./references#CD002243-bbs2-0046" title="SlusherT , GbaderoD , HowardC , LewinsonL , GiroirB , ToroL , et al. Randomized, placebo‐controlled, double blinded trial of dexamethasone in African children with sepsis. Pediatric Infectious Diseases Journal1996;15(7):579‐83. [PUBMED: 8823850] ">Slusher 1996</a>, <a href="./references#CD002243-bbs2-0055" title="TorresA , SibilaO , FerrerM , PolverinoE , MenendezR , MensaJ , et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community‐acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; Vol. 313, issue 7:677‐86. [PUBMED: 25688779] ">Torres 2015</a>), ICU mortality rates (<a href="./references#CD002243-bbs2-0020" title="HuB , LiJG , LiangH , ZhouQ , YuZ , LiL , et al. The effect of low‐dose hydrocortisone on requirement of norepinephrine and lactate clearance in patients with refractory septic shock. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue2009;21(9):529‐31. [PUBMED: 19751560] ">Hu 2009</a>, <a href="./references#CD002243-bbs2-0044" title="SabryNA , El‐Din OmarE . Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacology and Pharmacy2011;2:73‐81. ">Sabry 2011</a>), 14‐day mortality rates (<a href="./references#CD002243-bbs2-0008" title="BoneRG , FisherCJ , ClemmerTP , SlotmanGJ , MetzCA , BalkRA . A controlled clinical trial of high‐dose methylprednisolone in the treatment of severe sepsis and septic shock. New England Journal of Medicine1987;317(11):653‐8. [PUBMED: 3306374] ">Bone 1987</a>, <a href="./references#CD002243-bbs2-0057" title="Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high‐dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. New England Journal of Medicine1987;317(11):659‐65. [PUBMED: 2888017] ">VASSCSG 1987</a>), and short term mortality rates (<a href="./references#CD002243-bbs2-0026" title="KurugundlaN , IrugulapatiL , KilariD , AmchentsevA , DevakondaA , GeorgeL , et al. Effect of steroids in septic shock patients without relative adrenal insufficiency. American Thoracic Society2008;116. ">Kurungundla 2008</a>, <a href="./references#CD002243-bbs2-0037" title="MireaL , UngureanuR , PavelescuD , GrintescuIC , DumitracheC , GrintescuI , et al. Continuous administration of corticosteroids in septic shock can reduce risk of hypernatraemia. Critical Care2014;18:S86. ">Mirea 2014</a>, <a href="./references#CD002243-bbs2-0039" title="NagyB , GasparI , PappA , BeneZ , NagyBJr , VokoZ , et al. Efficacy of methylprednisolone in children with severe community acquired pneumonia. Pediatric Pulmonology2013;48:168‐75. [PUBMED: 22588852] ">Nagy 2013</a>, <a href="./references#CD002243-bbs2-0042" title="RezkNA , IbrahimAM . Effects of methyl prednisolone in early ARDS. Egyptian Journal of Chest Diseases and Tuberculosis2013;62(1):167–72. [DOI: 10.1016/j.ejcdt.2013.02.013] ">Rezk 2013</a>). </p> <p>Sixteen trials explicitly reported ICU mortality rates, and the primary authors of three additional trials reported this outcome (<a href="./references#CD002243-bbs2-0010" title="ChawlaK , KupferY , TesslerS . Hydrocortisone reverses refractory septic shock. Critical Care Medicine1999;27(1):A33. ">Chawla 1999</a>; <a href="./references#CD002243-bbs2-0043" title="RinaldiS , AdembriC , GrechiS , DeGaudioR . Low‐dose hydrocortisone during severe sepsis: effects on microalbuminemia. Critical Care Medicine2006;34(9):2334‐9. [PUBMED: 16850006] ">Rinaldi 2006</a>; <a href="./references#CD002243-bbs2-0055" title="TorresA , SibilaO , FerrerM , PolverinoE , MenendezR , MensaJ , et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community‐acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; Vol. 313, issue 7:677‐86. [PUBMED: 25688779] ">Torres 2015</a>). </p> <p>Hospital mortality rates were available for 26 trials.</p> <p>Mortality rates at 90 days and in the long term were reported for seven trials.</p> <p>Rates of shock reversal at day seven and at day 28 were reported in 16 and 13 trials, respectively. </p> <p>Ten trials reported the numbers of dysfunctional organs, that is, SOFA scores, at day seven. </p> <p>Twenty‐one trials reported length of ICU stay, and 22 reported on length of hospital stay. </p> </section> </section> <section id="CD002243-sec-0100"> <h4 class="title">Excluded studies</h4> <p>We excluded 28 trials (see <a href="./references#CD002243-sec-0210" title="">Characteristics of excluded studies</a> for details). </p> <section id="CD002243-sec-0101"> <h5 class="title">Ongoing studies</h5> <p>From trial registries, we identified nine additional RCTs of corticosteroids for sepsis (see <a href="./references#CD002243-sec-0211" title="">Characteristics of ongoing studies</a>). These trials are still recruiting patients, and we will follow the status of these trials to include them in a future update of the review whenever data become publicly available. </p> </section> <section id="CD002243-sec-0102"> <h5 class="title">Studies awaiting classification</h5> <p>We found no studies awaiting classification</p> </section> </section> </section> <section id="CD002243-sec-0103"> <h3 class="title">Risk of bias in included studies</h3> <p>We reported the detailed methodological quality of individual trials in the 'Risk of bias' tables in <a href="#CD002243-fig-0002">Figure 2</a> and <a href="./appendices#CD002243-sec-0186">Appendix 6</a>. </p> <div class="figure" id="CD002243-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD002243-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <p>We judged 19 trials as being at low risk of bias, that is, we assessed them as having low risk of bias for the five domains (allocation, blinding, incomplete data, selective reporting, and other potential sources of bias). </p> <section id="CD002243-sec-0104"> <h4 class="title">Allocation</h4> <section id="CD002243-sec-0105"> <h5 class="title">Random sequence generation</h5> <p>In one trial, the method of generation of allocation sequence was based on a card system (<a href="./references#CD002243-bbs2-0045" title="SchumerW . Steroids in the treatment of clinical septic shock. Annals of Surgery1976;184(3):333‐41. [PUBMED: 786190 ] ">Schumer 1976</a>); we judged this trial to be at high risk of selection bias. For 16 trials, the method was unclear. We judged the remaining trials to have low risk of bias. </p> </section> <section id="CD002243-sec-0106"> <h5 class="title">Allocation concealment</h5> <p>We judged the method used for allocation concealment to be at low risk of bias in all but 10 trials. One trial assigned treatment using unsealed envelopes (<a href="./references#CD002243-bbs2-0045" title="SchumerW . Steroids in the treatment of clinical septic shock. Annals of Surgery1976;184(3):333‐41. [PUBMED: 786190 ] ">Schumer 1976</a>). In another trial, investigators enrolling participants at one of the two participating centres could have foreseen the upcoming assignment, as the local ethical committee refused to accept concealed allocation (<a href="./references#CD002243-bbs2-0048" title="SprungCL , CaralisPV , MarcialEH , PierceM , GelbardMA , LongWM , et al. The effects of high‐dose corticosteroids in patients with septic shock. A prospective, controlled study. New England Journal of Medicine1984;311(18):1137‐43. [PUBMED: 6384785 ] ">Sprung 1984</a>). In 20 trials, study authors did not report the method used for allocation concealment. </p> </section> </section> <section id="CD002243-sec-0107"> <h4 class="title">Blinding</h4> <section id="CD002243-sec-0108"> <h5 class="title">Blinding of participants and personnel</h5> <p>For 13 trials, we judged the method used for blinding of participants and personnel as having high risk of bias. Twelve trials used open‐label treatments. For one trial (<a href="./references#CD002243-bbs2-0048" title="SprungCL , CaralisPV , MarcialEH , PierceM , GelbardMA , LongWM , et al. The effects of high‐dose corticosteroids in patients with septic shock. A prospective, controlled study. New England Journal of Medicine1984;311(18):1137‐43. [PUBMED: 6384785 ] ">Sprung 1984</a>), the local ethical committee at one of the two centres did not permit double‐blind allocation and administration of treatment. Therefore, blinding was not possible for 40 of the 59 participants included in the trial. </p> <p>Eleven additional trials did not report the method used to ensure blinding.</p> <p>For the remaining trials, blinding of participants and personnel was deemed appropriate. We judged these trials to be at low risk of bias for this domain. </p> </section> <section id="CD002243-sec-0109"> <h5 class="title">Blinding of outcomes assessors</h5> <p>In 12 trials, outcome assessors were not blinded to study treatments. We judged these trials to be at high risk of detection bias. </p> <p>Twelve trials did not report any information that could be used to judge the risk of detection bias. </p> <p>For the remaining trials, blinding of outcomes assessors was deemed appropriate. We judged these trials to be at low risk of bias for this domain. </p> </section> </section> <section id="CD002243-sec-0110"> <h4 class="title">Incomplete outcome data</h4> <p>Twenty‐eight trials explicitly provided the numbers of and reasons for withdrawals or losses to follow‐up. </p> <p>Nineteen trials explicitly reported the use of intention‐to‐treat analysis (as the primary analysis) and the numbers of, and reasons for, non‐adherence to the protocol. One trial reported only use of intention‐to‐treat analysis (<a href="./references#CD002243-bbs2-0030" title="LuceJM , MontgomeryAB , MarksJD , TurnerJ , MetzCA , MurrayJF . Ineffectiveness of high‐dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. American Review of Respiratory Diseases1988;138(1):62‐8. [PUBMED: 3202402 ] ">Luce 1988</a>). The remaining trials provided no information about these criteria. However, the number of analysed participants matched the number of randomly assigned participants, except for 16 trials. One trial did not include one of 191 participants in the placebo group in the mortality analysis (<a href="./references#CD002243-bbs2-0008" title="BoneRG , FisherCJ , ClemmerTP , SlotmanGJ , MetzCA , BalkRA . A controlled clinical trial of high‐dose methylprednisolone in the treatment of severe sepsis and septic shock. New England Journal of Medicine1987;317(11):653‐8. [PUBMED: 3306374] ">Bone 1987</a>). In four trials (<a href="./references#CD002243-bbs2-0002" title="AnnaneD , SebilleV , CharpentierC , BollaertPE , FrançoisB , KorachJM , et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA2002;288(7):862‐71. [PUBMED: 12186604] ">Annane 2002</a>; <a href="./references#CD002243-bbs2-0031" title="LvQQ , GuXH , ChenQH , YuJQ , ZhengRQ . Early initiation of low‐dose hydrocortisone treatment for septic shock in adults: a randomized clinical trial. American Journal of Emergency Medicine2017;35(12):1810‐4. [PUBMED: 28615145] ">Lv 2017</a>; <a href="./references#CD002243-bbs2-0049" title="SprungC , AnnaneD , KehD , MorenoR , SingerM , FreivogelK , et al. Hydrocortisone therapy for patients with septic shock. New England Journal of Medicine2008;358(2):111‐24. [PUBMED: 18184957] ">Sprung 2008</a>; <a href="./references#CD002243-bbs2-0054" title="TongyooS , PermpikulC , MongkolpunW , VattanavanitV , UdompanturakS , KocakM , et al. Hydrocortisone treatment in early sepsis associated acute respiratory distress syndrome: results of a randomized controlled trial. Critical Care2016;20(1):329. [PUBMED: 27741949] ">Tongyoo 2016</a>), participants withdrew their consent, and study authors did not include in the analyses one of 300, two of 120, one of 500, and nine of 206 randomly assigned participants, respectively. For two trials, contact with the primary author allowed us to obtain information on participants who were dropped out from the analysis (<a href="./references#CD002243-bbs2-0041" title="OppertM , SchindlerR , HusungC , OffermanK , GraefKJ , BoenischO , et al. Low‐dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Critical Care Medicine2005;33(11):2457‐64. [PUBMED: 16276166 ] ">Oppert 2005</a>; <a href="./references#CD002243-bbs2-0043" title="RinaldiS , AdembriC , GrechiS , DeGaudioR . Low‐dose hydrocortisone during severe sepsis: effects on microalbuminemia. Critical Care Medicine2006;34(9):2334‐9. [PUBMED: 16850006] ">Rinaldi 2006</a>). In the first study, seven randomly assigned participants (five in the corticosteroid group and two in the placebo group) were not analysed (<a href="./references#CD002243-bbs2-0041" title="OppertM , SchindlerR , HusungC , OffermanK , GraefKJ , BoenischO , et al. Low‐dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Critical Care Medicine2005;33(11):2457‐64. [PUBMED: 16276166 ] ">Oppert 2005</a>). Four of these participants (two in the corticosteroid group and two in the placebo group) were discharged alive from the ICU and then were lost to follow‐up. The three remaining participants (in the corticosteroid group) died: two before receiving hydrocortisone, and the last at study day 17. In the second study, 12 of 52 participants dropped out of the study: six in the control group and six in the corticosteroid group (<a href="./references#CD002243-bbs2-0043" title="RinaldiS , AdembriC , GrechiS , DeGaudioR . Low‐dose hydrocortisone during severe sepsis: effects on microalbuminemia. Critical Care Medicine2006;34(9):2334‐9. [PUBMED: 16850006] ">Rinaldi 2006</a>). Nine participants (four in the control group) were excluded, as they developed renal failure. Two control participants died in the ICU at day five and at day seven, respectively. Three of the corticosteroid‐treated participants died, at days 5, 6, and 28, respectively. Three other participants (two in the control group) were excluded, as they developed septic shock. All died at days 3, 5, and 6, respectively. </p> <p>Two trials gave additional open‐label corticosteroids to some participants (<a href="./references#CD002243-bbs2-0018" title="GordonAC , MasonAJ , PerkinsGD , StotzM , TerblancheM , AshbyD , et al. The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Critical Care Medicine2014;42(6):1325‐33. [PUBMED: 24557425] ">Gordon 2014</a>; <a href="./references#CD002243-bbs2-0047" title="SnijdersD , DanielsJMA , deGraaffCS , van derWerfTS , BoersmaWG . Efficacy of corticosteroids in community‐acquired pneumonia – a randomized double blinded clinical trial. American Journal of Respiratory and Critical Care Medicine2010;181(9):975‐82. [PUBMED: 20133929] ">Snijders 2010</a>). In the first trial, five (23.3%) participants in the placebo arm were given rescue corticosteroids for treatment of life‐threatening hypotension and were considered as cross‐overs (<a href="./references#CD002243-bbs2-0018" title="GordonAC , MasonAJ , PerkinsGD , StotzM , TerblancheM , AshbyD , et al. The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Critical Care Medicine2014;42(6):1325‐33. [PUBMED: 24557425] ">Gordon 2014</a>). In the second trial, 37 (17.4%) participants did not complete the full course of study treatment as a consequence of premature death of 10 participants, consent withdrawal for five participants, post‐randomization exclusion for eight participants, and additional open‐label corticosteroid treatment for 14 participants (<a href="./references#CD002243-bbs2-0047" title="SnijdersD , DanielsJMA , deGraaffCS , van derWerfTS , BoersmaWG . Efficacy of corticosteroids in community‐acquired pneumonia – a randomized double blinded clinical trial. American Journal of Respiratory and Critical Care Medicine2010;181(9):975‐82. [PUBMED: 20133929] ">Snijders 2010</a>). In seven trials, from 4% to 20% were withdrawn from the primary analysis for various reasons that were explained in the trial report (<a href="./references#CD002243-bbs2-0006" title="BlumCA , NigroN , BrielM , SchuetzP , UllmerE , Suter‐WidmerI , et al. Adjunct prednisone therapy for patients with community‐acquired pneumonia: a multicentre, double‐blind, randomised, placebo‐controlled trial. Lancet2015;385(9977):1511‐8. [PUBMED: 25608756] ">Blum 2015</a>; <a href="./references#CD002243-bbs2-0017" title="Fernández‐SerranoS , DorcaJ , Garcia‐VidalC , Fernández‐SabéN , CarratalàJ , Fernández‐AgüeraA , et al. Effect of corticosteroids on the clinical course of community‐acquired pneumonia: a randomized controlled trial. Critical Care2011;15(2):R96. [PUBMED: 21406101] ">Fernández‐Serrano 2011</a>; <a href="./references#CD002243-bbs2-0025" title="KehD , TripsE , MarxG , WirtzSP , AbduljawwadE , BerckerS , et al. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA2016;316(17):1775‐85. [PUBMED: 27695824] ">Keh 2016</a>; <a href="./references#CD002243-bbs2-0019" title="GordonAC , MasonAJ , ThirunavukkarasuN , PerkinsGD , CecconiM , CepkovaM , et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA2016;316(5):509‐18. [PUBMED: 27483065] ">Gordon 2016</a>; <a href="./references#CD002243-bbs2-0036" title="MenonK , McNallyD , O'HearnK , AcharyaA , WongHR , LawsonM , et al. A randomized controlled trial of corticosteroids in paediatric septic shock: a pilot feasibility study. Pediatric Critical Care Medicine2017;18(6):505‐12. [PUBMED: 28406862] ">Menon 2017</a>; <a href="./references#CD002243-bbs2-0053" title="TiloucheN , JaouedO , Ben Sik AliH , GharbiR , Fekih HassenM , ElatrousS . Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock2019;52:481‐6. [DOI: 10.1097/SHK.0000000000001316.; PUBMED: 30628950] ">Tilouche 2019</a>; <a href="./references#CD002243-bbs2-0058" title="VenkateshB , FinferS , CohenJ , RajbhandariD , ArabiY , BellomoR , et al. Adjunctive glucocorticoid therapy in patients with septic shock. New England Journal of Medicine2018;378:797–808. [DOI: 10.1056/NEJMoa1705835; PUBMED: 29347874] VenkateshB , FinferS , MybrughJ , CohenJ , BillotL . Long‐term outcomes of the ADRENAL trial [2018]. New England Journal of Medicine2018;378(18):174‐5. [PUBMED: 29694789] ">Venkatesh 2018</a>). </p> </section> <section id="CD002243-sec-0111"> <h4 class="title">Selective reporting</h4> <p>For 34 trials, we could rule out selective reporting bias after contact with authors, full access to trial protocols, or access to individual participant data. We judged these trials to be at low risk of bias for this domain. </p> <p>Seventeen trials were published before it was mandatory to register trials in an open access repository, and we have had no access to trial protocols. We judged these trials as having unclear risk of selective reporting bias. For the remaining trials, we could not obtain access to protocols, we could not find trials on an open access registry, and our attempts to contact trial authors failed. </p> </section> <section id="CD002243-sec-0112"> <h4 class="title">Other potential sources of bias</h4> <p>One trial recruited only 500 of the 800 expected participants, mainly as the result of loss of equipoise among investigators (<a href="./references#CD002243-bbs2-0049" title="SprungC , AnnaneD , KehD , MorenoR , SingerM , FreivogelK , et al. Hydrocortisone therapy for patients with septic shock. New England Journal of Medicine2008;358(2):111‐24. [PUBMED: 18184957] ">Sprung 2008</a>). Another trial was halted prematurely for futility after enrolment of 75 of 150 foreseen participants (<a href="./references#CD002243-bbs2-0005" title="ArabiYM , AljumahA , DabbaghO , TamimHM , RishuAH , Al‐AbdulkareemA , et al. Low‐dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. Canadian Medical Association Journal2010;182(18):1971‐7. [PUBMED: 21059778] ">Arabi 2011</a>). </p> <p>No trials used the Sepsis 3 definition as all were designed before publication of the new definition for sepsis (<a href="./references#CD002243-bbs2-0170" title="SingerM , DeutschmanCS , SeymourCW , Shankar‐HariM , AnnaneD , BauerM , et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis‐3). JAMA2016;315(8):801‐10. [PUBMED: 26903338] ">Singer 2016</a>). Thirty trials provided an explicit definition of sepsis (as defined in the Methods section of this review). Seven trials provided a definition of septic shock without referring to the need for vasopressor agents (<a href="./references#CD002243-bbs2-0008" title="BoneRG , FisherCJ , ClemmerTP , SlotmanGJ , MetzCA , BalkRA . A controlled clinical trial of high‐dose methylprednisolone in the treatment of severe sepsis and septic shock. New England Journal of Medicine1987;317(11):653‐8. [PUBMED: 3306374] ">Bone 1987</a>; <a href="./references#CD002243-bbs2-0030" title="LuceJM , MontgomeryAB , MarksJD , TurnerJ , MetzCA , MurrayJF . Ineffectiveness of high‐dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. American Review of Respiratory Diseases1988;138(1):62‐8. [PUBMED: 3202402 ] ">Luce 1988</a>; <a href="./references#CD002243-bbs2-0043" title="RinaldiS , AdembriC , GrechiS , DeGaudioR . Low‐dose hydrocortisone during severe sepsis: effects on microalbuminemia. Critical Care Medicine2006;34(9):2334‐9. [PUBMED: 16850006] ">Rinaldi 2006</a>; <a href="./references#CD002243-bbs2-0045" title="SchumerW . Steroids in the treatment of clinical septic shock. Annals of Surgery1976;184(3):333‐41. [PUBMED: 786190 ] ">Schumer 1976</a>; <a href="./references#CD002243-bbs2-0046" title="SlusherT , GbaderoD , HowardC , LewinsonL , GiroirB , ToroL , et al. Randomized, placebo‐controlled, double blinded trial of dexamethasone in African children with sepsis. Pediatric Infectious Diseases Journal1996;15(7):579‐83. [PUBMED: 8823850] ">Slusher 1996</a>; <a href="./references#CD002243-bbs2-0057" title="Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high‐dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. New England Journal of Medicine1987;317(11):659‐65. [PUBMED: 2888017] ">VASSCSG 1987</a>; <a href="./references#CD002243-bbs2-0059" title="YildizO , DoganayM , AygenB , GuvenM , KeleutimurF , TutuuA . Physiological‐dose steroid therapy in sepsis. Critical Care2002;6(3):251‐9. [PUBMED: 12133187] ">Yildiz 2002</a>). One study did not explicitly provide the definition used for sepsis (<a href="./references#CD002243-bbs2-0013" title="Cooperative Study Group. The effectiveness of hydrocortisone in the management of severe infections. JAMA1963;183(6):462‐5. [DOI: 10.1001/jama.1963.63700060029012] ">CSG 1963</a>). Eleven trials explicitly defined sepsis due to community‐acquired pneumonia. Two trials randomly assigned participants on the basis of the presence of ARDS, and data provided in these papers confirmed the presence of sepsis (<a href="./references#CD002243-bbs2-0028" title="LiuL , LiJ , HuangYZ , LiuSQ , YangCS , GuoFM , et al. The effect of stress dose glucocorticoid on patients with acute respiratory distress syndrome combined with critical illness‐related corticosteroid insufficiency. Zhonghua Nei Ke Za Zhi2012;51(8):599‐603. [PUBMED: 23158856] ">Liu 2012</a>; <a href="./references#CD002243-bbs2-0042" title="RezkNA , IbrahimAM . Effects of methyl prednisolone in early ARDS. Egyptian Journal of Chest Diseases and Tuberculosis2013;62(1):167–72. [DOI: 10.1016/j.ejcdt.2013.02.013] ">Rezk 2013</a>). In another trial on early ARDS, contact with the primary author confirmed that explicit definitions of sepsis were used (<a href="./references#CD002243-bbs2-0033" title="MeduriGU , GoldenE , FreireAX , TaylorE , ZamanM , CarsonSJ , et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest2007;131(4):954‐63. [PUBMED: 17426195] ">Meduri 2007</a>). </p> </section> </section> <section id="CD002243-sec-0113"> <h3 class="title" id="CD002243-sec-0113">Effects of interventions</h3> <p>See: <a href="./full#CD002243-tbl-0001"><b>Summary of findings for the main comparison</b> Corticosteroids compared to placebo or usual care for treating sepsis</a> </p> <p>We did not pool the data from one trial that included both children and adults (<a href="./references#CD002243-bbs2-0013" title="Cooperative Study Group. The effectiveness of hydrocortisone in the management of severe infections. JAMA1963;183(6):462‐5. [DOI: 10.1001/jama.1963.63700060029012] ">CSG 1963</a>), one cross‐over trial (<a href="./references#CD002243-bbs2-0024" title='KehD , BoehnkeT , Weber‐CartensS , SchulzC , AhlersO , BerckerS , et al. Immunologic and hemodynamic effects of "low‐dose" hydrocortisone in septic shock: a double‐blind, randomized, placebo‐controlled, crossover study. American Journal of Respiratory and Critical Care Medicine2003;167(4):512‐20. [PUBMED: 12426230 ] '>Keh 2003</a>), one trial that compared two durations of hydrocortisone treatment (<a href="./references#CD002243-bbs2-0022" title="HuhJW , LimCM , KohY , HongSB . Effect of low doses of hydrocortisone in patient with septic shock and relative adrenal insufficiency: 3 days versus 7 days treatment. Critical Care Medicine2006;34(12 suppl):A101. ">Huh 2007</a>), and one trial that compared hydrocortisone versus the combination of hydrocortisone plus fludrocortisone (<a href="./references#CD002243-bbs2-0003" title="COIITSS Study Investigators, AnnaneD , CariouA , MaximeV , AzoulayE , D'honneurG , et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA2010;303(4):341‐8. [PUBMED: 20103758] ">Annane 2010</a>). </p> <p>In this update, we introduced a new comparison (i.e. continuous infusion vs intermittent boluses of steroids). </p> <section id="CD002243-sec-0114"> <h4 class="title">Corticosteroids versus placebo or usual care</h4> <p>We have summarized the main results in <a href="./full#CD002243-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD002243-sec-0115"> <h5 class="title">Primary outcome</h5> <section id="CD002243-sec-0116"> <h6 class="title">28‐Day all‐cause mortality</h6> <p>Data for 28‐day mortality were available for 32 trials. In addition, we used data on 14‐day mortality (two trials), hospital mortality (10 trials), or ICU mortality (2 trials), or data on short‐term mortality (four trials). Thus, we computed data from 50 trials that accounted for 11,233 participants. In the treated group, 1388 of 5667 participants died by day 28 compared with 1469 of 5566 participants in the control group. Some heterogeneity was evident in the results (Chi² test = 68.06; P = 0.03; I² = 29%). The risk ratio (RR) of dying at 28 days was 0.91 (95% confidence interval (CI) 0.84 to 0.99; P = 0.04; random‐effects model; <a href="./references#CD002243-fig-0008" title="">Analysis 1.1</a>). We downgraded the certainty of evidence for this outcome from high to moderate for inconsistency (significant heterogeneity across trial results). </p> <p>Differences in methodological quality across trials may have accounted for observed heterogeneity in the results. A sensitivity analysis based on trials judged as being at low risk of bias showed an RR for dying at 28 days of 0.91 (95% CI 0.84 to 0.98; P = 0.01; 7896 participants; 17 studies; I² = 0%; <a href="./references#CD002243-fig-0009" title="">Analysis 1.2</a>). </p> <p>Heterogeneity across trials also may have been the result of different therapeutic regimens. Subgroup analyses based on types of corticosteroids did not suggest that this may influence the response to treatment (test for subgroup differences: Chi² = 1.48; df = 3; P = 0.69; I² = 0%; <a href="./references#CD002243-fig-0010" title="">Analysis 1.3</a>). Likewise there was no evidence that dose/duration (test for subgroup differences: Chi² = 0.29; df = 1; P = 0.59; I² = 0%; <a href="./references#CD002243-fig-0011" title="">Analysis 1.4</a>) or mode (continuous vs intermittent bolus) of corticosteroid administration (test for subgroup differences: Chi² = 0.41; df = 1; P = 0.52; I² = 0%; <a href="./references#CD002243-fig-0012" title="">Analysis 1.5</a>) influences the response to treatment. Meta‐regression analyses showed no evidence of interaction between the RR for dying at 28 days and the dose given at day 1 (P = 0.14; <a href="#CD002243-fig-0003">Figure 3</a>), total dose (P = 0.12; <a href="#CD002243-fig-0004">Figure 4</a>), or duration of treatment (P = 0.86). One trial of a large dose of corticosteroids was a statistical outlier and was excluded from the meta‐regression analysis (<a href="./references#CD002243-bbs2-0045" title="SchumerW . Steroids in the treatment of clinical septic shock. Annals of Surgery1976;184(3):333‐41. [PUBMED: 786190 ] ">Schumer 1976</a>). </p> <div class="figure" id="CD002243-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Figure represents the results from meta‐regression of log of risk ratio of dying and the dose of corticosteroids given at day 1 and expressed as equivalent milligrams of hydrocortisone. Estimates from each study are represented by circles. Circle sizes depend on the precision of each estimate (the inverse of its within‐study variance), which is the weight given to each study in the fixed‐effect model.Meta‐regression included 53 trials.REML estimate of between‐study variance: tau² = .008551.  % residual variation due to heterogeneity: I² res = 28.86%.  Proportion of between‐study variance explained: Adj R² = 43.76%." data-id="CD002243-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Figure represents the results from meta‐regression of log of risk ratio of dying and the dose of corticosteroids given at day 1 and expressed as equivalent milligrams of hydrocortisone. Estimates from each study are represented by circles. Circle sizes depend on the precision of each estimate (the inverse of its within‐study variance), which is the weight given to each study in the fixed‐effect model. </p> <p>Meta‐regression included 53 trials.</p> <p>REML estimate of between‐study variance: tau² = .008551.<br/> % residual variation due to heterogeneity: I² res = 28.86%.<br/> Proportion of between‐study variance explained: Adj R² = 43.76%. </p> </div> </div> </div> <div class="figure" id="CD002243-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Figure represents results from meta‐regression of log of risk ratio of dying and log of cumulated dose of corticosteroids expressed as equivalent milligrams of hydrocortisone. Estimates from each study are represented by circles. Circle sizes depend on the precision of each estimate (the inverse of its within‐study variance), which is the weight given to each study in the fixed‐effect model.Meta‐regression included 53 trials.REML estimate of between‐study variance: tau² = .008628.  % residual variation due to heterogeneity: I² res = 28.68%.  Proportion of between‐study variance explained: Adj R² = 43.25%." data-id="CD002243-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Figure represents results from meta‐regression of log of risk ratio of dying and log of cumulated dose of corticosteroids expressed as equivalent milligrams of hydrocortisone. Estimates from each study are represented by circles. Circle sizes depend on the precision of each estimate (the inverse of its within‐study variance), which is the weight given to each study in the fixed‐effect model. </p> <p>Meta‐regression included 53 trials.</p> <p>REML estimate of between‐study variance: tau² = .008628.<br/> % residual variation due to heterogeneity: I² res = 28.68%.<br/> Proportion of between‐study variance explained: Adj R² = 43.25%. </p> </div> </div> </div> <p>By contrast, trials in which corticosteroids were not tapered off found an RR of dying at 28 days of 0.87 (95% CI 0.78 to 0.98; 8770 participants; 30 studies; I² = 42%; random‐effects model) in favour of corticosteroids, whereas trials in which corticosteroids were tapered off found no evidence of mortality differences between groups (RR 1.04, 95% CI 0.92 to 1.18; P = 0.54; 2136 participants; 17 studies; I² = 0%) (test for subgroup differences: Chi² = 3.94; df = 1; P = 0.05; I² = 74.6%; <a href="./references#CD002243-fig-0013" title="">Analysis 1.6</a>). </p> <p>Heterogeneity across trials may have resulted from factors related to participants. There was no evidence of differences in response to treatment between children and adults (test for subgroup differences: Chi² = 0.29; df = 1; P = 0.62; I² = 0%; <a href="./references#CD002243-fig-0014" title="">Analysis 1.7</a>). Subgroup analysis based on targeted populations showed non‐significant subgroup differences (test for subgroup differences: Chi² = 7.60; df = 3; P = 0.06; I² = 60.5%; <a href="./references#CD002243-fig-0015" title="">Analysis 1.8</a>). In studies of heterogeneous populations of participants with sepsis, the RR for dying at 28 days was 1.17 (95% CI 0.98 to 1.39; P = 0.09; 1358 participants; 10 studies; I² = 25%; fixed‐effect model). In studies of only participants with septic shock, the RR for dying at 28 days was 0.91 (95% CI 0.83 to 1.00; P = 0.06; 7428 participants; 23 studies; I² = 32%; random‐effects model). In studies of participants with sepsis and ARDS, the RR was 0.66 (95% CI 0.46 to 0.94; P = 0.02; 411 participants; 4 studies; I² = 8%; fixed‐effect model), and in studies of participants with sepsis and community‐acquired pneumonia, the RR was 0.69 (95% CI 0.50 to 0.96; P = 0.03; 2038 participants; 13 studies; I² = 0%; fixed‐effect model). Likewise, meta‐regression showed no evidence of interaction between the RR of dying at 28 days and severity of illness as assessed by crude mortality in the control arm (P = 0.29; <a href="#CD002243-fig-0005">Figure 5</a>). Subgroup analysis of participants with adrenal insufficiency showed no heterogeneity in the results. Investigators reported 251 deaths among 525 participants in the treated group and 291 deaths among 554 in the placebo group. The RR for dying was 0.92 (95% CI 0.82 to 1.03; P = 0.16; 1079 participants; 12 studies; I² = 0%; fixed‐effect model; <a href="./references#CD002243-fig-0016" title="">Analysis 1.9</a>). </p> <div class="figure" id="CD002243-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Meta‐regression of the log of the risk ratio for 28‐day mortality against actual mortality at 28 days in the control arm." data-id="CD002243-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Meta‐regression of the log of the risk ratio for 28‐day mortality against actual mortality at 28 days in the control arm. </p> </div> </div> </div> <p>Funnel plot analysis, including all trials, suggested some asymmetry (<a href="#CD002243-fig-0006">Figure 6</a>). Contour‐enhanced funnel plot analysis including trials of a long course of low‐dose corticosteroids suggested no significant asymmetry (<a href="#CD002243-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD002243-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Steroids vs control, outcome: 1.1 28‐Day all‐cause mortality." data-id="CD002243-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Steroids vs control, outcome: 1.1 28‐Day all‐cause mortality.</p> </div> </div> </div> <div class="figure" id="CD002243-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Contour‐enhanced funnel plot.Log of risk ratio for 28‐day mortality is plotted against its standard error." data-id="CD002243-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Contour‐enhanced funnel plot.</p> <p>Log of risk ratio for 28‐day mortality is plotted against its standard error.</p> </div> </div> </div> <p>In one trial comparing hydrocortisone alone versus hydrocortisone plus fludrocortisone, the hazard ratio of death was 0.94 (95% CI 0.73 to 1.21; <a href="./references#CD002243-bbs2-0003" title="COIITSS Study Investigators, AnnaneD , CariouA , MaximeV , AzoulayE , D'honneurG , et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA2010;303(4):341‐8. [PUBMED: 20103758] ">Annane 2010</a>). </p> </section> </section> <section id="CD002243-sec-0117"> <h5 class="title">Secondary outcomes</h5> <section id="CD002243-sec-0118"> <h6 class="title">90‐Day all‐cause mortality</h6> <p>We could extract data on 90‐day mortality from seven trials. A total of 961 of 2975 participants in the treated group and 1026 of 2959 in the control group died within 90 days. The RR of dying within 90 days was 0.93 (95% CI 0.87 to 1.00; P = 0.05; 5934 participants; 7 studies; I² = 0%; fixed‐effect model; <a href="./references#CD002243-fig-0017" title="">Analysis 1.10</a>) in favour of the corticosteroid group. This was based on moderate‐certainty evidence (lowered for imprecision). </p> </section> <section id="CD002243-sec-0119"> <h6 class="title">Long‐term mortality</h6> <p>We could extract data on mortality beyond three months for seven trials. The RR of dying was 0.97 (95% CI 0.91 to 1.03; P = 0.29; 6236 participants; 7 studies; I² = 28%; <a href="./references#CD002243-fig-0018" title="">Analysis 1.11</a>). We downgraded the certainty of evidence to low owing to inconsistency in results and imprecision. </p> </section> <section id="CD002243-sec-0120"> <h6 class="title">Intensive care unit (ICU) mortality</h6> <p>Data were available from 18 trials, accounting for 7267 participants. All of these trials investigated a long course of low‐dose corticosteroids. A total of 908 of 3636 participants in the treated group and 1015 of 3631 participants in the control group died in the ICU. There was little heterogeneity in the results (Chi² = 19.18; df = 17; P = 0.32; I² = 11%). The RR for dying in the ICU was 0.89 (95% CI 0.83 to 0.96; fixed ‐effect model; <a href="./references#CD002243-fig-0019" title="">Analysis 1.12</a>). This was based on high‐certainty evidence. </p> </section> <section id="CD002243-sec-0121"> <h6 class="title">Hospital mortality</h6> <p>We could extract data on hospital mortality from 26 trials that accounted for 8183 participants. A total of 1223 of 4109 participants in the treated group compared with 1315 of 4074 in the control group died in hospital. Heterogeneity in the results was significant (Chi² = 39.58; df = 25; P = 0.03; I² = 37%). The RR for dying in hospital was 0.90 (95% CI 0.82 to 0.99; P = 0.03; random‐effects model; <a href="./references#CD002243-fig-0020" title="">Analysis 1.13</a>). We downgraded the certainty of evidence for this outcome from high to moderate for inconsistency. </p> </section> <section id="CD002243-sec-0122"> <h6 class="title">Number of participants with shock reversal (as defined by stable haemodynamic status ≥ 24 hours after withdrawal of vasopressor therapy) at day 7 </h6> <p>We could extract data from 16 trials that accounted for 6711 participants. A total of 2642 of 3361 participants in the treated group and 2168 of 3350 in the control group had shock reversed at day 7. Significant heterogeneity was evident in the results (Chi² = 43.87; df = 15; P = 0.0001; I² = 66%). The RR for having shock reversed at day 7 was 1.23 (95% CI 1.13 to 1.34; P &lt; 0.0001; random‐effects model) in favour of the corticosteroid group (<a href="./references#CD002243-fig-0021" title="">Analysis 1.14</a>). This was based on moderate‐certainty evidence (lowered for inconsistency). </p> <p>Sensitivity analysis excluding the two trials that evaluated a short course of high‐dose corticosteroids did not reduce heterogeneity in the results (RR 1.26, 95% CI 1.16 to 1.37; 6408 participants; 16 studies; I² = 59%) (<a href="./references#CD002243-bbs2-0008" title="BoneRG , FisherCJ , ClemmerTP , SlotmanGJ , MetzCA , BalkRA . A controlled clinical trial of high‐dose methylprednisolone in the treatment of severe sepsis and septic shock. New England Journal of Medicine1987;317(11):653‐8. [PUBMED: 3306374] ">Bone 1987</a>; <a href="./references#CD002243-bbs2-0048" title="SprungCL , CaralisPV , MarcialEH , PierceM , GelbardMA , LongWM , et al. The effects of high‐dose corticosteroids in patients with septic shock. A prospective, controlled study. New England Journal of Medicine1984;311(18):1137‐43. [PUBMED: 6384785 ] ">Sprung 1984</a>). </p> <p>In one cross‐over trial, hydrocortisone was given for three days at a dose of 240 mg per day (<a href="./references#CD002243-bbs2-0024" title='KehD , BoehnkeT , Weber‐CartensS , SchulzC , AhlersO , BerckerS , et al. Immunologic and hemodynamic effects of "low‐dose" hydrocortisone in septic shock: a double‐blind, randomized, placebo‐controlled, crossover study. American Journal of Respiratory and Critical Care Medicine2003;167(4):512‐20. [PUBMED: 12426230 ] '>Keh 2003</a>). Although this trial could not provide information on shock reversal at day 7, investigators showed that at day 3, fewer hydrocortisone patients than placebo‐treated patients required norepinephrine treatment (6/20 vs 14/20; P = 0.025). </p> </section> <section id="CD002243-sec-0123"> <h6 class="title">Number of participants with shock reversal (as defined by stable haemodynamic status ≥ 24 hours after withdrawal of vasopressor therapy) at day 28 </h6> <p>We could extract data from 13 trials, accounting for 6753 participants. A total of 2767 of 3382 participants in the treated group had shock reversed at day 28, as did 2629 of 3397 in the placebo group. No heterogeneity was evident in the results (I² = 0%). The RR for having shock reversed was 1.06 (95% CI 1.03 to 1.08; P &lt; 0.00001) in favour of the corticosteroid group (<a href="./references#CD002243-fig-0022" title="">Analysis 1.15</a>). This was based on high‐certainty evidence. </p> </section> <section id="CD002243-sec-0124"> <h6 class="title">Number of organs affected and severity of organ dysfunction at day 7, as measured by the sequential organ failure assessment (SOFA) score </h6> <p>Ten studies (2157 participants) reported the SOFA score at seven days post randomization. The mean difference (MD) in the SOFA score at day 7 was ‐1.37 (95% CI ‐1.84 to ‐0.90; P &lt; 0.00001; random‐effects model) in favour of corticosteroids. Moderate heterogeneity across studies was noted (Chi² = 17.03; df = 9; P = 0.05; I² = 47%; <a href="./references#CD002243-fig-0023" title="">Analysis 1.16</a>). This was based on moderate‐certainty evidence (lowered for inconsistency). </p> <p>In one study (<a href="./references#CD002243-bbs2-0009" title="BriegelJ , ForstH , HallerM , SchellingG , KilgerE , KupratG , et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double‐blind, single‐center study. Critical Care Medicine1999;27(4):723‐32. [PUBMED: 10321661] ">Briegel 1999</a>), corticosteroid treatment was associated with a non‐significant (P = 0.18) trend toward earlier resolution of organ dysfunction. </p> </section> <section id="CD002243-sec-0125"> <h6 class="title">Length of stay in the intensive care unit</h6> <section id="CD002243-sec-0126"> <p><b>For all participants</b></p> <p>In 21 trials (7612 participants), the MD for ICU length of stay for all participants was ‐1.07 days (95% CI ‐1.95 to ‐0.19; P = 0.02; random‐effects model) in favour of the corticosteroid group, with some heterogeneity evident across studies (Chi² = 31.49; df = 20; P = 0.05; I² = 36%; <a href="./references#CD002243-fig-0024" title="">Analysis 1.17</a>). We judged the certainty of evidence for this outcome as high. There was some heterogeneity in the results. However, the treatment effect was large. </p> </section> <section id="CD002243-sec-0127"> <p><b>For survivors only</b></p> <p>We could extract data from 10 trials on 778 ICU survivors. The MD for ICU length of stay among these survivors was ‐2.19 days (95% CI ‐3.93 to ‐0.46; P = 0.01; fixed‐effect model). No heterogeneity was evident across studies (Chi² test = 8.63; P= 0.47; I² = 0%; <a href="./references#CD002243-fig-0025" title="">Analysis 1.18</a>). </p> </section> </section> <section id="CD002243-sec-0128"> <h6 class="title">Length of hospital stay</h6> <section id="CD002243-sec-0129"> <p><b>For all participants</b></p> <p>From 22 trials (8795 participants), we could extract data on all participants. We noted heterogeneity in the results (heterogeneity: Chi² = 51.44; df = 201; P = 0.0002; I² = 59%). The MD for length of hospital stay for all participants was ‐1.63 days (95% CI ‐2.93 to ‐0.33 ; P = 0.01; random‐effects model; <a href="./references#CD002243-fig-0026" title="">Analysis 1.19</a>). We judged the certainty of evidence for this outcome as high. There was some heterogeneity in the results. However, the treatment effect was large. </p> </section> <section id="CD002243-sec-0130"> <p><b>For survivors only</b></p> <p>We could extract data for hospital survivors from nine studies (710 participants). We noted some heterogeneity in the results (I² = 43%). No evidence suggested a difference between the two groups (MD ‐4.11 days, 95% CI ‐8.50 to 0.28; P = 0.07; random‐effects model; <a href="./references#CD002243-fig-0027" title="">Analysis 1.20</a>). </p> </section> </section> <section id="CD002243-sec-0131"> <h6 class="title">Adverse events</h6> <section id="CD002243-sec-0132"> <p><b>Gastroduodenal bleeding</b></p> <p>We could extract data from 25 trials (5171 participants). A total of 131 of 2607 participants in the treated group and 120 of 2564 in the control group had an episode of gastroduodenal bleeding. We noted no heterogeneity in the results (I² = 0%). The RR for having gastroduodenal bleeding was 1.07 (95% CI 0.85 to 1.35; P = 0.55; fixed‐effect model; <a href="./references#CD002243-fig-0028" title="">Analysis 1.21</a>). We judged this to be based on moderate‐certainty evidence (lowered due to imprecision). </p> </section> <section id="CD002243-sec-0133"> <p><b>Superinfection</b></p> <p>We could extract data from 25 trials (5356 participants). A total of 487 of 2695 participants in the treated group and 451 of 2661 participants in the control group had an episode of nosocomial infection. We noted no heterogeneity in the results (Chi² = 20.66; df = 21; P = 0.48; I² = 0%). The RR for superinfection was 1.06 (95% CI 0.95 to 1.19; P = 0.27; fixed‐effect model; <a href="./references#CD002243-fig-0028" title="">Analysis 1.21</a>). We judged the certainty of evidence as moderate for this outcome (lowered for imprecision). </p> </section> <section id="CD002243-sec-0134"> <p><b>Hyperglycaemia</b></p> <p>The number of participants who presented with hyperglycaemia was reported for 20 trials (8594 participants). There was heterogeneity in the results (Chi² = 35.96; df = 17; P = 0.005; I² = 53%). The RR for hyperglycaemia was 1.20 (95% CI 1.10 to 1.31; P &lt; 0.00001; random‐effects model; <a href="./references#CD002243-fig-0028" title="">Analysis 1.21</a>). This was based on moderate‐certainty evidence (lowered for inconsistency). </p> <p>One trial comparing tight glucose control versus standard care found no benefit in normalizing blood glucose levels among corticosteroid‐treated septic shock participants (<a href="./references#CD002243-bbs2-0003" title="COIITSS Study Investigators, AnnaneD , CariouA , MaximeV , AzoulayE , D'honneurG , et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA2010;303(4):341‐8. [PUBMED: 20103758] ">Annane 2010</a>). </p> </section> <section id="CD002243-sec-0135"> <p><b>Hypernatraemia</b></p> <p>The number of participants who presented with hypernatraemia was reported for six trials (5069 participants). We noted no heterogeneity in the results (Chi² = 4.45; df = 5; P = 0.49; I² = 0%). The RR for hypernatraemia was 1.66 (95% CI 1.34 to 2.06; P &lt; 0.00001; fixed‐effect model; <a href="./references#CD002243-fig-0028" title="">Analysis 1.21</a>). This was based on high‐certainty evidence. </p> </section> <section id="CD002243-sec-0136"> <p><b>Muscle weakness</b></p> <p>The number of participants who presented with muscle weakness was reported for six trials (6145 participants). There was little to no heterogeneity in the results (Chi² = 5.42; df = 5; P = 0.37; I² = 8%). The RR for muscle weakness was 1.21 (95% CI 1.01 to 1.44; P = 0.04; fixed‐effect model; <a href="./references#CD002243-fig-0028" title="">Analysis 1.21</a>) in favour of the control group. We judged the certainty of evidence as high for this outcome. </p> </section> <section id="CD002243-sec-0137"> <p><b>Neuropsychiatric events</b></p> <p>The number of participants who presented with neuropsychiatric events was reported for eight trials (6941 participants). There was some heterogeneity in the results (Chi² = 9.93; df = 7; P = 0.19; I² = 30%). The RR for neuropsychiatric events was 1.15 (95% CI 0.52 to 2.57; P = 0.73; random‐effects model; <a href="./references#CD002243-fig-0028" title="">Analysis 1.21</a>). This was based on low‐certainty evidence (lowered for imprecision and inconsistency). </p> </section> <section id="CD002243-sec-0138"> <p><b>Stroke</b></p> <p>The number of participants who presented with stroke was reported for four trials (2842 participants). There was no heterogeneity in the results (Chi² = 1.66; df = 3; P = 0.64; I² = 0%). The RR for stroke was 0.83 (95% CI 0.41 to 1.68; P = 0.73; fixed‐effect model; <a href="./references#CD002243-fig-0028" title="">Analysis 1.21</a>). This was based on moderate‐certainty evidence (lowered for imprecision). </p> </section> <section id="CD002243-sec-0139"> <p><b>Cardiac events</b></p> <p>The number of participants who presented with cardiac events was reported for six trials (3567 participants). There was no heterogeneity in the results (Chi² = 3.51; df = 5; P = 0.62; I² = 0%). The RR for acute coronary events was 1.12 (95% CI 0.66 to 1.88; P = 0.68; fixed‐effect model; <a href="./references#CD002243-fig-0028" title="">Analysis 1.21</a>). This was based on moderate‐certainty evidence (lowered for imprecision). </p> </section> </section> </section> </section> <section id="CD002243-sec-0140"> <h4 class="title">Continuous infusion versus intermittent bolus of corticosteroids</h4> <p>We have summarized the main results in <a href="#CD002243-tbl-0002">Table 1</a>. </p> <div class="table" id="CD002243-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Continuous infusion compared to bolus administration of corticosteroids for children and adults with sepsis</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Continuous infusion compared to bolus administration of corticosteroids for children and adults with sepsis</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children and adults with sepsis<br/> <b>Setting:</b> hospitalized patients; trials were performed in France, Tunisia, Romania, and Finland<br/> <b>Intervention:</b> continuous infusion<br/> <b>Comparison:</b> bolus administration of corticosteroids </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with bolus administration of corticosteroids</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with continuous infusion</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28‐Day all‐cause mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (0.81 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>310<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Evidence is very uncertain about the effect of continuous infusion on 28‐day all‐cause mortality </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457 per 1000<br/> (359 to 581) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Long‐term mortality<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.36<br/> (1.02 to 1.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>d,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Evidence is very uncertain about the effect of continuous infusion on long‐term mortality</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>636 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>865 per 1000<br/> (649 to 1000) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hospital mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/> (0.72 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>240<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Evidence is very uncertain about the effect of continuous infusion on hospital mortality</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435 per 1000<br/> (329 to 572) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of intensive care unit stay for all participants in days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean length of intensive care unit stay for all participants was 13 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.05 lower<br/> (4.54 lower to 2.45 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence is very uncertain about the effect of continuous infusion on length of intensive care unit stay for all participants </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay for all participants in days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean length of hospital stay for all participants was 17 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 higher<br/> (5.05 lower to 5.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence is very uncertain about the effect of continuous infusion on length of hospital stay for all participants </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events ‐ superinfection (up to longest follow‐up)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/> (0.37 to 3.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>193<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Evidence is very uncertain about the effect of continuous infusion on number of participants with adverse events ‐ superinfection </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229 per 1000<br/> (76 to 680) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events ‐ muscle weakness (up to longest follow‐up)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.13 to 5.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Evidence suggests that continuous infusion may result in little to no difference in the number of participants with adverse events ‐ muscle weakness </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/> (8 to 362) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; MD: mean difference; RCT: randomized controlled trial; RR: risk ratio. </p> <p>The unit of measure for length of stay is days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level as only one of the four trials was judged as having low risk of bias. </p> <p><sup>b</sup>Downgraded one level as trials were small and the 95% confidence interval was large. </p> <p><sup>d</sup>Downgraded one level as the only trial reporting this outcome was open‐labelled and at high risk of performance bias. </p> <p><sup>e</sup>Downgraded one level as only one trial reported this outcome. </p> <p><sup>f</sup>Downgraded one level as the observed increase in risk of dying in the long term is not consistent with treatment effects on 28‐day mortality. </p> <p><sup>g</sup>Downgraded one level as results show some heterogeneity. </p> <p><sup>h</sup>Downgraded two levels as heterogeneity in the results is strong. </p> <p><sup>c</sup>Long‐term mortality was assessed up to six months. </p> </div> </div> <section id="CD002243-sec-0141"> <h5 class="title">Primary outcome</h5> <section id="CD002243-sec-0142"> <h6 class="title">28‐Day all‐cause mortality</h6> <p>Data for 28‐day mortality were available for three trials accounting for 310 participants. There was no heterogeneity in the results (Chi² = 1.94; df = 2; P = 0.38; I² = 0%). A total of 73 of 159 participants in the continuous infusion group and 67 of 151 participants in the intermittent bolus group died at 28 days. The RR of dying at 28 days was 1.03 (95% CI 0.81 to 1.31; P = 0.82; fixed‐effect model; <a href="./references#CD002243-fig-0029" title="">Analysis 2.1</a>) in favour of the intermittent bolus group. We downgraded the certainty of evidence to very low due to high risk of bias in all except one trial and due to imprecision. </p> </section> </section> <section id="CD002243-sec-0143"> <h5 class="title">Secondary outcomes</h5> <section id="CD002243-sec-0144"> <h6 class="title">90‐Day all‐cause mortality</h6> <p>Data for 90‐day mortality were available for only one trial (<a href="./references#CD002243-bbs2-0023" title="HyvernatH , BarelR , GentilhommeA , Césari‐GiordaniJF , FrecheA , KaidomarM , et al. Effects of increasing hydrocortisone to 300 mg per day in the treatment of septic shock: a pilot study. Shock2016;46:498‐505. [PUBMED: 27405061] ">Hyvernat 2016</a>). This trial provided no evidence of a difference between groups for 90‐day all‐cause mortality (RR 0.87, 95% CI 0.61 to 1.22; <a href="./references#CD002243-fig-0030" title="">Analysis 2.2</a>). We judged this to be very low‐certainty evidence (with very high risk of bias and imprecision). </p> </section> <section id="CD002243-sec-0145"> <h6 class="title">Long‐term mortality</h6> <p>In one trial that reported mortality at one year, the RR of dying was 1.36 (95% CI 1.02 to 1.81; 70 participants; <a href="./references#CD002243-fig-0031" title="">Analysis 2.3</a>) (<a href="./references#CD002243-bbs2-0053" title="TiloucheN , JaouedO , Ben Sik AliH , GharbiR , Fekih HassenM , ElatrousS . Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock2019;52:481‐6. [DOI: 10.1097/SHK.0000000000001316.; PUBMED: 30628950] ">Tilouche 2019</a>). We downgraded the certainty of evidence to very low owing to the fact that data were available from only one small trial that was at high risk of performance and detection bias. </p> </section> <section id="CD002243-sec-0146"> <h6 class="title">Intensive care unit mortality</h6> <p>We could extract data from four trials. We found no evidence of a difference between the two groups (RR 1.02, 95% CI 0.80 to 1.29; 358 participants; I² = 0%; fixed‐effect model; <a href="./references#CD002243-fig-0032" title="">Analysis 2.4</a>). This was based on very low‐certainty evidence (with very high risk of bias and imprecision). </p> </section> <section id="CD002243-sec-0147"> <h6 class="title">In‐hospital mortality</h6> <p>We could extract data from two trials. We found no evidence of a difference between the two groups (RR 0.95, 95% CI 0.72 to 1.25; P = 0.70; 240 participants; 4 studies; I² = 0%; fixed‐effect model; <a href="./references#CD002243-fig-0033" title="">Analysis 2.5</a>). We downgraded the certainty of evidence to very low owing to imprecision and risk of bias in one study. </p> </section> <section id="CD002243-sec-0148"> <h6 class="title">Number of participants with shock reversal (as defined by stable haemodynamic status ≥ 24 hours after withdrawal of vasopressor therapy) at day 7 </h6> <p>We could extract data about shock reversal from four trials (358 participants). The results showed heterogeneity (Chi² = 10.09; df = 3; P = 0.02; I² = 70%). A total of 104 of 183 participants in the continuous infusion group and 118 of 175 participants in the intermittent bolus group had shock reversal. The RR of shock reversal was 0.80 (95% CI 0.59 to 1.10; P = 0.17; random‐effects model; <a href="./references#CD002243-fig-0034" title="">Analysis 2.6</a>). This was based on very low‐certainty evidence (due to risk of bias, imprecision, and inconsistency). </p> </section> <section id="CD002243-sec-0149"> <h6 class="title">Number of participants with shock reversal (as defined by stable haemodynamic status ≥ 24 hours after withdrawal of vasopressor therapy) at 28 days </h6> <p>Data were available from one trial (<a href="./references#CD002243-bbs2-0053" title="TiloucheN , JaouedO , Ben Sik AliH , GharbiR , Fekih HassenM , ElatrousS . Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock2019;52:481‐6. [DOI: 10.1097/SHK.0000000000001316.; PUBMED: 30628950] ">Tilouche 2019</a>). The RR of having shock reversed by 28 days was 0.78 (95% CI 0.45 to 1.34; 70 participants; <a href="./references#CD002243-fig-0035" title="">Analysis 2.7</a>). This was based on very low‐certainty evidence (due to risk of bias and very severe imprecision). </p> </section> <section id="CD002243-sec-0150"> <h6 class="title">Number of organs affected and severity of organ dysfunction at day 7, as measured by the sequential organ failure assessment (SOFA) score </h6> <p>The SOFA score at day 7 was available for three trials. The mean difference between groups for the SOFA score was 1.00 (95% CI ‐0.25 to 2.26; 260 participants; I² = 7%; fixed‐effect model; <a href="./references#CD002243-fig-0036" title="">Analysis 2.8</a>). This was based on very low‐certainty evidence (due to risk of bias and very severe imprecision). </p> </section> <section id="CD002243-sec-0151"> <h6 class="title">Length of stay in the intensive care unit</h6> <section id="CD002243-sec-0152"> <p><b>For all participants</b></p> <p>We could extract data about length of stay in the ICU for three trials. We found no evidence of a difference between groups (MD ‐1.05 days, 95% CI ‐4.54 to 2.45; P = .56; 310 participants; I² = 67%; random‐effects model; <a href="./references#CD002243-fig-0037" title="">Analysis 2.9</a>). We downgraded the certainty of evidence to very low owing to inconsistency, imprecision, and high risk of bias in two studies. </p> </section> <section id="CD002243-sec-0153"> <p><b>For survivors only</b></p> <p>No trial provided data for length of ICU stay among survivors only.</p> </section> </section> <section id="CD002243-sec-0154"> <h6 class="title">Length of stay in the hospital</h6> <section id="CD002243-sec-0155"> <p><b>For all participants</b></p> <p>We could extract data about length of stay in the hospital from three trials. We found no evidence of a difference between groups (MD 0.01 days, 95% CI ‐5.05 to 5.07; P = 1.00; 310 participants; I² = 70%; random‐effects model; <a href="./references#CD002243-fig-0038" title="">Analysis 2.10</a>). We downgraded the certainty of evidence to very low owing to inconsistency, imprecision, and high risk of bias in two studies. </p> </section> <section id="CD002243-sec-0156"> <p><b>For survivors only</b></p> <p>No trial provided data for length of hospital stay among survivors only.</p> </section> </section> <section id="CD002243-sec-0157"> <h6 class="title">Adverse events</h6> <section id="CD002243-sec-0158"> <p><b>Gastroduodenal bleeding</b></p> <p>Data from two trials suggest no evidence of a difference between groups in the risk of gastroduodenal bleeding (RR 0.79, 95% CI 0.10 to 6.37; P = 0.83; 193 participants; I² = 67%; random‐effects model; <a href="./references#CD002243-fig-0039" title="">Analysis 2.11</a>). This was based on very low‐certainty evidence (due to risk of bias, inconsistency, and very severe imprecision). </p> </section> <section id="CD002243-sec-0159"> <p><b>Superinfection</b></p> <p>Data from two trials suggest no evidence of a difference between groups in the risk of superinfection (RR 1.12, 95% CI 0.37 to 3.33; P = 0.84; 193 participants; I² = 74%; random‐effects model; <a href="./references#CD002243-fig-0039" title="">Analysis 2.11</a>). We downgraded the certainty of evidence to very low owing to inconsistency, imprecision, and high risk of bias in one of the studies. </p> </section> <section id="CD002243-sec-0160"> <p><b>Hyperglycaemia</b></p> <p>Data from three trials suggest no evidence of a difference between groups in the number of patients with at least one episode of hyperglycaemia (RR 0.89, 95% CI 0.47 to 1.71; P = 0.74; 310 participants; I² = 80%; random‐effects model; <a href="./references#CD002243-fig-0039" title="">Analysis 2.11</a>). This was based on very low‐certainty evidence (due to risk of bias, inconsistency, and imprecision). </p> <p>Two trials reported mean blood glucose levels. One trial found slightly lower mean blood glucose levels in the continuous infusion group when compared to the intermittent boluses group (6.4 ± 0.7 mmol/L vs 6.2 ± 0.7; P = 0.04) (<a href="./references#CD002243-bbs2-0029" title="LoisaP , ParviainenI , TenhunenJ , HovilehtoS , RuokonenE . Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial. Critical Care2007;11(1):R21. [PUBMED: 17306016] ">Loisa 2007</a>). Another trial found no statistically significant difference between these groups (9.± 2.5 mmol/L vs 8.5 ± 6.0; P = 0.55) (<a href="./references#CD002243-bbs2-0023" title="HyvernatH , BarelR , GentilhommeA , Césari‐GiordaniJF , FrecheA , KaidomarM , et al. Effects of increasing hydrocortisone to 300 mg per day in the treatment of septic shock: a pilot study. Shock2016;46:498‐505. [PUBMED: 27405061] ">Hyvernat 2016</a>). In addition, three trials found that managing hyperglycaemia required higher doses of insulin in continuous infusion versus bolus administration. The MDs for insulin dose were 12.92 (95% CI ‐15.43 to 41.27) (<a href="./references#CD002243-bbs2-0023" title="HyvernatH , BarelR , GentilhommeA , Césari‐GiordaniJF , FrecheA , KaidomarM , et al. Effects of increasing hydrocortisone to 300 mg per day in the treatment of septic shock: a pilot study. Shock2016;46:498‐505. [PUBMED: 27405061] ">Hyvernat 2016</a>), ‐5.00 (95% CI ‐28.50 to 18.50) (<a href="./references#CD002243-bbs2-0029" title="LoisaP , ParviainenI , TenhunenJ , HovilehtoS , RuokonenE . Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial. Critical Care2007;11(1):R21. [PUBMED: 17306016] ">Loisa 2007</a>), and 7.57 (95% CI 4.07 to 11.07) (<a href="./references#CD002243-bbs2-0053" title="TiloucheN , JaouedO , Ben Sik AliH , GharbiR , Fekih HassenM , ElatrousS . Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock2019;52:481‐6. [DOI: 10.1097/SHK.0000000000001316.; PUBMED: 30628950] ">Tilouche 2019</a>). </p> </section> <section id="CD002243-sec-0161"> <p><b>Hypernatremia</b></p> <p>Data from two trials suggest no evidence of a difference between groups (RR 0.74, 95% CI 0.34 to 1.61; P = 0.45; 187 participants; I² = 47%; random‐effects model; <a href="./references#CD002243-fig-0039" title="">Analysis 2.11</a>). This was based on very low‐certainty evidence (due to risk of bias, inconsistency, and imprecision). </p> </section> <section id="CD002243-sec-0162"> <p><b>Muscle weakness</b></p> <p>Only one trial reported data about muscle weakness (<a href="./references#CD002243-bbs2-0053" title="TiloucheN , JaouedO , Ben Sik AliH , GharbiR , Fekih HassenM , ElatrousS . Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock2019;52:481‐6. [DOI: 10.1097/SHK.0000000000001316.; PUBMED: 30628950] ">Tilouche 2019</a>). This trial provided no evidence of a difference in this outcome between groups (RR 0.89, 95% CI 0.13 to 5.98). We downgraded the certainty of evidence to very low as this outcome was available from only one trial that was at high risk of performance and detection bias. </p> </section> <section id="CD002243-sec-0163"> <p><b>Neuropsychiatric events</b></p> <p>Only one trial reported data about neuropsychiatric events (<a href="./references#CD002243-bbs2-0053" title="TiloucheN , JaouedO , Ben Sik AliH , GharbiR , Fekih HassenM , ElatrousS . Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock2019;52:481‐6. [DOI: 10.1097/SHK.0000000000001316.; PUBMED: 30628950] ">Tilouche 2019</a>). This trial provided no evidence of a difference in this outcome between groups (RR 1.56, 95% CI 0.50 to 4.86). This was based on very low‐certainty evidence (due to risk of bias, inconsistency, and very severe imprecision). </p> </section> <section id="CD002243-sec-0164"> <p><b>Stroke</b></p> <p>One trial reported that this outcome did not occur during patient follow‐up (<a href="./references#CD002243-bbs2-0053" title="TiloucheN , JaouedO , Ben Sik AliH , GharbiR , Fekih HassenM , ElatrousS . Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock2019;52:481‐6. [DOI: 10.1097/SHK.0000000000001316.; PUBMED: 30628950] ">Tilouche 2019</a>). The other trials did not report information about this outcome. </p> </section> <section id="CD002243-sec-0165"> <p><b>Cardiac events</b></p> <p>One trial reported that this outcome did not occur during patient follow‐up (<a href="./references#CD002243-fig-0039" title="">Analysis 2.11</a>) (<a href="./references#CD002243-bbs2-0053" title="TiloucheN , JaouedO , Ben Sik AliH , GharbiR , Fekih HassenM , ElatrousS . Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock2019;52:481‐6. [DOI: 10.1097/SHK.0000000000001316.; PUBMED: 30628950] ">Tilouche 2019</a>). The other trials did not report information about this outcome. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002243-sec-0166" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002243-sec-0166">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002243-sec-0248">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002243-sec-0166"></div> <section id="CD002243-sec-0167"> <h3 class="title" id="CD002243-sec-0167">Summary of main results</h3> <section id="CD002243-sec-0168"> <h4 class="title">Effects of corticosteroids on mortality</h4> <p>Overall, this review suggests that in sepsis, corticosteroids reduce all‐cause mortality at 28 days and at 90 days, as well as mortality at intensive care unit (ICU) and hospital discharge. For these outcomes, results show some heterogeneity. </p> <p>Sensitivity analysis based on trials judged as being at low risk of bias found a significant reduction in 28‐day all‐cause mortality with corticosteroids. </p> <p>Subgroup analysis based on the specific study drug used did not find significant subgroup differences, although treatment effects on 28‐day mortality might be greater with the combination of hydrocortisone and fludrocortisone. Only one trial directly compared hydrocortisone alone to hydrocortisone and fludrocortisone and found a non‐statistically significant 3% absolute reduction in in‐hospital mortality in favour of the combination (<a href="./references#CD002243-bbs2-0003" title="COIITSS Study Investigators, AnnaneD , CariouA , MaximeV , AzoulayE , D'honneurG , et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA2010;303(4):341‐8. [PUBMED: 20103758] ">Annane 2010</a>). Meta‐regression and subgroup analyses based on treatment modalities show that dose and duration did not influence response to corticosteroids. Nevertheless, most trials published in the past two decades provided a long course (&gt; 72 hours at full dose) of low‐dose (&lt; 400 mg per day of hydrocortisone equivalent) corticosteroids. Researchers provided no evidence of subgroup differences based on continuous infusion versus intermittent bolus administration of corticosteroids. Likewise, trials that directly compared continuous infusion versus intermittent bolus of corticosteroids reported no evidence of a difference between groups in mortality at 28 days, at 90 days, in the long term, and at ICU and hospital discharge. Subgroup analysis based on modalities for stopping corticosteroids suggests that survival benefit from corticosteroids was greater without versus with tapering off. </p> <p>Subgroup analyses based on factors related to participants suggest that age (children vs adults) did not influence patients' response to corticosteroids. Patients with septic shock, those with acute respiratory distress syndrome (ARDS), and those with community‐acquired pneumonia may be more likely to derive a survival benefit from corticosteroids than patients with less severe sepsis, although subgroup differences were barely statistically significant. Analysis of trials including patients with critical illness‐related corticosteroid insufficiency (CIRCI) did not show a significant reduction in the risk of death at 28 days. However, studies did not use the same definition for adrenal insufficiency. Additional studies are needed to determine the best diagnostic tool for CIRCI (<a href="./references#CD002243-bbs2-0107" title="AnnaneD , PastoresSM , RochwergB , ArltW , BalkRA , BeishuizenA , et al. Guidelines for the diagnosis and management of critical illness‐related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Medicine2017;43(12):1751‐63. [PUBMED: 28940011] ">Annane 2017b</a>). </p> </section> <section id="CD002243-sec-0169"> <h4 class="title">Effects of corticosteroids on morbidity outcomes</h4> <p>The beneficial effects of corticosteroids on mortality may be related to favourable effects of this treatment on the duration of shock. Indeed, this review shows that treatment with corticosteroids resulted in a substantial reduction in shock duration, with fewer patients remaining on vasopressor therapy by day 7 and by day 28. Treatment with corticosteroids may attenuate the severity of inflammation (<a href="./references#CD002243-bbs2-0012" title="ConfalonieriM , UrbinoR , PotenaA , PiatellaM , ParigiP , GiacomoP , et al. Hydrocortisone infusion for severe community acquired pneumonia: a preliminary randomized study. American Journal of Respiratory and Critical Care Medicine2005;171(3):242‐8. [PUBMED: 15557131] ">Confalonieri 2005</a>; <a href="./references#CD002243-bbs2-0024" title='KehD , BoehnkeT , Weber‐CartensS , SchulzC , AhlersO , BerckerS , et al. Immunologic and hemodynamic effects of "low‐dose" hydrocortisone in septic shock: a double‐blind, randomized, placebo‐controlled, crossover study. American Journal of Respiratory and Critical Care Medicine2003;167(4):512‐20. [PUBMED: 12426230 ] '>Keh 2003</a>; <a href="./references#CD002243-bbs2-0077" title="MikamiK , SuzukiM , KitagawaH , KawakamiM , HirotaN , YamaguchiH , et al. Efficacy of corticosteroids in the treatment of community‐acquired pneumonia requiring hospitalization. Lung2007;185(5):249‐55. [PUBMED: 17710485] ">Mikami 2007</a>; <a href="./references#CD002243-bbs2-0041" title="OppertM , SchindlerR , HusungC , OffermanK , GraefKJ , BoenischO , et al. Low‐dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Critical Care Medicine2005;33(11):2457‐64. [PUBMED: 16276166 ] ">Oppert 2005</a>; <a href="./references#CD002243-bbs2-0043" title="RinaldiS , AdembriC , GrechiS , DeGaudioR . Low‐dose hydrocortisone during severe sepsis: effects on microalbuminemia. Critical Care Medicine2006;34(9):2334‐9. [PUBMED: 16850006] ">Rinaldi 2006</a>), as well as the intensity and duration of organ system failure (<a href="./references#CD002243-bbs2-0009" title="BriegelJ , ForstH , HallerM , SchellingG , KilgerE , KupratG , et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double‐blind, single‐center study. Critical Care Medicine1999;27(4):723‐32. [PUBMED: 10321661] ">Briegel 1999</a>; <a href="./references#CD002243-bbs2-0012" title="ConfalonieriM , UrbinoR , PotenaA , PiatellaM , ParigiP , GiacomoP , et al. Hydrocortisone infusion for severe community acquired pneumonia: a preliminary randomized study. American Journal of Respiratory and Critical Care Medicine2005;171(3):242‐8. [PUBMED: 15557131] ">Confalonieri 2005</a>; <a href="./references#CD002243-bbs2-0024" title='KehD , BoehnkeT , Weber‐CartensS , SchulzC , AhlersO , BerckerS , et al. Immunologic and hemodynamic effects of "low‐dose" hydrocortisone in septic shock: a double‐blind, randomized, placebo‐controlled, crossover study. American Journal of Respiratory and Critical Care Medicine2003;167(4):512‐20. [PUBMED: 12426230 ] '>Keh 2003</a>; <a href="./references#CD002243-bbs2-0041" title="OppertM , SchindlerR , HusungC , OffermanK , GraefKJ , BoenischO , et al. Low‐dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Critical Care Medicine2005;33(11):2457‐64. [PUBMED: 16276166 ] ">Oppert 2005</a>; <a href="./references#CD002243-bbs2-0049" title="SprungC , AnnaneD , KehD , MorenoR , SingerM , FreivogelK , et al. Hydrocortisone therapy for patients with septic shock. New England Journal of Medicine2008;358(2):111‐24. [PUBMED: 18184957] ">Sprung 2008</a>), as shown in this review by a marked decrease in sequential organ failure assessment (SOFA) score at day 7. In addition, subsequent to favourable effects on cardiovascular and other organ functions, corticosteroid therapy resulted in substantial shortening of ICU and hospital length of stay. </p> <p>These favourable effects of corticosteroids on sepsis‐related morbidity were not influenced by modalities of treatment administration, as was found in trials that directly compared continuous infusion versus intermittent boluses of corticosteroids. </p> </section> <section id="CD002243-sec-0170"> <h4 class="title">Tolerance of corticosteroids</h4> <p>Finally, this review also found no evidence of an effect of corticosteroids on rates of gastroduodenal bleeding or superinfection, nor on the proportion of patients with neuropsychiatric events, stroke, or cardiac events. Corticosteroids were associated with increased risk for developing hyperglycaemia and hypernatraemia, and for developing acquired muscle weakness. </p> <p>Evidence from four trials that compared continuous infusion versus intermittent bolus of corticosteroids does not show significant differences in rates of hyperglycaemia, mean blood glucose levels, or the need for higher insulin doses when corticosteroids were administered as continuous infusion. One trial including 509 corticosteroid‐treated patients with septic shock reported no benefit for normalizing blood glucose levels (<a href="./references#CD002243-bbs2-0003" title="COIITSS Study Investigators, AnnaneD , CariouA , MaximeV , AzoulayE , D'honneurG , et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA2010;303(4):341‐8. [PUBMED: 20103758] ">Annane 2010</a>). The rates of any other serious adverse events were not significantly different between continuous infusion and intermittent bolus administration of corticosteroids. </p> </section> </section> <section id="CD002243-sec-0171"> <h3 class="title" id="CD002243-sec-0171">Overall completeness and applicability of evidence</h3> <p>We identified 61 trials addressing the question of corticosteroids versus control for sepsis. These trials accounted for a large population (i.e. 12,192 participants). Most of the eligible trials contributed to the primary outcome for this review. In addition, four trials provided information on direct comparison of continuous infusion versus intermittent bolus administration of corticosteroids. We found no evidence of publication bias. </p> <p>Owing to the large number of trials, and to the large size of some individual trials, we could investigate all foreseen outcomes. We found mild heterogeneity in results for the primary outcome, which we explored through sensitivity analyses, subgroup analyses, and meta‐regression analyses. Although subgroup analyses represent a between‐study ‐ not a within‐study ‐ hypothesis, we thought its validity was acceptable according to proposed criteria (<a href="./references#CD002243-bbs2-0130" title="GuyattGH , WyerP , IoannidisJ . When to believe a subgroup analysis. In: GuyattG , RennieR , MeadeM , CookD editor(s). User’s Guides to the Medical Literature: A Manual for Evidence‐Based Clinical Practice. New York: McGraw‐Hill, 2008. ">Guyatt 2008b</a>). First, we defined the hypothesis for an interaction between practical modalities of administration and effects of corticosteroids on mortality a priori. Second, we conducted subgroup analyses based on only two factors (i.e. modalities of drug administration and population). Third, findings show that the treatment effect was consistent in terms of 28‐day, ICU, hospital, 90‐day, and long‐term mortality (risk ratios (RRs) 0.91, 0.89, 0.90, 0.93, and 0.97, respectively). Fourth, strong external evidence supports these results. Experimental and human studies have shown that a dose of 400 mg or less of hydrocortisone or equivalent can reverse the systemic inflammatory response, endothelial activation, and coagulation disorders secondary to infection (<a href="./references#CD002243-bbs2-0104" title="AnnaneD , BellissantE , CavaillonJM . Septic shock. Lancet2005;365(9453):63‐78. [PUBMED: 15639681] ">Annane 2005</a>; <a href="./references#CD002243-bbs2-0133" title="HemingN , SivanandamoorthyS , MengP , BounabR , AnnaneD . Immune effects of corticosteroids in sepsis. Frontiers in Immunology2018;9:1736. [DOI: 10.3389/fimmu.2018.01736; PUBMED: 30105022] ">Heming 2018</a>), thus arguing against the use of higher doses. Moreover, at these low doses, corticosteroids have been shown to improve rather than suppress innate immunity in patients with septic shock (<a href="./references#CD002243-bbs2-0069" title="KaufmannI , BriegelJ , SchliephakeF , HoelzlA , ChoukerA , HummelT , et al. Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization‐dependent neutrophil functions. Intensive Care Medicine2008;34(2):344‐9. [PUBMED: 17906853 ] ">Kaufman 2008</a>). It is now established that sepsis results in a sustained pro‐inflammatory state, arguing against a short course of treatment (<a href="./references#CD002243-bbs2-0101" title="AngusDC , van derPollT . Severe sepsis and septic shock. New England Journal of Medicine2013;369(21):840‐51. [PUBMED: 23984731] ">Angus 2013</a>; <a href="./references#CD002243-bbs2-0143" title="KellumJA , KongL , FinkMP , WeissfeldLA , YealyDM , PinskyMR , et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Archives of Internal Medicine2007;167(15):1655‐63. [PUBMED: 17698689] ">Kellum 2007</a>; <a href="./references#CD002243-bbs2-0175" title="van derPollT , van deVeerdonkFL , SciclunaBP , NeteaMG . The immunopathology of sepsis and potential therapeutic targets. Nature Reviews. Immunology2017;17(7):407‐20. [PUBMED: 28436424] ">van der Poll 2017</a>). </p> <p>Review authors noted some variation in the routine use of corticosteroids in sepsis. A survey of 542 US critical care physicians found that 83% do not routinely use corticosteroids in adults with sepsis, contrasting with 81% reporting common use of corticosteroids for septic shock (<a href="./references#CD002243-bbs2-0112" title="BrunoJJ , DeeBM , AndereggBA , HernandezM , PravinkumarSE . US practitioner opinions and prescribing practices regarding corticosteroid therapy for severe sepsis and septic shock. Journal of Critical Care2012;27(4):351‐61. [PUBMED: 22341726] ">Bruno 2012</a>). The findings of this review suggest that treatment effects on mortality may be greater in sepsis with versus without shock. Roughly one out of three respondents to the survey believed that corticosteroids reduce mortality in septic shock, whereas 27% did not and 45% were unsure. Hydrocortisone was the most common corticosteroid prescribed (93%), with a median dosage of 200 mg/d and administration via intermittent intravenous injection. </p> </section> <section id="CD002243-sec-0172"> <h3 class="title" id="CD002243-sec-0172">Quality of the evidence</h3> <p>We judged the certainty of evidence for 28‐day mortality as moderate rather than high because of some inconsistency across trials that was related in part to differences in study populations and to differences in the types of corticosteroids used and the ways in which corticosteroids were given. </p> </section> <section id="CD002243-sec-0173"> <h3 class="title" id="CD002243-sec-0173">Potential biases in the review process</h3> <p>For this review, we performed a comprehensive search of the literature with no restriction on language, so we can assume that the risk of missing important trials was very limited. Slight asymmetry in the funnel plot for the primary outcome of this review may suggest some publication bias. However, potential sources of an asymmetrical funnel plot also include selection biases, poor methodological quality of smaller studies, true heterogeneity, artefacts, and chance (<a href="./references#CD002243-bbs2-0122" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [PUBMED: 9310563] ">Egger 1997</a>). Visual inspection of the funnel plot suggests a small‐study effect (i.e. among small studies, the positive ones are more likely to be published). Nevertheless, our thorough search strategy and the need to enrol studies in public clinical trial registries may have decreased the risk of missing any randomized controlled trials. True heterogeneity seems to be a more plausible explanation for the observed asymmetrical funnel plot. Indeed, the effects of corticosteroids on mortality may be proportionate to the basal risk of death, and the two large trials that did not find survival benefit ‐ <a href="./references#CD002243-bbs2-0049" title="SprungC , AnnaneD , KehD , MorenoR , SingerM , FreivogelK , et al. Hydrocortisone therapy for patients with septic shock. New England Journal of Medicine2008;358(2):111‐24. [PUBMED: 18184957] ">Sprung 2008</a> and <a href="./references#CD002243-bbs2-0058" title="VenkateshB , FinferS , CohenJ , RajbhandariD , ArabiY , BellomoR , et al. Adjunctive glucocorticoid therapy in patients with septic shock. New England Journal of Medicine2018;378:797–808. [DOI: 10.1056/NEJMoa1705835; PUBMED: 29347874] VenkateshB , FinferS , MybrughJ , CohenJ , BillotL . Long‐term outcomes of the ADRENAL trial [2018]. New England Journal of Medicine2018;378(18):174‐5. [PUBMED: 29694789] ">Venkatesh 2018</a> ‐ included patients at lower risk of death than was seen in the two large trials that found a survival benefit ‐ <a href="./references#CD002243-bbs2-0002" title="AnnaneD , SebilleV , CharpentierC , BollaertPE , FrançoisB , KorachJM , et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA2002;288(7):862‐71. [PUBMED: 12186604] ">Annane 2002</a> and <a href="./references#CD002243-bbs2-0004" title="AnnaneD , RenaultA , Brun‐BuissonC , MegarbaneB , QuenotJP , SiamiS , et al. Hydrocortisone plus fludrocortisone for adults with septic shock. New England Journal of Medicine2018;378(9):809‐18. [PUBMED: 29490185] ">Annane 2018</a>. Finally, the asymmetrical funnel plot may have been due to chance. </p> <p>One trial used a cross‐over design (<a href="./references#CD002243-bbs2-0024" title='KehD , BoehnkeT , Weber‐CartensS , SchulzC , AhlersO , BerckerS , et al. Immunologic and hemodynamic effects of "low‐dose" hydrocortisone in septic shock: a double‐blind, randomized, placebo‐controlled, crossover study. American Journal of Respiratory and Critical Care Medicine2003;167(4):512‐20. [PUBMED: 12426230 ] '>Keh 2003</a>), and we could obtain none of the foreseen outcomes for this review. This trial concluded that prolonged treatment with a low dose of hydrocortisone improved haemodynamic and immune outcomes. Another trial compared three days versus seven days of hydrocortisone therapy and provided no evidence of differences in outcomes between patients treated for three days or seven days (<a href="./references#CD002243-bbs2-0022" title="HuhJW , LimCM , KohY , HongSB . Effect of low doses of hydrocortisone in patient with septic shock and relative adrenal insufficiency: 3 days versus 7 days treatment. Critical Care Medicine2006;34(12 suppl):A101. ">Huh 2007</a>). However, this trial had some limitations, including lack of blinding and small sample size. We considered that pooling the results of remaining trials in a meta‐analysis was acceptable. </p> <p>Three trials were published only as an abstract (<a href="./references#CD002243-bbs2-0010" title="ChawlaK , KupferY , TesslerS . Hydrocortisone reverses refractory septic shock. Critical Care Medicine1999;27(1):A33. ">Chawla 1999</a>; <a href="./references#CD002243-bbs2-0037" title="MireaL , UngureanuR , PavelescuD , GrintescuIC , DumitracheC , GrintescuI , et al. Continuous administration of corticosteroids in septic shock can reduce risk of hypernatraemia. Critical Care2014;18:S86. ">Mirea 2014</a>; <a href="./references#CD002243-bbs2-0052" title="TandanSM , GuleriaR , GuptaN . Low dose steroids and adrenocortical insufficiency in septic shock: a double‐blind randomised controlled trial from India. Proceedings of the American Thoracic Society Meeting. 2005:A24. ">Tandan 2005</a>). Nevertheless, the primary investigators for these studies provided sufficient unpublished data for review authors to compute the primary outcome and several secondary outcomes for this review, allowing us to include these trials in the meta‐analysis. Both published and unpublished data were available for 28 trials (<a href="./appendices#CD002243-sec-0185">Appendix 5</a>), and the primary author for each trial validated the data extraction form. For four studies, contact with the primary investigator yielded no additional data (<a href="./references#CD002243-bbs2-0030" title="LuceJM , MontgomeryAB , MarksJD , TurnerJ , MetzCA , MurrayJF . Ineffectiveness of high‐dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. American Review of Respiratory Diseases1988;138(1):62‐8. [PUBMED: 3202402 ] ">Luce 1988</a>; <a href="./references#CD002243-bbs2-0035" title="MeijvisSC , HardemanH , RemmeltsHH , HeijligenbergR , RijkersGT , vanVelzen‐BladH , et al. Dexamethasone and length of hospital stay in patients with community‐acquired pneumonia: a randomised, double‐blind, placebo‐controlled trial. Lancet2011;377(9782):2023‐30. [PUBMED: 21636122] ">Meijvis 2011</a>; <a href="./references#CD002243-bbs2-0042" title="RezkNA , IbrahimAM . Effects of methyl prednisolone in early ARDS. Egyptian Journal of Chest Diseases and Tuberculosis2013;62(1):167–72. [DOI: 10.1016/j.ejcdt.2013.02.013] ">Rezk 2013</a>; <a href="./references#CD002243-bbs2-0047" title="SnijdersD , DanielsJMA , deGraaffCS , van derWerfTS , BoersmaWG . Efficacy of corticosteroids in community‐acquired pneumonia – a randomized double blinded clinical trial. American Journal of Respiratory and Critical Care Medicine2010;181(9):975‐82. [PUBMED: 20133929] ">Snijders 2010</a>). </p> <p>We chose to convert outcome measures that correspond to censored data into dichotomous variables, that is, the proportion of participants with a particular event after one week and after four weeks, or at ICU or hospital discharge. </p> </section> <section id="CD002243-sec-0174"> <h3 class="title" id="CD002243-sec-0174">Agreements and disagreements with other studies or reviews</h3> <p>Findings in this review that a short course of high‐dose corticosteroids provides no benefit for patients with sepsis are in line with reports from previous systematic reviews (<a href="./references#CD002243-bbs2-0117" title="CroninL , CookDJ , CarletJ , HeylandDK , KingD , LansangMAD , et al. Corticosteroid treatment for sepsis: a critical appraisal and meta‐analysis of the literature. Critical Care Medicine1995;23(8):1430‐9. [PUBMED: 7634816 ] ">Cronin 1995</a>; <a href="./references#CD002243-bbs2-0145" title="LeferingR , NeugebauerEAM . Steroid controversy in sepsis and septic shock: a meta‐analysis. Critical Care Medicine1995;23(7):1294‐303. [PUBMED: 7600840 ] ">Lefering 1995</a>), as well as with current international guidelines (<a href="./references#CD002243-bbs2-0107" title="AnnaneD , PastoresSM , RochwergB , ArltW , BalkRA , BeishuizenA , et al. Guidelines for the diagnosis and management of critical illness‐related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Medicine2017;43(12):1751‐63. [PUBMED: 28940011] ">Annane 2017b</a>; <a href="./references#CD002243-bbs2-0164" title="RhodesA , EvansLE , AlhazzaniW , LevyMM , AntonelliM , FerrerR , et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Medicine2017;43(3):304‐77. [PUBMED: 28101605] ">Rhodes 2017</a>). </p> <p>We found scarce data that could not allow conclusions on the effects of corticosteroids in children with sepsis, in keeping with a recent systematic review (<a href="./references#CD002243-bbs2-0151" title="MenonK , McNallyD , ChoongK , SampsonM . A systematic review and meta‐analysis on the effect of steroids in pediatric shock. Pediatric Critical Care Medicine2013;14(5):474‐80. [PUBMED: 23867428] ">Menon 2013</a>). Nevertheless, we found no evidence of a difference in response to corticosteroids between children and adults. </p> <p>The beneficial effects of corticosteroids on shock reversal in patients with septic shock are consistent across recent systematic reviews (<a href="./references#CD002243-bbs2-0100" title="AllenJM , FeildC , ShouldersBR , VoilsSA . Recent updates in the pharmacological management of sepsis and septic shock: a systematic review focused on fluid resuscitation, vasopressors, and corticosteroids. Annals of Pharmacotherapy2018;53:385‐95. [DOI: 10.1177/1060028018812940; PUBMED: 30404539 ] ">Allen 2018</a>; <a href="./references#CD002243-bbs2-0125" title="FangF , ZhangY , TangJ , LunsfordLD , LiT , TangR , et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta‐analysis. JAMA Internal Medicine2019;179(2):213‐23. [DOI: 10.1001/jamainternmed.2018.5849; PUBMED: 30575845] ">Fang 2018</a>; <a href="./references#CD002243-bbs2-0140" title="KalilAC , SunJ . Low‐dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies. Intensive Care Medicine2011;37(3):420–9. [PUBMED: 21243334] ">Kalil 2011</a>; <a href="./references#CD002243-bbs2-0153" title="MoranJL , GrahamPL , RockliffS , BerstenAD . Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta‐analytic perspective. Critical Care2010;14(4):R134. [PUBMED: 20626892] ">Moran 2010</a>; <a href="./references#CD002243-bbs2-0154" title="NiYN , LiuYM , WangYW , LiangBM , LiangZA . Can corticosteroids reduce the mortality of patients with severe sepsis? A systematic review and meta‐analysis. American Journal of Emergency Medicine2018;S0735‐6757:30953‐7. [PUBMED: 30522935] ">Ni 2018</a>; <a href="./references#CD002243-bbs2-0165" title="RochwergB , OczkowskiSJ , SiemieniukRAC , AgoritsasT , Belley‐CoteE , D'AragonF , et al. Corticosteroids in sepsis: an updated systematic review and meta‐analysis. Critical Care Medicine2018;46(9):1411‐20. [PUBMED: 29979221] ">Rochwerg 2018</a>; <a href="./references#CD002243-bbs2-0167" title="RygårdSL , ButlerE , GranholmA , MøllerMH , CohenJ , FinferS , et al. Low‐dose corticosteroids for adult patients with septic shock: a systematic review with meta‐analysis and trial sequential analysis. Intensive Care Medicine2018;44(7):1003‐16. [PUBMED: 29761216] ">Rygard 2018</a>; <a href="./references#CD002243-bbs2-0169" title="SherwinRL , GarciaAJ , BilkovskiR . Do low‐dose corticosteroids improve mortality or shock reversal in patients with septic shock? A systematic review and position statement prepared for the American Academy of Emergency Medicine. Journal of Emergency Medicine2012;43(1):7‐12. [PUBMED: 22221983] ">Sherwin 2012</a>). The survival benefit derived from corticosteroids for patients with sepsis was suggested by some previous authors (<a href="./references#CD002243-bbs2-0100" title="AllenJM , FeildC , ShouldersBR , VoilsSA . Recent updates in the pharmacological management of sepsis and septic shock: a systematic review focused on fluid resuscitation, vasopressors, and corticosteroids. Annals of Pharmacotherapy2018;53:385‐95. [DOI: 10.1177/1060028018812940; PUBMED: 30404539 ] ">Allen 2018</a>; <a href="./references#CD002243-bbs2-0125" title="FangF , ZhangY , TangJ , LunsfordLD , LiT , TangR , et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta‐analysis. JAMA Internal Medicine2019;179(2):213‐23. [DOI: 10.1001/jamainternmed.2018.5849; PUBMED: 30575845] ">Fang 2018</a>; <a href="./references#CD002243-bbs2-0153" title="MoranJL , GrahamPL , RockliffS , BerstenAD . Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta‐analytic perspective. Critical Care2010;14(4):R134. [PUBMED: 20626892] ">Moran 2010</a>; <a href="./references#CD002243-bbs2-0154" title="NiYN , LiuYM , WangYW , LiangBM , LiangZA . Can corticosteroids reduce the mortality of patients with severe sepsis? A systematic review and meta‐analysis. American Journal of Emergency Medicine2018;S0735‐6757:30953‐7. [PUBMED: 30522935] ">Ni 2018</a>; <a href="./references#CD002243-bbs2-0165" title="RochwergB , OczkowskiSJ , SiemieniukRAC , AgoritsasT , Belley‐CoteE , D'AragonF , et al. Corticosteroids in sepsis: an updated systematic review and meta‐analysis. Critical Care Medicine2018;46(9):1411‐20. [PUBMED: 29979221] ">Rochwerg 2018</a>), but not by others (<a href="#CD002243-tbl-0003">Table 2</a>) (<a href="./references#CD002243-bbs2-0140" title="KalilAC , SunJ . Low‐dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies. Intensive Care Medicine2011;37(3):420–9. [PUBMED: 21243334] ">Kalil 2011</a>; <a href="./references#CD002243-bbs2-0167" title="RygårdSL , ButlerE , GranholmA , MøllerMH , CohenJ , FinferS , et al. Low‐dose corticosteroids for adult patients with septic shock: a systematic review with meta‐analysis and trial sequential analysis. Intensive Care Medicine2018;44(7):1003‐16. [PUBMED: 29761216] ">Rygard 2018</a>; <a href="./references#CD002243-bbs2-0169" title="SherwinRL , GarciaAJ , BilkovskiR . Do low‐dose corticosteroids improve mortality or shock reversal in patients with septic shock? A systematic review and position statement prepared for the American Academy of Emergency Medicine. Journal of Emergency Medicine2012;43(1):7‐12. [PUBMED: 22221983] ">Sherwin 2012</a>). Nevertheless, this systematic review included trials that were not included in previous systematic reviews, as they were published only recently or were published in a non‐English language. The current review included non‐published information for a large number of trials after contact was made with original study authors, resulting in inclusion of qualitatively and quantitatively better data than were provided previously. </p> <div class="table" id="CD002243-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Recent systematic reviews about the use of corticosteroids in sepsis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Author</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Estimate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% CI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002243-bbs2-0154" title="NiYN , LiuYM , WangYW , LiangBM , LiangZA . Can corticosteroids reduce the mortality of patients with severe sepsis? A systematic review and meta‐analysis. American Journal of Emergency Medicine2018;S0735‐6757:30953‐7. [PUBMED: 30522935] ">Ni 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28‐Day mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sepsis: RR = 0.91</p> <p>Septic shock: RR = 0.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 to 0.98</p> <p>0.85 to 0.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002243-bbs2-0100" title="AllenJM , FeildC , ShouldersBR , VoilsSA . Recent updates in the pharmacological management of sepsis and septic shock: a systematic review focused on fluid resuscitation, vasopressors, and corticosteroids. Annals of Pharmacotherapy2018;53:385‐95. [DOI: 10.1177/1060028018812940; PUBMED: 30404539 ] ">Allen 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only qualitative assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only qualitative assessment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002243-bbs2-0165" title="RochwergB , OczkowskiSJ , SiemieniukRAC , AgoritsasT , Belley‐CoteE , D'AragonF , et al. Corticosteroids in sepsis: an updated systematic review and meta‐analysis. Critical Care Medicine2018;46(9):1411‐20. [PUBMED: 29979221] ">Rochwerg 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28‐ to 31‐day mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 0.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 to 1.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002243-bbs2-0167" title="RygårdSL , ButlerE , GranholmA , MøllerMH , CohenJ , FinferS , et al. Low‐dose corticosteroids for adult patients with septic shock: a systematic review with meta‐analysis and trial sequential analysis. Intensive Care Medicine2018;44(7):1003‐16. [PUBMED: 29761216] ">Rygard 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short‐term mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 0.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 to 1.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002243-bbs2-0125" title="FangF , ZhangY , TangJ , LunsfordLD , LiT , TangR , et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta‐analysis. JAMA Internal Medicine2019;179(2):213‐23. [DOI: 10.1001/jamainternmed.2018.5849; PUBMED: 30575845] ">Fang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28‐Day mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 to 0.98</p> </td> </tr> </tbody> </table> </div> <p>A recent network meta‐analysis suggests that hydrocortisone was more likely than methylprednisolone to achieve shock reversal (<a href="./references#CD002243-bbs2-0184" title="GibbisonB , López‐LópezJA , HigginsJP , MillerT , AngeliniGD , LightmanSL , et al. Corticosteroids in septic shock: a systematic review and network meta‐analysis. Critical Care2017;21:78. [PUBMED: 28351429] ">Gibbison 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002243-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD002243-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD002243-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Figure represents the results from meta‐regression of log of risk ratio of dying and the dose of corticosteroids given at day 1 and expressed as equivalent milligrams of hydrocortisone. Estimates from each study are represented by circles. Circle sizes depend on the precision of each estimate (the inverse of its within‐study variance), which is the weight given to each study in the fixed‐effect model.Meta‐regression included 53 trials.REML estimate of between‐study variance: tau² = .008551.  % residual variation due to heterogeneity: I² res = 28.86%.  Proportion of between‐study variance explained: Adj R² = 43.76%." data-id="CD002243-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Figure represents the results from meta‐regression of log of risk ratio of dying and the dose of corticosteroids given at day 1 and expressed as equivalent milligrams of hydrocortisone. Estimates from each study are represented by circles. Circle sizes depend on the precision of each estimate (the inverse of its within‐study variance), which is the weight given to each study in the fixed‐effect model. </p> <p>Meta‐regression included 53 trials.</p> <p>REML estimate of between‐study variance: tau² = .008551.<br/> % residual variation due to heterogeneity: I² res = 28.86%.<br/> Proportion of between‐study variance explained: Adj R² = 43.76%. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Figure represents results from meta‐regression of log of risk ratio of dying and log of cumulated dose of corticosteroids expressed as equivalent milligrams of hydrocortisone. Estimates from each study are represented by circles. Circle sizes depend on the precision of each estimate (the inverse of its within‐study variance), which is the weight given to each study in the fixed‐effect model.Meta‐regression included 53 trials.REML estimate of between‐study variance: tau² = .008628.  % residual variation due to heterogeneity: I² res = 28.68%.  Proportion of between‐study variance explained: Adj R² = 43.25%." data-id="CD002243-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Figure represents results from meta‐regression of log of risk ratio of dying and log of cumulated dose of corticosteroids expressed as equivalent milligrams of hydrocortisone. Estimates from each study are represented by circles. Circle sizes depend on the precision of each estimate (the inverse of its within‐study variance), which is the weight given to each study in the fixed‐effect model. </p> <p>Meta‐regression included 53 trials.</p> <p>REML estimate of between‐study variance: tau² = .008628.<br/> % residual variation due to heterogeneity: I² res = 28.68%.<br/> Proportion of between‐study variance explained: Adj R² = 43.25%. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Meta‐regression of the log of the risk ratio for 28‐day mortality against actual mortality at 28 days in the control arm." data-id="CD002243-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Meta‐regression of the log of the risk ratio for 28‐day mortality against actual mortality at 28 days in the control arm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Steroids vs control, outcome: 1.1 28‐Day all‐cause mortality." data-id="CD002243-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Steroids vs control, outcome: 1.1 28‐Day all‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Contour‐enhanced funnel plot.Log of risk ratio for 28‐day mortality is plotted against its standard error." data-id="CD002243-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Contour‐enhanced funnel plot.</p> <p>Log of risk ratio for 28‐day mortality is plotted against its standard error.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 1 28‐Day all‐cause mortality." data-id="CD002243-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 1 28‐Day all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 2 28‐Day all‐cause mortality ‐ sensitivity analysis based on methodological quality." data-id="CD002243-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 2 28‐Day all‐cause mortality ‐ sensitivity analysis based on methodological quality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 3 28‐Day all‐cause mortality by subgroups based on study drug." data-id="CD002243-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 3 28‐Day all‐cause mortality by subgroups based on study drug. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 4 28‐Day all‐cause mortality by subgroups based on treatment dose/duration." data-id="CD002243-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 4 28‐Day all‐cause mortality by subgroups based on treatment dose/duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 5 28‐Day all‐cause mortality based on mode of drug administration." data-id="CD002243-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 5 28‐Day all‐cause mortality based on mode of drug administration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 6 28‐Day all‐cause mortality based on mode of drug termination." data-id="CD002243-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 6 28‐Day all‐cause mortality based on mode of drug termination. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 7 28‐Day all‐cause mortality by subgroups based on age." data-id="CD002243-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 7 28‐Day all‐cause mortality by subgroups based on age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 8 28‐Day all‐cause mortality by subgroups based on targeted population." data-id="CD002243-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 8 28‐Day all‐cause mortality by subgroups based on targeted population. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 9 28‐Day mortality in participants with critical illness‐related corticosteroid insufficiency." data-id="CD002243-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 9 28‐Day mortality in participants with critical illness‐related corticosteroid insufficiency. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 10 90‐Day all‐cause mortality." data-id="CD002243-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 10 90‐Day all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 11 Long‐term mortality." data-id="CD002243-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 11 Long‐term mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 12 Intensive care unit mortality." data-id="CD002243-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 12 Intensive care unit mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 13 Hospital mortality." data-id="CD002243-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 13 Hospital mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 14 Number of participants with shock reversal at day 7." data-id="CD002243-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 14 Number of participants with shock reversal at day 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 15 Number of participants with shock reversal at 28 days." data-id="CD002243-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 15 Number of participants with shock reversal at 28 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 16 SOFA score at day 7." data-id="CD002243-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 16 SOFA score at day 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 17 Length of intensive care unit stay for all participants." data-id="CD002243-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 17 Length of intensive care unit stay for all participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 18 Length of intensive care unit stay for survivors." data-id="CD002243-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 18 Length of intensive care unit stay for survivors. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 19 Length of hospital stay for all participants." data-id="CD002243-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 19 Length of hospital stay for all participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 20 Length of hospital stay for survivors." data-id="CD002243-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 20 Length of hospital stay for survivors. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo or usual care, Outcome 21 Number of participants with adverse events." data-id="CD002243-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo or usual care, Outcome 21 Number of participants with adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 1 28‐Day all‐cause mortality." data-id="CD002243-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 1 28‐Day all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 2 90‐Day all‐cause mortality." data-id="CD002243-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 2 90‐Day all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 3 Long‐term mortality." data-id="CD002243-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 3 Long‐term mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 4 Intensive care unit mortality." data-id="CD002243-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 4 Intensive care unit mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 5 Hospital mortality." data-id="CD002243-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 5 Hospital mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 6 Number of participants with shock reversal at day 7." data-id="CD002243-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 6 Number of participants with shock reversal at day 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 7 Number of participants with shock reversal at day 28." data-id="CD002243-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 7 Number of participants with shock reversal at day 28. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 8 SOFA score at day 7." data-id="CD002243-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 8 SOFA score at day 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 9 Length of intensive care unit stay for all participants." data-id="CD002243-fig-0037" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 9 Length of intensive care unit stay for all participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 10 Length of hospital stay for all participants." data-id="CD002243-fig-0038" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 10 Length of hospital stay for all participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002243-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/urn:x-wiley:14651858:media:CD002243:CD002243-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_t/tCD002243-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 11 Number of participants with adverse events." data-id="CD002243-fig-0039" src="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Continuous infusion versus bolus administration of corticosteroids, Outcome 11 Number of participants with adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/media/CDSR/CD002243/image_n/nCD002243-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002243-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Corticosteroids compared to placebo or usual care for treating sepsis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Corticosteroids compared to placebo or usual care for treating sepsis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children and adults with sepsis<br/> <b>Setting:</b> hospitalised patients; trials were performed in numerous countries from the 5 continents<br/> <b>Intervention:</b> corticosteroids<br/> <b>Comparison:</b> placebo or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or usual care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with corticosteroids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28‐Day all‐cause mortality<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.84 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11233<br/> (50 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably slightly reduce 28‐day all‐cause mortality</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>264 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 per 1000<br/> (222 to 261) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Long‐term mortality<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.91 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6236<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids may result in little to no difference in long‐term mortality</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>386 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>374 per 1000<br/> (351 to 397) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hospital mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.82 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8183<br/> (26 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably slightly reduce hospital mortality</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>323 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>291 per 1000<br/> (265 to 320) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of intensive care unit stay for all participants in days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean length of intensive care unit stay for all participants was 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.07 lower<br/> (1.95 lower to 0.19 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7612<br/> (21 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids reduced length of intensive care unit stay for all participants</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay for all participants in days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean length of hospital stay for all participants was 21 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.63 lower<br/> (2.93 lower to 0.33 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8795<br/> (22 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids result in a large reduction in length of hospital stay for all participants</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events ‐ superinfection (up to longest follow‐up)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/> (0.95 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5356<br/> (25 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably do not increase the number of participants with adverse events ‐ superinfection </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000<br/> (161 to 202) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events ‐ muscle weakness (up to longest follow‐up)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.21<br/> (1.01 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6145<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids increase the number of participants with adverse events ‐ muscle weakness</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/> (57 to 81) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio. </p> <p>The unit of measure for length of stay is days.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Sensitivity analysis based on trials judged as being at low risk of bias showed an RR for dying at 28 days of 0.91 (95% CI 0.84 to 0.98; P = 0.01; 7896 participants; 17 studies; I² = 0%). </p> <p><sup>b</sup>Downgraded one level for inconsistency; there was significant statistical heterogeneity. </p> <p><sup>c</sup>Long‐term mortality was recorded up to six months for three trials (<a href="./references#CD002243-bbs2-0004" title="AnnaneD , RenaultA , Brun‐BuissonC , MegarbaneB , QuenotJP , SiamiS , et al. Hydrocortisone plus fludrocortisone for adults with septic shock. New England Journal of Medicine2018;378(9):809‐18. [PUBMED: 29490185] ">Annane 2018</a>; <a href="./references#CD002243-bbs2-0025" title="KehD , TripsE , MarxG , WirtzSP , AbduljawwadE , BerckerS , et al. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA2016;316(17):1775‐85. [PUBMED: 27695824] ">Keh 2016</a>; <a href="./references#CD002243-bbs2-0058" title="VenkateshB , FinferS , CohenJ , RajbhandariD , ArabiY , BellomoR , et al. Adjunctive glucocorticoid therapy in patients with septic shock. New England Journal of Medicine2018;378:797–808. [DOI: 10.1056/NEJMoa1705835; PUBMED: 29347874] VenkateshB , FinferS , MybrughJ , CohenJ , BillotL . Long‐term outcomes of the ADRENAL trial [2018]. New England Journal of Medicine2018;378(18):174‐5. [PUBMED: 29694789] ">Venkatesh 2018</a>), and up to one year for four trials (<a href="./references#CD002243-bbs2-0002" title="AnnaneD , SebilleV , CharpentierC , BollaertPE , FrançoisB , KorachJM , et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA2002;288(7):862‐71. [PUBMED: 12186604] ">Annane 2002</a>; <a href="./references#CD002243-bbs2-0009" title="BriegelJ , ForstH , HallerM , SchellingG , KilgerE , KupratG , et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double‐blind, single‐center study. Critical Care Medicine1999;27(4):723‐32. [PUBMED: 10321661] ">Briegel 1999</a>; <a href="./references#CD002243-bbs2-0033" title="MeduriGU , GoldenE , FreireAX , TaylorE , ZamanM , CarsonSJ , et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest2007;131(4):954‐63. [PUBMED: 17426195] ">Meduri 2007</a>; <a href="./references#CD002243-bbs2-0049" title="SprungC , AnnaneD , KehD , MorenoR , SingerM , FreivogelK , et al. Hydrocortisone therapy for patients with septic shock. New England Journal of Medicine2008;358(2):111‐24. [PUBMED: 18184957] ">Sprung 2008</a>). </p> <p><sup>d</sup>Large 95% confidence interval overlapping the neutrality line. </p> <p><sup>e</sup>Upgraded one level due to large size effects. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Corticosteroids compared to placebo or usual care for treating sepsis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002243-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Continuous infusion compared to bolus administration of corticosteroids for children and adults with sepsis</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Continuous infusion compared to bolus administration of corticosteroids for children and adults with sepsis</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children and adults with sepsis<br/> <b>Setting:</b> hospitalized patients; trials were performed in France, Tunisia, Romania, and Finland<br/> <b>Intervention:</b> continuous infusion<br/> <b>Comparison:</b> bolus administration of corticosteroids </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with bolus administration of corticosteroids</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with continuous infusion</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28‐Day all‐cause mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (0.81 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>310<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Evidence is very uncertain about the effect of continuous infusion on 28‐day all‐cause mortality </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457 per 1000<br/> (359 to 581) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Long‐term mortality<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.36<br/> (1.02 to 1.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>d,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Evidence is very uncertain about the effect of continuous infusion on long‐term mortality</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>636 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>865 per 1000<br/> (649 to 1000) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hospital mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/> (0.72 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>240<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Evidence is very uncertain about the effect of continuous infusion on hospital mortality</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435 per 1000<br/> (329 to 572) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of intensive care unit stay for all participants in days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean length of intensive care unit stay for all participants was 13 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.05 lower<br/> (4.54 lower to 2.45 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence is very uncertain about the effect of continuous infusion on length of intensive care unit stay for all participants </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay for all participants in days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean length of hospital stay for all participants was 17 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 higher<br/> (5.05 lower to 5.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence is very uncertain about the effect of continuous infusion on length of hospital stay for all participants </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events ‐ superinfection (up to longest follow‐up)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/> (0.37 to 3.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>193<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Evidence is very uncertain about the effect of continuous infusion on number of participants with adverse events ‐ superinfection </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229 per 1000<br/> (76 to 680) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events ‐ muscle weakness (up to longest follow‐up)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.13 to 5.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Evidence suggests that continuous infusion may result in little to no difference in the number of participants with adverse events ‐ muscle weakness </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/> (8 to 362) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; MD: mean difference; RCT: randomized controlled trial; RR: risk ratio. </p> <p>The unit of measure for length of stay is days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level as only one of the four trials was judged as having low risk of bias. </p> <p><sup>b</sup>Downgraded one level as trials were small and the 95% confidence interval was large. </p> <p><sup>d</sup>Downgraded one level as the only trial reporting this outcome was open‐labelled and at high risk of performance bias. </p> <p><sup>e</sup>Downgraded one level as only one trial reported this outcome. </p> <p><sup>f</sup>Downgraded one level as the observed increase in risk of dying in the long term is not consistent with treatment effects on 28‐day mortality. </p> <p><sup>g</sup>Downgraded one level as results show some heterogeneity. </p> <p><sup>h</sup>Downgraded two levels as heterogeneity in the results is strong. </p> <p><sup>c</sup>Long‐term mortality was assessed up to six months. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Continuous infusion compared to bolus administration of corticosteroids for children and adults with sepsis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002243-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Recent systematic reviews about the use of corticosteroids in sepsis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Author</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Estimate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% CI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002243-bbs2-0154" title="NiYN , LiuYM , WangYW , LiangBM , LiangZA . Can corticosteroids reduce the mortality of patients with severe sepsis? A systematic review and meta‐analysis. American Journal of Emergency Medicine2018;S0735‐6757:30953‐7. [PUBMED: 30522935] ">Ni 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28‐Day mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sepsis: RR = 0.91</p> <p>Septic shock: RR = 0.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 to 0.98</p> <p>0.85 to 0.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002243-bbs2-0100" title="AllenJM , FeildC , ShouldersBR , VoilsSA . Recent updates in the pharmacological management of sepsis and septic shock: a systematic review focused on fluid resuscitation, vasopressors, and corticosteroids. Annals of Pharmacotherapy2018;53:385‐95. [DOI: 10.1177/1060028018812940; PUBMED: 30404539 ] ">Allen 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only qualitative assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only qualitative assessment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002243-bbs2-0165" title="RochwergB , OczkowskiSJ , SiemieniukRAC , AgoritsasT , Belley‐CoteE , D'AragonF , et al. Corticosteroids in sepsis: an updated systematic review and meta‐analysis. Critical Care Medicine2018;46(9):1411‐20. [PUBMED: 29979221] ">Rochwerg 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28‐ to 31‐day mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 0.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 to 1.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002243-bbs2-0167" title="RygårdSL , ButlerE , GranholmA , MøllerMH , CohenJ , FinferS , et al. Low‐dose corticosteroids for adult patients with septic shock: a systematic review with meta‐analysis and trial sequential analysis. Intensive Care Medicine2018;44(7):1003‐16. [PUBMED: 29761216] ">Rygard 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short‐term mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 0.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 to 1.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002243-bbs2-0125" title="FangF , ZhangY , TangJ , LunsfordLD , LiT , TangR , et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta‐analysis. JAMA Internal Medicine2019;179(2):213‐23. [DOI: 10.1001/jamainternmed.2018.5849; PUBMED: 30575845] ">Fang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28‐Day mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 to 0.98</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Recent systematic reviews about the use of corticosteroids in sepsis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/full#CD002243-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002243-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Corticosteroids versus placebo or usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 28‐Day all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.84, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies reporting actual 28‐day mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Studies reporting short‐term mortality at other timing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.52, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 28‐Day all‐cause mortality ‐ sensitivity analysis based on methodological quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Adequate generation of allocation sequence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10076</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Adequate allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Blinded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Studies judged at low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.84, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 28‐Day all‐cause mortality by subgroups based on study drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.84, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Hydrocortisone plus fludrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Prednisone/Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.71, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Methylprednisolone/Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.61, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 28‐Day all‐cause mortality by subgroups based on treatment dose/duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Long course of low‐dose corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.86, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Short course of high‐dose corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.80, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 28‐Day all‐cause mortality based on mode of drug administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Intravenous bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.83, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Continuous infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.66, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 28‐Day all‐cause mortality based on mode of drug termination <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.83, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Without taper off</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.78, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 With taper off</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.92, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 28‐Day all‐cause mortality by subgroups based on age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.83, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.56, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 28‐Day all‐cause mortality by subgroups based on targeted population <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.89, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Septic shock only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.83, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Sepsis and ARDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.45, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Sepsis and community‐acquired pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.50, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 28‐Day mortality in participants with critical illness‐related corticosteroid insufficiency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 90‐Day all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5934</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Long‐term mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.91, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Intensive care unit mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.83, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Hospital mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Number of participants with shock reversal at day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.13, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Number of participants with shock reversal at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [1.03, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 SOFA score at day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.37 [‐1.84, ‐0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Length of intensive care unit stay for all participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.07 [‐1.95, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Length of intensive care unit stay for survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>778</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.19 [‐3.93, ‐0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Length of hospital stay for all participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.63 [‐2.93, ‐0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Length of hospital stay for survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.11 [‐8.50, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Number of participants with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Gastroduodenal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.85, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Superinfection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.95, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 Hyperglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.13, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4 Hypernatraemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.34, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5 Muscle weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.01, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.6 Neuropsychiatric event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.53, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7 Stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.41, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.8 Cardiac event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.66, 1.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Corticosteroids versus placebo or usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002243-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Continuous infusion versus bolus administration of corticosteroids</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 28‐Day all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.81, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 90‐Day all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.61, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Long‐term mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.02, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Intensive care unit mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.80, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Hospital mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants with shock reversal at day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.59, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of participants with shock reversal at day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.45, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 SOFA score at day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐0.25, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Length of intensive care unit stay for all participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.05 [‐4.54, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Length of hospital stay for all participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐5.05, 5.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Number of participants with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Gastrointestinal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.10, 6.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Superinfection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.37, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Hyperglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.47, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Hypernatraemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.34, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Muscle weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.13, 5.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 Neuropsychiatric event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.50, 4.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 Stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.8 Cardiac event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Continuous infusion versus bolus administration of corticosteroids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002243.pub4/references#CD002243-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002243.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD002243-note-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD002243-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002243-note-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002243-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002243-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD002243-note-0001">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD002243-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD002243-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD002243-note-0010">Português</a> </li> <li class="section-language"> <a class="" href="ro#CD002243-note-0018">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD002243-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD002243-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002243-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002243\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002243\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002243\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002243\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002243\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002243.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002243.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002243.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002243.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002243.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715170371"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002243.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715170375"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002243.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d808d0fb51bde',t:'MTc0MDcxNTE3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 